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Cardiovascular diseases are the primary cause of death in industrialized world. Despite 
significant advances in the management of heart disease over the last two decades, 
there remains an obviously unmet clinical need in treating this large and expanding 
patient population. The development and progression of cardiovascular diseases are 
complex, dynamic and time dependent processes that involve a variety of 
pathophysiological modifications that contribute to adverse cardiac remodelling. The most 
common manifestations are hypertension, coronary artery disease, heart failure and 
stroke. Heart failure is a leading cause of mortality. Heart failure is dictated by an 
uncompensated reduction in the number of viable and fully functional cardiomyocytes. 
The prevalence of heart failure in industrialized nations has reached epidemic 
proportions; in the U.S., it is nearly 6 million and continues to rise (Roger VL et al., 
2011). The number of patients is steadily increasing as a consequence of an aging 
population and/or enlarging prevalence of cardiovascular risk factors such as diabetes 
(Gilbert RE and Krum H, 2015) and improved survival rates after acute myocardial 
infarction (MI) putting a greater number of patients at risk of developing a late left 
ventricular dysfunction. The poor prognosis of symptomatic heart failure is likely 
associated with the limited long-term efficacy of conventional therapeutic strategies on 
the underlying ongoing loss of cardiomyocytes, which is followed by the deleterious 
formation of a fibrotic scar in the failing heart. Unlike other tissue,  the  heart  has been 
regarded until recently as an organ in which cardiomyocytes were unable to proliferate.  
Therefore, repair of damaged myocardium leads to replacement  by  fibrotic  tissue,  
which  disrupts  contractile  function  resulting  in  decreased  cardiac  performance. 
Long-term survival has improved with recent medical therapies aiming at reducing 
cardiac overload and neurohumoral activation, as well as mineralcorticoid deregulation. 
Significant advances have also been achieved through surgical revascularization 
strategies including percutaneous coronary angioplasty and coronary artery bypass 
grafting. More than 50% of heart failure patients die in 4 years and 40% of them perish 
or are readmitted to hospital within the first year. In the last years efforts have been 
performed to promote cardiac tissue regeneration with stem cell-based therapy (Leri  A  
et al., 2011). 
Over the last decade, the classical paradigm that the human heart is a post-mitotic and 
terminally developed organ with no cell renewal capability has been undermined with the 
demonstration that cardiomyocytes turnover can occur in adult mammals, including 
humans. Experimental and clinical evidences of the regenerative potential of the adult 
human heart has accumulated over the years. However, such inherent capability of 
human to regenerate myocardium with aging or after injury in adulthood is entirely 
insufficient to fully compensate for the loss of function associated with these conditions. 
One of the major therapeutic goals of modern cardiology is to design strategies aimed at 
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minimizing myocardial necrosis and optimizing cardiac repair following myocardial 
infarction. However, a sound understanding of the biology is necessary before a specific 
intervention is pursued on a therapeutic basis. 
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1.1. Tissue damage and response to injury 
 
Mammals respond to organ damage through either compensatory growth of the 
remaining tissue, by activating resident precursor cell proliferation, or by the formation of 
a scar. Successful mammalian regeneration requires precise coordination of multiple 
processes, which include scavenging cellular debris, proliferation and activation of 
progenitor cells, immune modulation, angiogenesis, and innervation of the newly forming 
tissue. While the involvement of immune cells in tissue repair has been appreciated since 
Metchnikoff observed that macrophages play a role in tissue repair in the late 1800s, 
recent advances highlight new mechanisms that the immune system employs to regulate 
regeneration. 
Pathologists define two normal kinds of repair in response to injury: healing and 
regeneration (Kumar V et al., 2005). Healing is a tissue response to a wound or to 
inflammatory processes in internal organs due to necrosis or infection, and consists of 
variable proportions of cellular regrowth and fibrous tissue production or scar formation. 
Regeneration refers to the growth of cells or tissues that replace both form and function 
in damaged organs of mammals or amputated appendages of amphibians or teleosts 
(Goss RJ, 1992). Unlike the normal healing response, functional organ regeneration 
typically involves minimal scarring and requires an intact or a reconstituted connective 
tissue scaffold (Kumar V et al., 2005). Innate immune mechanisms, driving the early 
inflammatory phase of both wound healing and organ regeneration, help activate 
signaling pathways required for nuclear programming of local cells (Antonio et al., 2015). 
Various receptors that sense cellular damage or microorganisms, including toll-like 
receptors (TLRs) expressed by fibroblasts and keratinocytes (Portou et al., 2015), 
stimulate signaling pathways that increase epigenetic plasticity and render cells more 
responsive to microenvironmental cues capable of changing the cells phenotype (Cooke 
et al., 2014; Lee et al., 2012). Phenotypic change and reprogramming of gene expression 
in cells of injured tissues are generally more important during organ regeneration than in 
tissue repair (Jessen et al., 2015; Knapp and Tanaka, 2012). Other cues that impinge on 
cells undergoing reprogramming in regenerating systems direct these cells in forming 
new tissues and include factors from signaling centers which establish the pattern of the 
regenerated organ. 
Myocardial infarction is associated with an inflammatory reaction, which is a prerequisite 
for healing and scar formation (Entman ML et al., 1994; Frangogiannis NG et al. 1997; 
Frangogiannis NG  et al., (a) 1998). Coronary artery occlusion critically reduces blood 
flow to the portion of the myocardium subserved, markedly impairing the energy 
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metabolism. Ischemia of significant duration to induce infarction does result in an 
inflammatory response; this response is both accelerated and augmented if the ischemic 
tissue is reperfused. The first experimental evidence that inflammation can extend 
myocardial injury came as the result of implementing anti-inflammatory strategies in 
animal models of myocardial ischemia and reperfusion. Subsequent investigation 
suggested that corticosteroids inhibit the inflammatory process decreasing the number of 
infiltrating leukocytes, but also delay healing and collagen deposition (Kloner et al., 
1978). This process is dependent on a complex interaction between a variety of 
pleiotropic inflammatory mediators. 
 
 
1.2. Humoral inflammatory response 
 
Complement activation 
Hill and Ward were the first to demonstrate that ischemic myocardial injury can activate 
the complement cascade in a rat model of myocardial infarction (Hill JH and Ward PA, 
1971). Subsequently Pinckard and colleagues (Pinckard RN et al., 1975) suggested that 
myocardial cell necrosis results in the release of subcellular membrane constituents rich 
in mitochondria, which are capable of triggering the early acting components (C1, C4, C2 
and C3) of the complement cascade. Rossen and colleagues (Rossen et al., 1994) have 
suggested that during myocardial ischemia, mitochondria, extruded through breaks in the 
sarcolemma, unfold and release membrane fragments rich in cardiolipin and proteins. By 
binding C1 and supplying sites for the assembly of later acting complement components, 
these subcellular fragments provide the means to disseminate the complement-mediated 
inflammatory response to ischemic injury. mRNA and proteins for all the components of 
the classical complement pathway are upregulated in areas of myocardial infarcts 
(Vakeva AP et al., 1998; Yasojima K et al., 1998). Complement activation may have an 
important role in mediating neutrophils and monocytes recruitment in the injured 
myocardium. 
 
Reactive oxygen species 
Reactive oxygen species (ROS) are molecules with unpaired electrons in their outer orbit. 
They have the potential to directly injure cardiac myocytes and vascular cells and may be 
involved in triggering inflammatory cascades through the induction of cytokines (Lefer DJ 
t al. 2000). ROS have been shown to exert a direct inhibitory effect on myocardial 
function in vivo and have a critical role in the pathogenesis of myocardial stunning. In 
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addition, Granger and colleagues (Granger DN et al., 1988) have provided evidence for a 
potential role of reactive oxygen in leukocyte chemotaxis. Potential mechanisms through 
which reactive oxygen intermediates may generate a leukotactic stimulus include 
complement activation (Shingu M et al., 1984), induction of P-selectin expression (Akgur 
FM et al., 2000; Patel KD et al., 1991), chemokine upregulation (Lakshminarayanan V et 
al. 1997; Lakshminarayanan V et al., 1998), and increase in the ability of endothelial 
ICAM-1 to bind to neutrophils (Sellak H et al., 1994). 
 
1.3. The immune system in myocardial infarction 
Activation of the immune system is a hallmark of myocardial infarction (MI). After 15-20 
minutes of severe ischemia cardiomyocytes exhibit irreversible alterations that ultimately 
result in their death. Subendocardial cardiomyocytes are more susceptible to ischemic 
injury; thus, a “wavefront” of necrosis is noted that extends from the subendocardial area 
to the subepicardium (Reimer KA et al., 1977). Ischemia and necrotic cardiomyocytes 
trigger a reparative process that can be divided into three distinct but overlapping 
phases. During the inflammatory phase, activation of innate immune signals results in 
induction of chemokines and cytokines leading to infiltration of the infarct with 
neutrophils and pro-inflammatory monocytes that clear the infarct from dead cells and 
matrix debris. Apoptotic death of neutrophils marks the end of the inflammatory phase 
and may activate signals that inhibit inflammation and induce resolution of the leukocyte 
infiltrate. The proliferative phase follows, as reparative monocytes are recruited in the 
infarct and macrophages may acquire an angiogenic or fibrogenic phenotype that 
promotes differentiation and growth of myofibroblasts and endothelial cells. Activated 
myofibroblasts contribute to wound contraction and produce structural matrix proteins 
forming a scar. Maturation of the infarct follows and is characterized by progressive 
apoptotic death of the cellular elements and by collagen cross linking. As the infarct 
heals, the ventricle dilates, while non-infarcted segments become hypertrophic and 
exhibit increased interstitial fibrosis. The extent of adverse remodeling is dependent not 
only on the size of the infarct, but also on the qualitative characteristics of the wound.  
 
 
Initiation of the immune response in the infarcted myocardium 
Acute sudden death of cardiomyocytes in the infarcted heart rapidly activates the 
immune system triggering an intense, but transient, inflammatory reaction. In the 
infracted myocardium, cellular necrosis and matrix fragmentation generate alarm signals 
that activate the innate immune response; these molecules are known as danger-
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associated molecular patterns (DAMPs) (Timmers L et al., 2012). The nuclear chromatin-
binding protein High-mobility group box-1 (HMGB1) plays a crucial role in initiation of the 
inflammatory response through actions that may involve Toll-Like Receptor (TLR) and 
RAGE signaling (Andrassy M et al., 2008). Heat shock proteins (HSPs), ATP and matrix 
fragments (including low molecular weight hyaluronan and fibronectin fragments) also 
serve as “danger signals” activating the immune response (Arslan F et al., 2011; 
Huebener P et al., 2008; Dobaczewski M et al., (a) 2010) The immune response following 
MI involves signaling through the TLRs, a family of transmembrane receptors that 
activate downstream pro-inflammatory cascades. TLRs recognize conserved motifs in 
pathogens, thus contributing to protection from infection, but are also activated by 
DAMPs, initiating immune responses that clear injured tissues from dead cells and matrix 
debris and activate reparative signals. 13 mammalian TLRs have been identified; in the 
infarcted myocardium, loss-of function approaches have identified TLR2 and TLR4, both 
localized in the cell surface, as important mediators of the inflammatory reaction. 
Impaired TLR4 signaling attenuated the inflammatory reaction following MI and reduced 
adverse remodeling; complete loss of TLR4 was also associated with a reduction in the 
size of the infarct (Agostini et al., 2004; Colotta et al., 1993). TLR2 signaling has also 
been reported to mediate inflammatory cardiomyocyte injury following coronary ischemia 
and reperfusion (Cullinan et al., 1998). DAMPs also activate the complement system, 
another essential cascade in transducing the immune response in the infarcted heart. Hill 
and Ward demonstrated C3 cleavage in the infarcted myocardium and documented a role 
for the complement system in leukocyte infiltration (Hill JH and Ward PA, 1971). 
Moreover, complement inhibition consistently attenuated leukocyte recruitment following 
MI (Lugrin J et al., 2015) highlighting the critical role of the complement cascade in 
triggering inflammation in the ischemic myocardium. Generation of ROS also activates 
immune cells in the infarcted heart. ROS promote leukocyte chemotaxis (Granger DN et 
al., 1988) by activating complement, by stimulating expression of P-selectin and by 
upregulating cytokine and chemokine synthesis through activation of the Nuclear Factor 
(NF)-κB system (Hensleyn K et al., 2000). Although reactive oxygen generation is 
important for cardiac repair following infarction, overactive ROS-mediated signaling has 
injurious potential by promoting cell apoptosis and by inducing degradation of the 
extracellular matrix. The normal heart possesses substantial ability to counterbalance the 
generation of ROS through inhibitory enzymatic pathways (such as catalase, glutathione 
peroxidase and the superoxide dismutases) and through the actions of intracellular 
antioxidants. Following MI, the antioxidant defenses are overwhelmed, resulting in net 
generation of free radicals that may suppress myocardial function and activate immune 
cells inducing inflammatory injury. Because of the pleiotropic effects of ROS, both 
beneficial and detrimental actions have been reported after administration of free radical 
scavengers in myocardial infarction. 
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Cytokine and chemokine signaling in the infarcted heart 
TLR-mediated, complement-activated and ROS-induced pathways in the infarcted 
myocardium converge on activation of NF-κB that drives induction of adhesion molecules 
in endothelial cells and production of pro-inflammatory cytokines and chemokines by 
fibroblasts, leukocytes and vascular cells. As the prototypical pro-inflammatory cytokine, 
Interleukin (IL)-1 mediates synthesis of chemotactic mediators in the infarct and 
stimulates leukocyte recruitment (Bujak M et al., 2008; Bujak M et al., 2009). Processing 
and generation of active IL-1 in inflamed tissues requires formation of specialized 
molecular platforms, called “inflammasomes” (Schroder K et al., 2010). Generation of 
active IL-1 is primarily mediated through processing of the precursor protein by the 
intracellular cysteine protease caspase-1; however, caspase-1-independent mechanisms 
of IL-1 activation have also been described (Netea MG et al., 2014). Activation of 
caspase-1 requires formation of a multi-component platform termed the inflammasome; 
one of the components of the inflammasome, Nucleotide-binding oligomerization domain-
Like Receptor with a Pyrin domain 3 (NLRP3), plays an important role in generation of 
active IL-1 (Agostini et al., 2004). 
Two investigations have demonstrated the activation of the inflammasome in the 
infarcted myocardium. Inflammasome activation in the infarct is localized in leukocytes, 
resident fibroblasts and border zone cardiomyocytes (Mezzaroma E et al., 2011; 
Kawaguchi M et al., 2011) and drives IL-1-mediated inflammatory cell infiltration and 
cytokine synthesis.  ROS production, ATP and potassium efflux may play a role in 
inflammasome activation in infarcted cells. Activation of the inflammasome in cardiac 
fibroblasts and in cardiomyocytes has been extensively documented in experimental 
models of MI and may contribute to the post-infarction inflammatory reaction extending 
injury (Sandanger O et al., 2013; Mezzaroma E et al., 2011; Kawaguchi M et al., 2011) 
The pro-inflammatory cytokine Tumor Necrosis Factor (TNF) is also released in the 
infarcted myocardium and may play a role in stimulating cytokine synthesis by 
mononuclear cells infiltrating the infarct (Frangogiannis NG et al., (b) 1998). In addition 
to its pro-inflammatory actions, TNF may also exert cytoprotective effects (Kurrelmeyer 
KM et al., 2000) and may regulate post-infarction cardiac remodeling through divergent 
actions involving TNFR1 and TNFR2 receptors (Hamid T et al., 2009). TNFR1 signaling 
stimulates cardiomyocyte apoptosis and enhances inflammatory activity in the infarcted 
heart, whereas TNFR2 reduces TNF-induced NF-κB activation and attenuates cardiac 
injury. Members of the IL6 family of cytokines (including IL6, cardiotrophin-1, oncostatin-
M and leukemia inhibitory factor) are also consistently upregulated in experimental 
models of MI and may modulate the inflammatory and reparative response, signaling 
through receptors that share the transmembrane glycoprotein (gp)130 (Fischer P et al., 
2008). Genetic loss of IL6 did not affect infarct size, ventricular function and cardiac 
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remodeling in nonreperfused infarcts (Fuchs M et al., 2003); in the absence of IL6 other 
gp130 cytokines may act in a compensatory manner, activating JAK/STAT signaling and 
maintaining STAT3 phosphorylation. On the other hand, experiments targeting IL6 
through administration of an anti-IL6 receptor antibody attenuated adverse remodeling 
(Kobara M et al., 2010). Timely activation and suppression of gp130 signaling may play 
an important role in the regulation of post-infarction remodeling. In an experimental 
model of myocardial infarction, failure to suppress gp130/STAT3 signaling resulted in 
prolonged and accentuated inflammation predisposing to cardiac rupture (Hilfiker-Kleiner 
D et al., 2010). Several members of the chemokine family are also prominently involved 
in the postinfarction inflammatory response (Frangogiannis NG, 2007) and provide key 
directional signals for recruitment of leukocyte subpopulations into the infarct. CC 
chemokines that serve as mononuclear cell chemoattractants, ELR+ CXC chemokines that 
function to attract neutrophils in sites of injury, and ELR-negative CXC chemokines that 
recruit lymphocytes and may exert antifibrotic and angiostatic actions are rapidly, but 
transiently, upregulated in the infarcted myocardium. The chemotactic actions of 
chemokines are dependent on their immobilization to glycosaminoglycans on the 
endothelial surface, or on the extracellular matrix; as leukocytes are captured by 
activated endothelial cells and roll on the endothelial surface (through selectin-mediated 
actions) they “sense” the bound chemokines, and exhibit integrin activation, thus 
engaging adhesive interactions with vascular endothelial cells. Various leukocyte 
subpopulations exhibit distinct chemokine receptor profiles and interact with different 
chemokines; thus selective activation of chemokine/chemokine receptor pairs 
orchestrates recruitment of leukocyte subpopulations with distinct properties (Nahrendorf 
M et al., 2007; Dobaczewski M et al., (a) 2010; Proudfoot AE et al., 2003). Activated 
leukocyte 2 integrins interact with endothelial Intercellular Adhesion Molecule (ICAM)-1 
resulting in firm adhesion of leukocytes to the endothelial layer. Transmigration of 
activated leukocytes follows, and is dependent on several adhesion molecules, including 
ICAM-1, members of the Junctional Adhesion Molecule (JAM) family and Vascular-
endothelial (VE)-cadherin (Corada M et al., 2005; Williams MR et al., 2011; Woodfin A et 
al., 2011;).  
 
 
1.4. The cellular effectors of the post-infarction inflammatory reaction 
Both resident and bone marrow-derived cells participate in the post-infarction 
inflammatory reaction; understanding the relative contribution of inflammatory activation 
of various cell types is limited by the absence of studies using cell-specific loss-of-
function approaches in vivo. 
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Cardiomyocytes: Necrotic cardiomyocytes release a variety of danger signals, thus 
actively contributing to activation of innate immune cascades. Moreover, border zone 
cardiomyocytes may exhibit activation of the inflammasome, thus serving as a source of 
bioactive IL-1. 
Endothelial cells: Endothelial cells actively participate in the post-infarction inflammatory 
reaction. Cytokine release in the infarct zone induces adhesion molecule expression on 
the endothelial cell surface, thus promoting adhesive interactions with circulating 
leukocytes. Endothelial cells are also a major source of pro-inflammatory chemokines 
(such as MCP-1 and IP-10) in the infarcted myocardium (Frangogiannis NG et al., 2001; 
Bujak M et al. 2009). 
Platelets: In addition to their hemostatic role, platelets modulate inflammatory responses 
and may link tissue injury with the activation of reparative pathways (von Hundelshausen 
P et al., 2007). In the healing infarct activated platelets aggregate in the site of injury 
and may contribute to the formation of a fibrin-based provisional matrix, necessary to 
support influx of hematopoietic cells and migration of reparative mesenchymal cells 
(Dobaczewski M et al., 2006). Platelets may also release chemokines, cytokines and 
growth factors in the infarcted tissue; however, their relative significance in the post-
infarction inflammatory reaction remains unknown. 
 
Neutrophils: Following either cardiac ischaemic injury or pressure overload, neutrophils 
are the first innate immune cells recruited to the myocardium in large numbers (Dreyer 
WJ et al., 1992). Activation of the complement cascade, ROS generation, and ELR+ CXC 
chemokines have been implicated in recruitment of neutrophils in the infarcted 
myocardium. By generating ROS and through the release of proteolytic enzymes, 
neutrophils infiltrating the infarcted myocardium contribute to the clearance of the infarct 
from dead cells and matrix debris. In addition, neutrophils are capable of secreting pro-
inflammatory mediators that may amplify recruitment of mononuclear cells. Experimental 
evidence, derived primarily through neutrophil depletion strategies, suggested that 
neutrophils may directly injure ischemic, but viable, cardiomyocytes increasing the size of 
the infarct through adhesive interactions involving neutrophil integrin activation and 
cardiomyocyte ICAM-1 expression (Albelda SM et al., 1994). However, the in vivo 
significance of neutrophil-induced cardiomyocyte injury has been challenged by loss-of-
function experiments in genetically targeted mice. ICAM-1 null mice had no significant 
difference in infarct size and scar formation after 1-3 weeks of reperfusion (Metzler B et 
al., 2001). Moreover, animals with a combined deficiency in both ICAM-1 and P-selectin 
and animals with disrupted IL-1 signaling showed no reduction in infarct size following 
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ischemia and reperfusion, despite a marked impairment in neutrophil trafficking (Briaud 
SA et al., 2001). 
Mast cells: In large animals, the heart contains a significant number of resident mast cells 
predominantly located in close proximity to vessels; the population of cardiac mast cells is 
smaller in mice, leading perhaps to underestimation of their role in heart disease when 
murine models of cardiac injury are used (Gersch C et al., 2002). In a canine model of 
experimental infarction, resident cardiac mast cells in the ischemic territory showed rapid 
and impressive degranulation, releasing large amounts of preformed pro-inflammatory 
mediators, including histamine and TNF (Frangogiannis NG et al., (b) 1998). 
 
1.4.1. Fibroblasts 
The role of fibroblasts has been intensively studied in both homeostatic heart and cardiac 
repair. Fibroblasts are the most abundant non-cardiomyocytes in the adult mammalian 
heart and are strategically located in the interstitial and perivascular space. In the 
infarcted heart, resident cardiac fibroblasts undergo inflammatory activation and activate 
the inflammasome platform (Kawaguchi M et al., 2011), thus serving as a source of 
bioactive IL-1. Activated fibroblasts may also secrete chemokines; however, their 
relative contribution to the activation and progression of the post-infarction inflammatory 
reaction remains unknown. After MI, fibroblasts undergo phenotypic changes involved in 
the post-MI inflammatory response and repair. 
Animal models of MI showed that cardiac extracellular matrix (ECM) response to injury 
can be divided to three stages: acute early response, proliferation, and late maturation. 
In rodents, the duration of early response is up to 2 days; the proliferative stage lasts 2–
5 days, and the maturation stage takes up 1 month. In large mammals, this time is 
prolonged for several days (early response), up to two weeks (proliferation), and 1–2 
months and longer (maturation) (Frangogiannis et al., 2008; Dobaczewski et al., (a) 
2010). Each of these stages is distinct but overlapping. In each stage, cardiac fibroblasts 
have a distinct phenotype. The inflammatory early post-MI response stage is 
characterized by acute reaction of innate immunity to massive death of heart muscle 
cells. 
In the proliferative stage, multiple fibroblasts and vascular cells migrate to the injured 
site to heal the damage. Activated fibroblasts transform to myofibroblasts that produce 
ECM proteins and generate the scar. Stimuli that inhibit pro fibrotic/angiogenic responses 
and mediate transition to the maturation stage are incompletely understood. The scar 
maturation is accompanied by apoptosis of cell elements with remaining cross-linked 
collagen matrix that constitute the mature scar (Chen W and Frangogiannis NG, 2013). 
13 
 
During the post-MI repair, the left ventricle is subjected to unfavorable morphological and 
functional changes. After MI, ventricular remodeling leads to the hypertrophy of survived 
myocardium, dilation and increased volume of the chamber (Pfeffer MA and Braunwald E, 
1990). Geometrical alterations are associated with induction of arhythmias and higher 
risk of heart failure and sudden death. The process of ventricular enlargement is mainly 
influenced by the infarct size. The large infarct typically leads to the abnormal 
remodeling. However, other factors also significantly contribute to adverse consequences 
of post MI ventricular remodeling. For example, excessive matrix formation induces 
rigidity of ventricle and diastolic heart failure (Yu CM et al., 2007). Prolonged post-MI 
inflammatory response leads to higher matrix metalloprotease (MMP) activity, impaired 
ventricular remodeling, and worse cardiac dilation (Dobaczewski M et al., (a) 2010). 
Cardiac fibroblasts play the most prominent role in the proliferative stage of heart repair 
but significantly contribute to each phase of healing process. 
Compared to cardiomyocytes, cardiac fibroblasts are significantly less sensitive to acute 
hypoxic conditions induced by MI. Due to their abundant presence in the heart 
interstitium and tight contacts with muscle cells, fibroblasts are among the first cardiac 
cells who sense and respond to heart injury. In cell culture experiments, fibroblasts 
demonstrate inflammatory activation and inflammatory responses (Heim A et al., 2000; 
Lafontant PJ et al., 2006). 
However, the actual impact of fibroblasts to the acute post-injury inflammation is 
hindered by the contribution of other resident non-immune cells such as vascular 
endothelium and mast cells, which are involved in the post-MI inflammatory mechanism 
and can produce a broad spectrum of proinflammatory factors (Frangogiannis NG et al., 
(a) 1998; Ruiz-Villalba A et al., 2015; Rohrbach S et al., 2015). The exact assessment of 
the inflammatory role of fibroblasts is hampered by the lack of specific markers of cardiac 
fibroblasts. Vimentin usually used as a fibroblast marker in cardiac investigations is not 
restricted to fibroblasts since it is expressed by other mesenchymal cells including 
endothelial cells (ECs) and smooth muscle cells (SMCs). -Smooth muscle actin (-SMA) 
employed as a marker of fibroblast transition to cardiomyocytes is abundantly produced 
by SMCs. Fibroblast-specific protein 1 (FSP1) that was suggested as a fibroblast-specific 
marker is widely produced by hematopoietic cells, ECs, and vascular SMCs (Kong P et al., 
2013). However, periostin, a secreted ECM protein, can serve as a specific marker of 
activated fibroblasts because its expression is greatly up-regulated in cardiac fibroblasts 
after MI and is almost absent in the normal heart (Oka T et al., 2007). 
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Activation of cardiac fibroblasts after myocardial injury 
Proinflammatory activation of cardiac fibroblasts is associated with the inflammasome 
induction that leads to caspase stimulation and release of IL-1 (Kawaguchi M et al., 
2011; Sandanger O et al., 2013). Inflammasome activation in cultured fibroblasts is 
induced by ROS-dependent signaling and K+ efflux (Kawaguchi M et al., 2011). Mouse 
myocardial fibroblasts primed in vitro with lipopolysaccharide (LPS), secrete IL-1 and IL-
18 (both are proinflammatory cytokines) in response to ATP (Sandanger  O et al., 2013), 
a danger signal molecule released by fibroblasts after cardiac injury (Lu D et al., 2012). 
Pro-inflammatory activation of cardiac fibroblasts leads to functional changes. In addition 
to the production of proinflammatory mediators (Sandanger O et al., 2013), fibroblasts 
up-regulate matrix-degrading properties through increased release of MMPs (Fan D et al., 
2012). In cultured rat heart fibroblasts, higher gelatinase activity was observed in 
response to oxidative stress and stimulation with IL-1 and TNF (Siwik DA et al., 2000; 
Siwik DA et al., 2001). In cultured cardiac fibroblasts, IL-1 and TNF also differentially 
regulated production of tissue inhibitors of metalloproteinases (TIMPs) and activated a 
desintegrin and metalloproteinase domain-containing protein 10 (ADAM10) (Li J et al., 
1999). Activation of matrix-degrading proteases is essential to facilitate migration of 
leukocytes in the site of injury and promote clearance of dead cells and ECM debris. 
Concomitantly, exposure to inflammatory stimuli led to the inhibition of collagen synthesis 
in cardiac fibroblasts (Siwik DA et al., 2000; Li J et al., 2002). Inflammatory cytokines 
also stimulate induction of the proinflammatory phenotype in fibroblasts and production 
of inflammatory mediators such as CXCL1, CXCL5 (Lafontant PJ et al., 2006), CXCL8 
(Seino Y et al., 1995), and CXCL10 (Zymek P et al., 2007). CXCL1, CXCL5, and CXCL8 
serve as attractants for neutrophils while CXCL10 helps to recruit monocytes. Indeed, in 
response to inflammatory signals, fibroblasts loose the quiescence and show principal 
functional switch from the matrix-producing activity to the matrix-degrading activity along 
with secretion of inflammatory factors and chemoattractants needed for cardiac 
recruitment of leukocytes. IL-1 seems to play a key role in mobilization of cardiac 
fibroblasts after heart injury. After ischemia-reperfusion-induced heart injury, IL-1 
receptor 1-deficient mice had decreased accumulation of neutrophils and macrophages in 
infarcted myocardium and diminished early inflammatory and pro fibrotic responses 
(Saxena A et al., 2013) suggesting for down-regulation of cardiac repair in a case of 
disrupted IL-1-dependent signaling. IL-1 inhibits proliferation of fibroblasts by inducing 
cell cycle arrest during G1/S transition (Palmer JN et al., 1995; Koudssi F et al., 1998). 
IL-1 also prevents fibroblast-myofibroblast transdifferentiation (Saxena A et al., 2013). 
Indeed, IL-1 too early suppresses the induction of a matrix-synthetic contractile 
phenotype in fibroblasts until the injury is cleared from dead cells and matrix. However, 
extended exposure of cardiac fibroblasts to inflammatory cytokines such as IL-1 
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observed in prolonged inflammatory phase of post-MI healing may have worse effects. 
Long-term action of IL-1 on cardiac fibroblasts delays or prevents transition from the 
proinflammatory stage to the proliferative phase of heart repair that may induce adverse 
remodeling and heart failure through reducing heart contractility, promoting 
cardiomyocyte apoptosis, and supporting prolonged production of matrix-degrading 
proteases (Bujak M and Frangogiannis NG, 2009). In contrast to IL-1, TNF may 
indirectly induce the profibrotic activity of fibroblasts through increasing expression of 
type 1 angiotensin II (AT1) receptors (Gurantz D et al., 1999 ; Peng J et al., 2002). 
However, TNF and IL-1have synergistic effect on the type 2 angiotensin II receptor 
through suppression of its activity including inhibition of collagen synthesis in rat cardiac 
fibroblasts (Tamura M et al., 1999 ). Indeed, some inflammatory cytokines that cooperate 
in pro-inflammatory activation of cardiac fibroblasts can demonstrate opposed effects on 
the fibrotic fibroblast activity. 
 
Cardiac fibroblasts during the inflammation resolution 
The acute inflammatory response should be dampened in a timely manner to avoid 
further exacerbation of cardiac inflammation and propagation of heart damage 
(Frangogiannis NG, 2012). Down-regulation of inflammation is triggered by gradual 
activation of anti-inflammatory mechanisms mediated by IL-10 and TGF  along with 
induction of intracellular inhibitors of innate immunity such as interleukin receptor 
associated kinase M (IRAK-M) (Maekawa Y et al., 2009 ; Chen W et al., 2012). IRAK-M 
serves as a functional decoy preventing excessive TLR/IL-1-mediated responses. IRAK-M 
suppresses IL-1-dependent signaling that leads to the prevention of adverse post-MI 
remodeling, down-regulation of in flammatory effects of leukocytes, and inhibition of the 
matrix-degrading activity of fibroblasts (Chen W et al., 2012; Cochain C et al. 2012)  
showed an important role of the chemokine decoy receptor D6 that specifically binds and 
scavenges inflammatory chemokines limiting heart inflammation and avoiding adverse 
cardiac remodeling after MI. The transmembrane receptor CD44 may also be involved in 
the resolution of inflammation and trafficking of fibroblast to the infarcted region. In a 
mouse model of reperfused infarction, CD44 deficiency was associated with extended 
heart inflammation, attenuated collagen deposition and decreased fibroblast 
proliferation/migration (Huebener P et al., 2008). A role of cardiac fibroblasts in the 
resolution of inflammation is poorly understood. It is unclear whether fibroblasts are 
among cell inducers of dampening cardiac inflammation or their role is limited to be 
effector cells. Cell mechanisms that control transition from inflammation to proliferation 
and heart repair should be further studied to identify key molecular modulators 
responsible for this process. 
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The role of fibroblasts in the proliferative stage 
In this stage, fibroblasts acquire the proliferative myofibroblast phenotype due to 
induction of the growth factor signaling that initiates synthesis of contractile and ECM 
proteins and cell mobility. Due to increased synthetic and secreting capacity, 
myofibroblasts develop a large endoplasmic reticulum network (Hinz B et al., 2007). 
Expression of -SMA, non-muscle myosin, and other contractile proteins is a 
characteristic of myofibroblasts. Myofibroblasts do not produce adult smooth muscle-
specific proteins including smooth-muscle isoforms of myosin SM1 and SM2, but 
abundantly express the embryonal isoform of myosin heavy chain (SMemb), a marker of 
dedifferentiated SMCs (Shiojima I et al., 1999; Frangogiannis NG et al., 2000). SMemb 
production may indicate the flexibility of myofibroblast phenotype in injured heart that 
can change depending on the physiological needs. 
In the proliferative repair stage, myofibroblasts occupy the infarct zone as well as the 
infarct border zone. In early stages of differentiation from fibroblasts, myofibroblasts 
form stress fibers from cytoskeletal actin and focal adhesions containing - and -actin 
micro filaments, which link to non-muscle myosin. These cells were called 
‘protomyofibroblasts ’ (Hinz B et al., 2007). 
 
Signaling mechanisms triggering transition of fibroblasts to myofibroblasts 
Transdifferentiation of heart fibroblasts to myofibroblasts is a complex process that is 
induced and mediated by multiple signaling mechanisms that cooperate to each other. 
TGF  is a key regulator of fibrosis (Meng XM et al., 2016). This growth factor induces -
SMA expression in fibroblasts via SMAD3-mediated signaling and by activation of nuclear 
trafficking of myocardin-related transcription factor (MRTF)-A (Bujak M et al., 2007; Small 
EM et al., 2010). MRTF-A is a coactivator of the serum-response transcription factor 
(SRF) that drives -SMA transcription. TGF  stimulates SRF expression in a p38 MAPK-
dependent manner (Penke LR et al., 2014). p38 MAPK signaling plays an important role 
in providing TGF -dependent stimuli through activating many downstream molecular 
substrates that control myofibroblast differentiation (Hashimoto S et al., 2001; Sousa AM 
et al., 2007). ECM mediates conversion of fibroblasts to myofibroblasts. Type I and III 
collagens activate cardiac fibroblast proliferation, while type VI collagen promotes 
myofibroblast differentiation (Naugle JE et al., 2006). Mechanical forces contribute to the 
transition from cardiac fibroblasts to myofibroblasts through several signaling 
mechanisms that involve selective activation of MAPKs (such as p38 MAPK and Erk1/2) 
and Rho kinases (Wang J et al., 2003; Wang J et al., 2005) regulating expression of -
17 
 
SMA and other contractile proteins. Mechanotransuction and TGF  can cooperate in the 
regulation of fibroblast transdifferentiation (Escudé M et al., 2014). Fibroblast-to-
myofibroblast conversion involves many effector pathways, whose activity and interaction 
should be strictly controlled during myocardial repair. Otherwise, extensive matrix-
building activity and proliferation of activated fibroblasts and myofibroblasts can cause 
adverse effects such as cardiac fibrosis and hypertrophy. 
Cardiac fibroblast migration can be induced by growth factors such as TGF  and FGFs 
(Detillieux KA et al., 2003; Stawowy P et al., 2004) and cytokines (IL-1, TNF, 
cardiotrophin-1) (Mitchell MD et al., 2007; Freed D et al., 2011). Stimulation of fibroblasts 
by IL-1 and TNF leads to the activation of MAPKs such as p38 MAPK, Jnk, and Erk1/2 
and subsequent induction of matrix-degrading proteases such as MMP2, MMP3, and 
MMP9. However, in cultured rat primary cardiac fibroblasts, TNF exhibited less 
prominent migration-inducing capacity and up-regulated only MMP-9 production 
compared with IL-1 (Mitchell MD et al., 2007; Brown RD et al., 2007; Xie Z et al., 2004) 
showed that IL-1-induced expression of MMP2 and MMP9 in rat cardiac fibroblasts is 
primed by NF-kB. Erk1/2, Jnk, and PKC/1 are involved in IL-1-induced expression of 
MMP9 not MMP2. Angiotensin II was shown to induce migration of murine heart 
fibroblasts through Erk-dependent stimulation of transcription factors AP-1, NF-kB, and 
Sp1 followed by increased expression of MMP2, MMP7, MMP9, and MMP14 (Siddesha JM 
et al., 2013). Matrix-degrading activity of MMPs is essential for migration of activated 
fibroblasts (Nong Z et al. 2011); reported that, collagen type 1 cleavage is required for 
efficient post-MI tissue repair. Fibroblast locomotion is highly varied depending on the 
local environment. 
When formation of collagen-rich scar is finished, the heart repair goes to the final stage 
in which scar maturates. In this stage, myofibroblasts transit to the quiescent state. This 
mechanism requires action of factors that inhibit proliferation and migration. The 
maturation stage is characterized by matrix cross-linking, decellularization, and vascular 
regression. Gradual depletion of resident myofibroblasts is observed during scar 
maturation. The mechanism of scar maturation is poorly understood. Apoptosis was 
suggested as a major mechanism driving removal of myofibroblasts from the mature scar 
(Takemura G et al., 1998). However, Kisseleva and colleagues (Kisseleva et al., 2012) 
showed that not all myofibroblasts undergo apoptotic death during fibrosis regression in 
the liver repair. 
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1.4.2. Monocytes and macrophages 
Monocyte subpopulations are sequentially recruited in the infarcted myocardium and 
regulate inflammatory and reparative cascades. Infiltrating monocytes are primarily 
derived from the circulating blood; however, the contribution of alternative sources, such 
as the spleen is increasingly recognized (Swirski FK et al., 2009;  Jung K et al., 2013). 
During the first few hours after reperfusion, complement activation and induction of the 
CC chemokine CCL2/monocyte chemoattractant protein (MCP)-1 play an important role in 
recruitment of pro-inflammatory monocytes (Denwald O et al., 2005); these cells exhibit 
potent pro inflammatory and phagocytotic properties. At a later stage, recruitment of 
reparative mononuclear cell subsets may play an important role in activation of 
fibroblasts and ECs, promoting formation of a scar. Understanding of the time course, 
phenotype and mechanism of recruitment of specific monocyte subsets in the healing 
infarct is limited. In response to the dynamic alterations in cytokine and growth factor 
expression in the infarct, infiltrating monocytes undergo phenotypic changes. Maturation 
of monocytes into mature macrophages involves the local upregulation of growth factors, 
such as Macrophage Colony Stimulating Factor (M-CSF) (Frangogiannis NG et al., 2003). 
Considering the remarkable potential of macrophages to acquire unique phenotypic 
characteristics in response to microenvironmental cues, differentiation of several distinct 
subpopulations of macrophages is likely to orchestrate the inflammatory and reparative 
response. Thus, macrophage subsets may play multiple roles in the healing infarct. First, 
they phagocytose dead cells and matrix debris and clear the infarct from apoptotic 
neutrophils and cardiomyocytes. Second, they may serve as a source of cytokines and 
growth factors regulating inflammatory activity, fibroblast growth and activation, and 
neovessel formation and maturation. Third, they may contribute to extracellular matrix 
remodeling by producing MMPs and their inhibitors.  
Recent studies of macrophage activity in various mammalian models of tissue repair and 
regeneration make clear that this cell population includes cells with a range of distinct 
functional phenotypes, with proinflammatory M1 macrophages associated with the first 
phases of acute inflammation gradually being replaced under the control of complex 
environmental stimuli by anti-inflammatory M2 cells (Chazaud B, 2014; Das A et al., 
2015). The emerging M2 macrophages not only promote the resolution of inflammation, 
but also exert many salutary effects on the parenchymal cells of damaged organs, 
promoting recovery of tissue homeostasis, stimulating stem and progenitor cell 
development, and contributing to conditions necessary for tissue repair and regeneration 
(Chazaud B, 2014).  Resolution of inflammation, an active process involving changes in 
the local population of macrophages and in gene expression in other immune cells, must 
occur in a timely manner for a successful regeneration. Macrophages are key players in 
several aspects of inflammation as well as resolution, and their participation is required 
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during the inflammatory response leading to regeneration, likely owing to their 
importance for resolution.  
Cardiac macrophages  
The adult mammalian heart, which lacks regenerative capacity, contains different cardiac 
macrophage subsets, with diverse functions, developmental origins, and mechanisms of 
homeostasis. The four populations, segregated by expression levels of CCR2, Ly6C, and 
MHC class II, perform different functions. Upon injury such as a MI, a biphasic monocyte 
response occurs to promote an initial inflammatory phase followed by a reparative phase 
mediated by Ly6Chi or Ly6Clow splenic monocytes, respectively. The two systems are 
linked by the ability of splenic Ly6Chi monocytes to replenish all four subsets in phase I. 
In the neonatal mouse heart, which can fully regenerate after MI, there is also a biphasic 
splenic monocyte response, although the characterization of subsets of resident cardiac 
macrophages has yet to be investigated. Interestingly, neonatal cardiac macrophages 
differ from those of the adult in their localization, abundance, and gene expression profile 
after injury and are required for regeneration by promoting angiogenesis. The 
regenerative subtype in the neonate has yet to be defined. 
The adult mammalian heart is notoriously resistant to regeneration after injury, due 
primarily to the irreversible withdrawal of postnatal cardiomyocytes from the cell cycle. 
After injury of the adult heart, the inflammatory response and specifically the 
monocyte/macrophage response has a dual function in scar formation. During the later 
phase, Ly6Clow and M2 macrophages are necessary for mediating angiogenesis 
concomitantly with fibrosis to form a scar (Nahrendorf M et al., 2007). In contrast, before 
postnatal day (P) 7, neonatal mice efficiently regenerate up to 20% of the mass of the 
heart after surgical ablation or myocardial infarction (Porrello ER et al., 2011; Porrello ER 
et al., 2013). Recent studies showed that the immune response to cardiac injury differs 
quantitatively and qualitatively during regeneration in comparison to the profibrotic 
response mentioned (Aurora AB et al., 2014). Also, depletion of macrophages in P1 mice 
subjected to myocardial infarction impaired heart regeneration, at least in part, due to a 
lack of neoangiogenesis. Given that the neonatal mouse does not mount a robust fibrotic 
response after ischemic cardiac injury, the data suggest that in mammalian heart 
regeneration, macrophages have the potential to promote angiogenesis without 
activating fibroblasts. The relative distribution in the neonate of the four cardiac 
macrophage populations found in the adult and the potential contribution of each 
population to the process of neonatal heart regeneration and angiogenesis remain to be 
defined. The unique gene expression profile of early neonatal macrophages is of future 
interest for developing therapies that target the immune system to promote angiogenesis 
and tissue regeneration. 
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There are two main subsets of circulating monocytes in mice, Ly6Chi monocytes and 
Ly6Clow monocytes. Ly6C+ monocyte progenitors give rise to Ly6Chi monocytes and, 
through a nuclear receptor subfamily 4 group A member 1 (NR4A1) dependent 
transcriptional programme, LY6Chi monocytes differentiate into Ly6Clow monocytes 
(Yona, S. et al., 2011) Global transcriptional profiling has shown that these monocyte 
subsets are conserved in humans (Ingersoll, M. A. et al. 2010) and they have very 
different roles in vivo. Ly6Clow monocytes adhere to and move along the endothelium, 
both clearing damaged cells and triggering inflammatory responses without entering 
tissue (Carlin, L. M. et al., 2013; Frangogiannis, N. G. et al., 2007). During cardiac stress, 
Ly6Chi monocytes are the primary subset recruited to the heart, either following 
ischaemic injury or hypertensive stress; whereas Ly6Clow monocytes do not seem to be 
directly recruited into the myocardium (Hashimoto, D. et al., 2013; Jakubzick, C. et al., 
2013). Monocytes recruited into ischaemic myocardium are found in the blood, but the 
spleen is also a monocyte reservoir that can be used when blood and bone marrow 
stores are insufficient (Leuschner, F. et al. 2010). Splenic monocytes also seem to have a 
protective role, as splenectomy leads to impaired infarct healing. Monocyte recruitment is 
in part dependent on innate B cells, which are also recruited to the ischaemic 
myocardium, and these B cells drive monocyte population expansion through a CC 
chemokine ligand 7 (CCL7) dependent process (Zouggari, Y. et al., 2013). Once 
monocytes enter the tissue, they begin to differentiate into macrophages. For many 
years, it has been very challenging to separate recruited monocytes from resident 
macrophages and, as a result, they have been analysed as a single population. However, 
these populations have different ontological lineages, and this has important functional 
implications. 
 
Cardiac macrophage subsets 
Recently, studies using genetic fate mapping, parabiosis and adoptive transfer techniques 
have defined resident cardiac macrophage populations in much more detail. Rather than 
being a homogenous population, resident cardiac macrophages comprise three discrete 
subsets that have different origins and functions (Epelman S et al., 2014). These three 
macrophage subsets are defined by their differential expression of MHC class II and CC-
chemokine receptor 2 (CCR2). MHC class IIhi and MHC class IIlow cardiac macrophages are 
both CCR2− and are, numerically, the dominant subsets in the heart (Epelman S et al., 
2014). These macrophage subsets are primarily derived from embryonic progenitors, with 
a substantial number arising from embryonic yolk sac precursors, and they renew 
through in situ proliferation, rather than through monocyte input. After birth, there is 
some dilution of embryonically-derived macrophages by recruited monocyte-derived 
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macrophages in the heart, but in adult mice the majority of resident cardiac macrophages 
remain of embryonic origin (Molawi, K. et al., 2014). The third cardiac macrophage 
subset is made up of CCR2+ macrophages, which are derived from, and slowly 
replenished by, circulating blood monocytes. Detailed studies during hypertensive stress 
suggest that embryonically derived macrophage populations expand solely through in situ 
proliferation, whereas monocyte derived macrophages require monocyte input prior to 
proliferative expansion in the tissue. CCR2+ macrophages express high levels of pro-
inflammatory genes, including those associated with the NLPR3 inflammasome, which is 
required to process and deliver IL-1 to the heart during cardiac stress (Epelman S et al., 
2014). Inflammasome activation promotes adverse cardiac remodeling following 
ischaemic injury, genetic cardiac hypertrophy and hypertensive cardiac disease 
(Bracey NA et al. 2014; Bracey NA et al. 2013); it is likely that CCR2+ cardiac 
macrophages are involved in inflammasome activation in each of these settings. The 
robust pro-inflammatory gene signature of CCR2+ cardiac macrophages suggests that 
they are important for immune protection against invading pathogens, but their 
inappropriate activation in the setting of sterile inflammation may lead to unwanted 
pathology (Dunay, IR et al., 2008; Kim YG et al., 2011). Prior studies have used 
dichotomous expression of two classical myeloid cell markers (F4/80 and CD11b) in order 
to discern embryonic versus adult monocyte origin (Schulz C. et al., 2012). However, 
different cardiac macrophage lineages (embryonic and adult) cannot be distinguished by 
these cell surface markers alone and, as such, genetic fate mapping remains the most 
accurate method for lineage discrimination of cardiac macrophages in adult mice 
(Molawi, K. et al., 2014). 
 
 
 
1.5. Resolution of the inflammatory response and activation of 
fibrogenic and angiogenic pathways 
Optimal tissue repair is dependent on activation of endogenous signals that restrain the 
inflammatory reaction and stimulate reparative cascades. These STOP signals are 
particularly important in the repair of the injured heart. In the myocardium, normal 
function is dependent on optimal preservation of structure; even subtile alterations in 
cardiac morphology may induce severe dysfunction. Thus, in the injured heart 
unrestrained, prolonged or extended inflammatory activity could have catastrophic 
consequences, leading to extensive matrix degradation, adverse dilative remodeling and 
progressive dysfunction. Because myocardial infarction activates several distinct 
inflammatory cascades in all cell types involved in cardiac repair, multiple inhibitory 
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signals may co-operate to restrain and suppress inflammatory signaling. Recent studies 
have identified specific cellular processes and STOP signals involved in negative 
regulation of the post-infarction inflammatory reaction; in their absence, remodeling of 
the infarcted heart is accentuated. 
 
Clearance of apoptotic neutrophils and removal of matrix debris 
Neutrophils participate in resolution of the inflammatory response through their death. 
Neutrophils infiltrating injured tissues are programmed to undergo apoptosis (Haslett C., 
1999); ingestion of apoptotic neutrophils by macrophages exerts potent anti-
inflammatory and immunosuppressive effects (Savill J et  al., 2002), mediated by 
macrophage-derived secretion of TGF , IL-10 and lipid-derived pro-resolving mediators 
(such as lipoxins). Clearance of apoptotic cells by macrophages may function as an 
important endogenous inhibitory mechanism; however, its role in resolution of 
inflammation following MI has not been investigated. Removal of matrix fragments 
generated in the injured heart also appears to play an essential role in restraining the 
post-infarction inflammatory response (Dobaczewski M et al., (a) 2010). Evidence 
suggested that clearance of low molecular weight hyaluronan fragments generates 
important inhibitory signals in the infarcted heart (Huebener P et al., 2008). Recent 
findings indicate that defects in debris clearance can prevent effective regeneration. 
Macrophages, the professional phagocytes of the immune system, mount a polarized, 
biphasic response to tissue injury. Macrophages and the monocytes from which they are 
derived exhibit considerable heterogeneity that is not yet fully understood. After 
conditioning by the inflammatory milieu including local growth factors and cytokines, 
macrophages polarize into classically activated (M1) or alternatively activated (M2) 
subtypes based on their markers, function, and cytokine profiles (Gordon S and Martinez 
FO, 2010). Typically, M1 cells produce high levels of proinflammatory cytokines and nitric 
oxide that aid in host defense but can also damage healthy tissue, while M2 
macrophages mediate wound healing, tissue repair, and the resolution of inflammation. 
However, M1 cells can also play a positive role in tissue regeneration. In the heart and 
skeletal muscle, early infiltration by M1 macrophages facilitates clearance of necrotic 
tissue (Arnold L et al., 2007; Nahrendorf M et al., 2007), and disrupting macrophage 
polarization impairs healing and regeneration, respectively (Perdiguero E  et al., 2011). 
While macrophages influence multiple facets of muscle regeneration, it appears that in 
some instances, debris clearance may supersede their roles in satellite cell proliferation, 
myofiber growth, and endothelial cell activation. For example, HIF-1, the master 
transcriptional regulator of the hypoxia response, is dispensable in satellite cells during 
skeletal muscle regeneration. Surprisingly, myeloid-specific deletion of HIF-1 leads to 
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decreased activation of Cox-2, decreased macrophage phagocytosis, and a subsequent 
delay in skeletal muscle regeneration (Scheerer N et al., 2013). 
 
Regulatory T cells (Tregs) and inhibitory monocytes/macrophages 
Mononuclear cell subpopulations with inhibitory properties are ideally suited as negative 
regulators of the post-infarction inflammatory reaction. The sequential recruitment of 
inflammatory and reparative monocytes in the healing infarct (Nahrendorf M et al., 2007) 
suggests that early activation of MCP-1/CCR2-dependent chemotaxis may be followed by 
late activation of chemotactic pathways that specifically attract inhibitory cells. The 
chemokine/chemokine receptor pairs that may be involved in recruitment of inhibitory 
monocytes remain poorly understood. Differentiated macrophages may also play an 
important role in suppression of the post-infarction inflammatory reaction. In the dynamic 
and complex microenvironment of the infarct, cytokine stimulation may drive 
differentiation of macrophage subpopulations with inhibitory properties that may serve as 
key effectors in negative regulation of the inflammatory reaction. Inhibitory lymphocytes 
are also recruited in the infarcted myocardium and may play an important role in 
restraining the post-infarction inflammatory response. Regulatory T cells (Tregs) infiltrate 
the healing infarct and may suppress macrophage and lymphocyte inflammatory activity 
through contact-dependent interactions and by secreting soluble inhibitory mediators, 
such as IL-10 and TGF . Interactions involving the chemokine receptor CCR5 are crucial 
for recruitment of Tregs in the infarct and play an important role in negative regulation of 
the inflammatory reaction (Dobaczewski M et al., (b) 2010). 
 
Molecular signals involved in suppression and resolution of inflammation 
Suppression and resolution of the post-infarction inflammatory reaction involves 
activation of a complex network of endogenous STOP signals that may co-operate to 
inhibit inflammatory activity in all cell types involved in cardiac repair. Secretion of soluble 
inhibitory mediators (such as IL-10 and TGF ), activation of endogenous cascades that 
inhibit innate immune response, increased expression of decoy receptors and deposition 
of matricellular proteins that modulate inflammatory signaling may play an important role 
in termination and resolution of the post-infarction inflammatory reaction. 
 
IL-10 
IL-10 expression shows a late and prolonged time course in the infarcted myocardium 
and is localized in T cells and in a subset of macrophages (Frangogiannis NG et al., 
24 
 
2000). Associative in vivo studies and in vitro experiments suggested that IL-10 may 
suppress pro-inflammatory cytokine synthesis and may contribute to stabilization of the 
matrix by inducing synthesis of protease inhibitors, such as Tissue Inhibitor of 
Metalloproteinases (TIMP)-1, by macrophages.  Experiments in IL-10 null mice have 
produced contradictory results on the role of IL-10 in negative regulation of the immune 
response following MI. Yang and coworkers suggested that IL-10 -/- mice had markedly 
increased mortality and exhibited an enhanced inflammatory response following 
reperfused MI (Yang Z et al., 2000). In contrast, Zymek P et al. found no effects of IL-10 
disruption on survival of mice undergoing reperfused infarction protocols and showed 
only subtle differences between IL-10 null and wildtype animals (Zymek P et al., 2007). 
Although IL-10 -/- mice had higher peak myocardial TNFand MCP-1 mRNA levels 
following infarction than wildtype animals, both groups had timely repression of pro-
inflammatory cytokine and chemokine mRNA synthesis, exhibited a similar time course of 
resolution of the neutrophil infiltrate and had comparable adverse remodeling (Zymek P 
et al., 2007). Recent findings suggested that IL-10 signaling plays a non-critical role in 
suppression of inflammatory mediators, resolution of the inflammatory response, fibrosis 
and matrix metabolism following MI. 
 
TGF  
The TGF s are pleiotropic cytokines, which are implicated in a wide variety of cell 
functions, critically regulating inflammation, ECM deposition, cell proliferation, 
differentiation and growth. Three structurally similar isoforms of TGF  (TGF 1, 2 and 
3), encoded by three distinct genes, have been identified in mammalian species (Schiller 
M et al., 2004). TGF 1 is the prevalent isoform and is found almost ubiquitously, 
whereas the other isoforms are expressed in a more limited spectrum of cells and tissues. 
Although the three isoforms have similar in vitro properties, their in vivo effects are 
distinct. TGF  is produced by many cell types and is secreted as a latent complex, 
unable to associate with its receptors. Activation of TGF  signaling pathways is primarily 
regulated by release of active TGF from the latent complex that is stored in significant 
amounts in most tissues. 
TGF  may play an important role in suppression of the immune response following 
infarction, orchestrating the transition from inflammation to fibrous tissue deposition. TGF 
 suppresses cytokine and chemokine synthesis by macrophages and ECs, reduces 
adhesion molecule expression and promotes Treg differentiation (Bujak M et al., 2007). 
On the other hand, TGF  activates fibroblasts, inducing transdifferentiation  to 
myofibroblast, stimulating synthesis of extracellular matrix proteins (including collagens, 
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fibronectin, matricellular proteins and proteoglycans) (Bassols A et al.,1988), and 
suppressing matrix degradation by inducing expression of protease inhibitors (such as 
Plasminogen Activator Inhibitor (PAI)-1 and TIMP-1) (Laiho M et al., 1986). In healing 
infarcts, TGF  may serve as a “master switch” that links repression of the inflammatory 
reaction with activation of a fibrogenic program. Unfortunately, the complex biology of 
TGF  activation, its pleiotropic and context dependent actions, and its multiple cellular 
targets have hampered our efforts to understand its role in modulating the immune 
response in the infarcted heart. A crucial role for TGF  in resolution of post-infarction 
inflammation was suggested in inhibition studies through injection of an adenovirus 
harboring soluble TGF  type II receptor in the hindlimb muscles. Late TGF  inhibition 
attenuated left ventricular remodeling by reducing cardiac fibrosis (Okada H et al., 2005); 
however, early TGF inhibition significantly increased mortality and exacerbated left 
ventricular dilation enhancing cytokine synthesis. These findings suggested that TGF  
signaling may play an important role in suppression of inflammatory mediator synthesis 
following MI (Ikeuchi M et al., 2004). TGF  exerts its cellular effects by binding to the 
constitutively active type II receptor (TRII); subsequently the complex 
transphosphorylates the cytoplasmic domain of the type I receptor (TRI). Activation of 
TRI propagates downstream intracellular signals, through the Smad proteins, essential 
components of the TGF  signaling pathway (Shi Y et al., 2003), but also activates Smad-
independent pathways; the Smad3 cascade is responsible for the fibrogenic, but not for 
the anti-inflammatory actions of TGF  in the infarcted myocardium (Bujak M et al., 
2007; Dobaczewski M et al., (c) 2010). 
 
 
Inflammation or innate defensive and reparative response (IRR) 
Inflammation is a tissue/cell response to a noxious agent and/or to a cell damage to 
protect, defend, repair and limit the harm of the organism. Acute inflammation was 
already well known to Hyppocrates and thereafter precisely described by Galeno as an 
acute phenomenon with prevalent vascular involvement. The modern picture is more 
complex and detailed due to the knowledge of pathways and molecular players for its 
local activation, specific tissue reactions, production of effectors, recruitment of distant 
cells, systemic involvement, production of damage, fine tuning regulation, and inhibition 
of progression for resolution and repair. Inflammation and reparative response (IRR) may 
result inadequate (that is ineffective in protecting and repairing), chronic (that is 
prolonged), inopportune (when activated untimely and awkwardly), excessive (when is 
not rightly controlled) during one or all its phases (Strowig, T et al., 2012). In these 
situations IRR is clinically chronic and contributes substantially to host damages, causing 
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multiorgan dysfunctions. In the progression of IRR it is possible to recognize typical signs 
and symptoms such as the accumulation of exudate, fever, leukocyte infiltration, excess 
of ROS production, damage to surrounding tissue, and a continuous fibrotic repair which 
leads to fibrosis and to organ insufficiency (Strowig, T et al., 2012). Inflammation is 
triggered by exogenous damaging agents such as viruses, bacteria, fungi, other 
pathogens and extraneous agents, presenting on their surface characteristic chemical 
pattern (PAMPs), or by endogenous signals (DAMPs) (Bianchi ME, 2007), which are 
usually released by damaged cells (necrosis, membrane shedding, exosomes, apoptosis). 
Collectively PAMPs and DAMPs are also known as alarmins (Iwasaki A and Medzhitov R,  
2004; Marshak-Rothstein A, 2006; Fritz  JH et al., 2006). These pleiomorphic molecules 
activate, with different specificity, a number of receptors belonging to highly conserved 
families with diverse signaling pathways, converging in the activation of NF-kB, AP-1 and 
other TFs which are recognized as the major players in the inflammation, controlling all 
the genes participating to this response (Grivennikov SI et al., 2010). Alarmin receptors 
(ARs) were firstly localized in tissue resident leukocytes (Iwasaki A and Medzhitov R, 
2004), but at present they have been described in many other cells and tissues. In fact, 
there are evidences that ARs can be induced and expressed de novo in resident or 
recruited stem cells and pluripotent undifferentiated progenitors from many tissues, 
under stressing conditions such as acute or chronic hypoxia  and cellular ROS increase 
(Ryan BJ et al., 2014; Reuter S et al., 2010). ARs, after sensing alarmins, generate a 
signal cascade that activates NF-kB (or other TFs), leading to the expression of genes 
belonging to the large families of the IRR, all involved in defence, protection and repair of 
cell and tissues. Another molecular component of the innate response is inflammasome 
constituted by large protein complexes assembled by cytosolic alarmin receptors (NOD-
like receptors or NLRs) activated into the cytosol (Martinon F et al., 2002; Tabas, I et al., 
2013). While surface membrane ARs interact with signals coming from extracellular space 
(of exogenous origin or released by damaged cells), inflammasomes are activated by 
intracellular molecules already present in damaged, stressed or aged cells. Examples of 
these molecules include monosodium urate crystals (gout), cholesterol crystals 
(hypercholesterolemia and atherosclerosis), islet amyloid polypeptide (stored in the 
pancreatic beta cells in type 2 diabetes) (Tabas I et al., 2013), viral and bacterial DNA 
and simpler molecules such as ATP, HMGB1 and membrane phosphatidylserine which 
become available in damaged or dying cells as membrane debris. Activated NLRs respond 
rapidly to different cytosolic PAMPs and DAMPs, recruiting and activating pro-caspase-1 
and other pro-inflammatory caspases (Martinon F et al., 2002). Caspase-1 activates the 
major pro inflammatory cytokines (IL-1 and IL-18) and is also responsible for degradation 
of many target proteins, contributing to cell degradation (Robbins GR et al., 2014). 
Defects in the structure and activity of inflammasomes can be responsible for a large 
number of chronic human diseases, including chronic arthritis, Crohn’s disease, irritable 
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bowel and other inflammatory diseases, diabetes, metabolic syndrome, cancer and 
ageing (Rastrick J and Birrel M, 2014; Walsh JG et al., 2014). Targeting these proteins 
represents an additional new therapeutic strategy for these pathologies (D'Elia RV et al., 
2013).   
 
Effectors and Cytokine Storm 
Inflammation or innate immunity involve signaling pathways leading to the production of 
inflammatory mediators or effectors in a cell-specific manner. Examples are classical 
mediators such as histamine, prostaglandins, leukotrienes, lipoxins, plasmalogens, 
cytokines, chemokines, reactive oxygen intermediates (ROI), reactive nitrogen 
intermediates (RNI), and anti-inflammatory molecules (IL-10, A20, IL-1RA). Sometimes a 
massive production of pro-inflammatory cytokines (cytokine storm) occurs leading to 
multiorgan irreversible damage and shock (D'Elia RV et al., 2013). As a matter of fact, all 
the effectors are a double-edge sword, having from one side an exquisite protective role 
to defeat invaders and limiting the harm of the host, from the other hand, when their 
action is excessive or improper, they can be the driving force responsible for tissue/organ 
damages. During inflammation, a production of numerous ROI, RNI and chlorine species 
occurs, in addition to the products of lipid and sugar oxidation (Mangge H et al.,2014; 
Asghar MN et al., 2014). Most of these products are capable of chemically modifying 
protein amino acids, changing the structure, folding and function of proteins. Increasing 
evidence demonstrates that such oxidative post translational modifications may generate 
neo-epitopes capable of eliciting both innate and adaptive immune responses giving 
origin to autoimmune diseases such as systemic lupus erythematosus, rheumatoid 
arthritis, chronic bowel diseases and others (Ryan BJ et al., 2014; Reuter S et al., 2010). 
Some new epitopes generated by oxidation are conserved along evolution as PAMPs 
(Ryan BJ et al., 2014; Reuter S et al., 2010). 
 
IRR Regulation 
Usually inflammatory response is self-limiting and well controlled, but in the presence of 
improper activation, aberrant amplification, mutated alarmin receptors or 
inflammasomes, inhibited or delayed resolution results in chronic diseases. Much 
attention has been focused on proinflammatory signaling but the precise mechanisms 
leading to the inhibitory control of inflammation is still unclear (Vallabhapurapu S and 
Karin M, 2009). The IkB kinase (IKK) complex contains two catalytic subunits,  and 
IKK, and controls the activation of NF-kB transcription factors, the pivotal 
actor/controller of the inflammation Napetschnig J  et al., 2013). NF-kB activation and 
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activity persistence are tightly controlled by a number of endogenous mechanisms that 
limit the excessive and prolonged production of pro-inflammatory mediators and the 
associated tissue damage (Napetschnig J and Wu H, 2013). NF-kB is a transcription 
factor that controls and modulates the expression of genes involved in both the innate 
and adaptive immune response (Vallabhapurapu S and Karin M, 2009). The regulatory 
ability of NF-kB is controlled by post transcriptional modifications such as phosphorylation 
and complex interactions with other cytosolic and nuclear proteins. Upon activation of the 
NF-kB signaling pathway, IkB kinases target IkBs for degradation. This allows NF-kB to 
translocate and accumulate in the nucleus, where it binds to DNA, resulting in the 
expression of target genes (Tafani M et al., 2013). One of the genes activated by NF-kB 
is that one encoding IkB. Newly synthesized IkB binds to NF-kB and attenuates the 
pathway of response to alarmin receptors, thereby creating a negative feedback loop 
within this signaling pathway. SOCS gene family is another major regulator of IRR once 
activated. Seven SOCS members have been identified but in particular SOCS-1 inhibits 
the cytokine signaling via Janus kinase (JAK) and STAT, efficiently negatively regulating 
NF-kB-directed pro-inflammatory expression. Most of the times, the IRR starts locally at 
the damaged site, and then rapidly eliminate the invading pathogen and/or repair the 
damaged cell and tissues. However, if the local activation is strong and the release of 
mediators (such as eicosanoids and cytokines) is abundant, distant leukocytes and cells 
are recruited, thus amplifying the response at systemic level. The necrosis of damaged 
tissues, such as in hypoxic tumours, contributes to the IRR amplification further 
activating resident leukocytes and recruiting the peripheral ones (Ahmed TJ et al., 2014; 
Pruessmeyer J et al., 2014). In summary IRR is a complex response to a pathogen or to 
a cell damage in which inflammatory cells (chiefly leukocytes and ECs, but also tissue 
cells) are activated and express a specific set of genes named “proinflammatory genes” 
acting to defend against pathogens, protecting and repairing damaged cells. 
Proinflammatory gene expression has been observed also in hypoxic tissue cells, 
especially stem cells and less differentiated progenitors, and appears basically similar to 
that of activated leukocytes. 
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2. Stem cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
The overall clinical cardiac regeneration experience suggests that stem cell therapy can 
be safely performed, but it also underlines the need for reproducible results for their 
effective use in a real-world scenario. One of the significant challenges is the 
identification and selection of the best suited stem cell type for regeneration therapy. 
Bone marrow mononuclear cells, bone marrow-derived mesenchymal stem cells, resident 
or endogenous cardiac stem cells, endothelial progenitor cells and induced pluripotent 
stem cells are some of the stem cell types which have been extensively tested for their 
ability to regenerate the lost myocardium. While most of these cell types are being 
evaluated in clinical trials for their safety and efficacy, results show significant 
heterogeneity in terms of efficacy. 
Preliminary efficacy studies indicate that stem cells have the potential to enhance 
myocardial perfusion and/or contractile performance in patients with heart failure, (a) by 
transdifferentiation into cardiomyocytes or vascular cells and (b) through paracrine 
effects by secreting growth factors which stimulate the repair and growth of host cells 
and the recruitment of endogenous stem cells (Gnecchi M et al., 2008). 
 
 
2.1. Stem cells from different sources in the treatment of 
cardiovascular disease 
For regenerative therapy in the treatment of cardiovascular disease, various cell types 
and stem cells from different sources at different developmental stages, including 
embryonic, foetal, and adult cells, have been considered for transplantation into the 
heart. 
 
Human embryonic stem cells 
Embryonic stem cells (ESCs) have the capacity to divide indefinitely and differentiate into 
any cell type. Although ESCs are incapable of spontaneous differentiation into 
cardiomyocytes, they can be directed to differentiate into cardiomyocytes or cardiac 
progenitor cells using various induction methods (Manuilova ES et al., 2001). One 
established advantage of the use of ESCs is the ability of ESC-derived cardiomyocytes 
(ESC-CMs) to electrically integrate with the heart muscle. In a swine model of an 
atrioventricular block, transplanted human ESC-CMs showed electrical coupling and a 
reversal of the block (Li R et al., 2005). One of the initial technical challenges faced in 
ESC research was the attainment of high purity and a large yield of differentiated cells 
belonging to a single lineage type (Chen A et al., 2014). Various approaches, such as 
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genetic modification, specialised culture methods, and treatment with chemical and 
biological factors, have been used to enrich, purify, and select homogeneous and 
functionally intact populations of ESC-CMs generated from heterogeneous ESCs 
(Bernstein HS, 2012; He W et al., 2012). Recently Chong and colleagues (Chong JJ et al., 
2014) succeeded in generating cardiomyocytes from ESCs on a large scale. These ESC-
CMs were able to successfully engraft and repair the injured myocardium in a primate 
model of MI. These results are encouraging, since only very few cell types have shown 
efficacy in large animals. Importantly, ESCs are pluripotent cells, which give them an 
advantage over other adult stem cell types with limited differentiation potential. Despite 
the evidence of ESCs’ efficacy in larger animal models, their clinical use has been 
hampered by important limitations, including their genetic instability, potential 
tumorigenic and immunogenic properties, and ethical considerations related to the origin 
of these cells (Robertson JA, 2001). In addition, few European nations, for example, have 
strict laws prohibiting ‘destructive embryo research’ , while federal laws in the USA permit 
the use of embryos which have been discarded after in vitro fertilisation (Dhar D et al., 
2009). 
 
Skeletal myoblasts 
Skeletal myoblasts, also referred to as skeletal muscle satellite cells, were one of the few 
cell types first considered for cardiac regeneration (Marelli D et al., 1992). These cells are 
a type of progenitor cell with myogenic capacity, and they are abundantly expressed in 
the human body. Isolated skeletal myoblasts can be made to proliferate and expand in 
vitro. The other advantages of these cells are their ability to contract and their capacity 
to withstand ischaemic insult (Reinecke H et al., 2002; DerSimonian H  et al., 2003). The 
evidence of efficacy in animal models facilitated the use of skeletal myoblasts in clinical 
trials. Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) was the first 
randomised placebo-controlled study of myoblast transplantation. However, this study did 
not demonstrate an incremental improvement in left ventricular function over that 
provided by CABG (Coronary Artery Bypass Grafting) alone (Menasche P et al., 2008). 
Later, multiple experiments were aimed towards trans-differentiating these cells into 
cardiomyocytes, but none of the attempts were successful, suggesting that skeletal 
myoblasts are committed towards a skeletal muscle fate (Reinecke H et al., 2002). 
Moreover, myofibres derived from the transplanted skeletal myoblasts fail to integrate 
electromechanically with the host myocardium due to a lack of adhesion proteins. This 
results in the failure to develop the intercalated discs required for electrical integration 
between adjacent myofibres. The excitement around skeletal myoblasts was further 
reduced when clinical studies reported the occurrence of ventricular arhythmias following 
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transplantation in patients: failure to electrically couple these cells with the existing tissue 
may be a reason for myofibres’ arrhythmogenicity. Genetic modification to introduce the 
expression of connexin 43, a gap junction protein, was considered as a strategy for 
overcoming this limitation (Roell W et al., 2007). However, a later study by Fernandes 
and colleagues (Fernandes S et al., 2009) found that this modification was not sufficient 
to reduce the arrhythmogenic potential of these cells. 
 
 
Bone marrow stem cells 
The first research on stem cells was conducted on bone marrow as early as 1950, which 
found at least two kinds of stem cells within bone marrow: hematopoietic stem cells 
(HSCs) and mesenchymal stem cells (MSCs). The ability of transplanted bone marrow-
derived cells (BMCs) to regenerate the infarcted myocardium was first shown by Orlic and 
colleagues in 2001 (Orlic D et al., 2001). They demonstrated that HSCs marked by the 
surface protein cKit were account able for the trans-differentiation of BMCs into mature 
cardiomyocytes (CMs), smooth muscle cells (SMCs), and ECs in a murine model of MI. In 
support of the above results, injection of isolated cKit+ cells into the peri-infarct regions 
resulted in improved left ventricular function in the infarcted heart (Orlic D et al., 2001). 
However, their claim regarding the ability of HSCs to transdifferentiate into cardiovascular 
cells has been questioned by several other studies (Murry C t al., 2005; Nygren JM et al., 
2004; Balsam LB et al., 2004). Nevertheless, the important outcome was that these cells 
showed a significant improvement in cardiac function after engraftment. Apart from cKit, 
many other cell surface markers have also been identified that define populations 
enriched for freshly isolated human HSCs, including the CD133+ and CD34+ 
hematopoietic cells (Yin AH et al., 1997). Interestingly, cKit+ HSCs have never been 
tested clinically, which is required to truly compare their efficacy with other cell types. 
Similar to the cKit+ cells, CD34+ cells have also been considered for cardiac regeneration. 
CD34+ cells are routinely used clinically to reconstitute the deficient hematopoietic system 
after radiation or chemotherapy (Sidney LE et al., 2014). In addition to being a resident 
population in the bone marrow, these cells were identified in the peripheral blood by 
Körbling and colleagues (Körbling M et al., 2002). Evidence has suggested that 
endothelial progenitor cells (EPCs) and differentiated ECs also express CD34, leading to 
studies testing the angiogenic capacity of bone marrow and peripheral blood-derived 
CD34+ cells. These cells also showed the ability to differentiate into CMs and smooth 
muscle, in addition to ECs, after transplantation into an infarcted heart (Yeh ET et al., 
2003). However, this approach was questioned by Norol and colleagues (Norol F et al., 
2007), who did not find any cardiac phenotype following transplantation of CD34+ cells 
into non-human primates. Despite these controversial findings, most clinical trials to date 
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have used total bone marrow mononuclear cells, which comprise HSCs, MSCs, and 
monocytes (Arnous S et al., 2012). A review by the Cochrane Heart Group summarised 
33 clinical trials (1,765 patients) on the effectiveness of BMCs for cardiac regeneration 
following acute MI and concluded that while no significant improvement was observed in 
the mortality and morbidity of the patients who received BMCs, they demonstrated a 
significant and sustained improvement (12 to 61 months follow-up period) in left 
ventricular ejection fraction (LVEF) was demonstrated (Clifford DM et al., 2012). Further, 
in a recent meta-analysis (23 clinical trials and 1,255 patients) the same group concluded 
that, in addition to the improvement in LVEF, BMCs were also able to improve the 
morbidity and mortality in patients with chronic ischaemic heart disease (IHD) and 
congestive heart failure (Fisher SA et al., 2014). Despite these promising results, debate 
continues about whether the therapeutic potential of BMCs in improving left ventricular 
function might be attributed mostly to their paracrine effects (Uemura R et al., 2006). 
The conclusions from the Cochrane Heart Group were optimistic but caveats included the 
high degree of heterogeneity observed in the results. A recent study utilised weighted 
regression and meta-analysis to compare the results from 49 trials using BMCs for cardiac 
regeneration (Nowbar AN et al., 2014) : this analysis identified 600 discrepancies in 133 
reports from these trials. Interestingly, the trials with the highest number of 
discrepancies also showed the maximum increment in LVEF in patients. The studies that 
failed to show any benefit from BMCs had the lowest number of discrepancies (Nowbar 
AN et al., 2014). With such differing data available from clinical trial results, it is 
extremely difficult to draw conclusions on the efficacy of BMCs (Abbott A, 2014). 
 
Mesenchymal stem cells 
MSCs have been typically considered as the cells with the capacity for self-renewal and 
differentiate into the mesenchymal lineages, including skeletal myoblasts, chondrocytes, 
and adipose tissue (Pittenger MF, 1999). This classical view is now challenged as they 
have been shown to differentiate into neural (non-mesenchymal) tissues as well (Long X 
et al., 2005). The adherent MSC population is shown to express cell surface markers 
CD73, CD105, CD29, CD44, and CD90 and lack CD34 and CD45, which are mainly 
expressed by HSCs (Dominici M et al., 2006). Considering that these cells can be isolated 
from a variety of tissues, including bone marrow, adipose tissue, and cord blood, it 
makes them a more practical option for regenerative therapy. The second advantage 
with MSCs is that they lack major histocompatibility complex II and B7 co-stimulatory 
molecule expression; hence, they are able to evade immune responses and have an 
innate ability to overcome the rejection. This opens the possibility of non autologous 
transplantation in patients (Kuraitis D et al., 2011). MSCs have been shown to 
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differentiate into CMs as well as vascular endothelial cells in vitro. Conversely, 
experimental evidence suggests that when transplanted in vivo, MSCs contribute to neo-
vascularisation and CM protection, mainly through the activation of paracrine factors. 
They may persist within the myocardium in a differentiated state, although substantial 
evidence for their ability to attain cardiac cell phenotype in vivo is still needed (Miyahara 
Y et al., 2006). Currently, clinical trials are being conducted to investigate the therapeutic 
effects of human MSCs in many cardiovascular and neurodegenerative disorders 
(Kalladka D and Miur KW, 2014; Mastri et al., 2014). As previously said, in addition to 
their multilineage differentiation potential, MSCs may exert their regenerative effect via 
the production of multiple paracrine factors (Kalladka D and Miur KW, 2014; Mastri et al., 
2014). Production of IL-6, vascular endothelial growth factor (VEGF), hepatocytes growth 
factor (HGF), brain-derived neurotrophic factors (BDNF), glial-derived neurotrophic factor 
(GDNF), neurotrophin-3 (NT3), fibroblast growth factor (FGF), and thrombospondins can 
be promoted by MSCs. 
Summarizing, MSCs have shown great promise in ischemic tissue repair and have the 
following advantages: 1) No ethical issues, as they are a self-derived bone marrow 
derivative 2) high proliferation rate, and so can be amplified in a short period of time; 3) 
no transplant rejection occurs so no immune-suppressants are required. 
 
Induced pluripotent stem cells 
The cellular differentiation process was once believed to be an irreversible process. In 
2006, however, Takahashi and Yamanaka (Takahashi K and Yamanaka S, 2006) 
successfully induced pluripotency in somatic cells through retroviral transduction of 
several factors involved in the self-renewal of ESCs. The combination of transcriptional 
factors commonly used for cellular reprogramming are Krüppel-like factor 4 (Klf-4), sex 
determining region Y-box 2 (Sox-2), c-Myc or octamer-binding transcription factor 4 
(Oct3/4), Nanog, and Lin-28 (Takahashi K and Yamanaka S, 2006). Since then, several 
studies have demonstrated the wide differentiation potential of induced pluripotent stem 
cells (iPSCs), which includes their ability to differentiate into cell types from any of the 
three germ layers (Lee J-H et al., 2014). iPSCs have been found to differentiate into CMs, 
ECs, and SMCs in vitro. When injected into the infarcted heart of mice, iPSCs can 
differentiate into the cardiac phenotype (Martens A et al., 2012; Yu SP  et al., 2013). One 
of the initial problems with using iPSCs was the poor experimental efficiency in the 
successful induction of pluripotency to somatic cells. The use of genetic factors, chemical 
inhibitors, and signalling molecules that can either replace core reprogramming factors or 
enhance reprogramming efficiency has now been investigated. Recently, Rais and 
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colleagues (Rais Y et al., 2013) found that the Mbd3/NuRD (nucleosome remodelling and 
de-acetylation) repressor complex is the predominant molecular block preventing the 
deterministic induction of ground-state pluripotency, and hence by depleting the Mbd3 
gene, they could successfully synchronise all cells to attain pluripotency. This does 
overcome a chief barrier to the clinical use of iPSCs (Rais Y et al., 2013). Due to their 
ESC-like properties, however, they were also found to be tumorigenic (Riggs JW et al., 
2013). Hence, to overcome the problem of tumorigenesis, Martens and colleagues 
(Martens A et al., 2012) differentiated iPSCs into cardiomyocytes in vitro before 
transplanting them into the infarcted heart. Transplanted cells not only improved the 
cardiac functions, but also localised to the host myocardium (Martens A et al., 2012). 
Further, biosynthetic tissues are also created from cardiac cells derived from iPSCs 
(Christoforou N et al., 2013). Several bioengineering strategies are being explored to 
improve the efficacy of iPSC-derived transplants to improve their engraftment, survival, 
and functionality in tissues (Fisher MB et al., 2013). The in vivo  safety and functionality 
of these cells need to be assured before their clinical translation is considered. 
 
 
2.2.  Stem cell types obtained from the heart 
In spite of the numerous conflicting reports concerning the regenerative capacity of 
myocardium, the majority of researchers agree that there is a profound difference in the 
regenerative capacity of skeletal and cardiac muscles. In the mammalian heart, it is 
generally accepted that adult CMs do not possess the ability to proliferate. Hence, they 
had long been classified as elementi perenni or cells of static cell populations 
(Rumyantsev PP, 1977). Based on this view, the participation of a pool of structurally 
undifferentiated myoblasts or “myogenic stem cells” in cardiac myogenesis had been 
hypothesized many decades ago (Rumery RE and Rieke WO, 1967; Shafiq SA et al., 
1968). Only recently, however, the identity of such a heart specific stem cell pool 
emerged. In 2007, Hsieh and colleagues provided strong evidence that stem cells renew 
adult mammalian CMs (Hsieh PC et al., 2007). Although this study was preceded by the 
discovery and characterization of different cardiac progenitor cell populations, including 
cKit+ cardiac stem cells (CSCs), it provided the first clear evidence for the presence of an 
undifferentiated cell population that directly contributes to myocardial renewal upon 
injury. 
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Evidence for existence of cardiac stem/progenitor cells 
Different groups have shown the presence of different cell populations in the adult heart 
that share some characteristics with stem cells. These cells, called CSCs, would be 
involved in the replacement of senescent or apoptotic cardiac cells, allowing the 
maintenance of cardiac homeostasis. They are self-renewing, clonogenic and multipotent, 
being able to differentiate into CMs, SMCs and ECs under in vitro stimulation. CSCs would 
also contribute to coronary vessels regeneration, in addition to CMs. During ischemic 
processes, several paracrine signals stimulate these CSCs to divide. However, these 
divisions are insufficient to replace the cell loss caused by a MI (Jezierska-Wozniak K et 
al., 2011). In several studies, CSCs have been isolated and expanded from human 
myocardium biopsies, offering a new source of stem cells for cardiovascular regenerative 
medicine (Sanz-Ruiz R et al., 2011). The different populations of CSCs have been 
classified mainly according to the expression of different surface markers. 
 
Identity of resident cardiac stem/progenitor cells 
The cKit+CSCs were originally considered a population apart from other progenitor cells 
as they did not appear to express endothelial or bone marrow progenitor markers, such 
as CD34 or CD45, expressed in hematopoietic stem cells. They were also negative for the 
transcription factors and cytoplasmic proteins found in mature CMs, ECs and SMCs, 
including Isl1 (Leri A et al., 2009). However, other studies have documented the 
presence of different subpopulation of cKit+CSCs, some of them expressing mesenchymal 
and endothelial markers (Bearzi C et al., 2009; Gambini E et al., 2011). 
So far, the best-characterized and well-studied CSC population is the cKit+/Lin- cells. 
cKit+/Lin- cells with properties of CSC were first described in the rat heart by Beltrami et 
al. in 2003 (Beltrami AP et al., 2003). The authors initially found rare cKit+/Lin- cells 
present in the rat myocardium. First described by Yarden et al. in 1987 as a proto-
oncogene (Yarden Y et al., 1987), cKit is a tyrosine kinase receptor expressed at high 
levels in hematopoietic stem cells, multipotent progenitors, common myeloid progenitors 
and less abundantly in other cell types. The ligand for this receptor has been described 
as stem cell factor (a substance that causes certain types of cells to grow), also known as 
steel factor or cKit ligand. The signaling pathways downstream of the cKit receptor are 
essential for regulating proliferation, survival and other vital functions in early 
hematopoietic cells (Edling CE and Hallberg B, 1995). Based on the presence of a stem 
cell marker cKit (Morrison SJ et al., 1997; Weissman IL et al., 2001) and the absence of 
pan leukocyte marker CD45 and endothelial/hematopoietic progenitor marker CD34, it 
was proposed that cKit+/Lin- cells represent a unique stem/progenitor population resident 
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in the heart (Beltrami AP et al., 2003). They were usually present in small clusters, most 
of which contained cells at early stages of cardiac myogenic differentiation, as 
demonstrated by the expression of the transcription factors Gata4, Nkx2.5, and Mef2, 
together with low levels of sarcomeric proteins in the cytoplasm. When isolated and 
grown in culture, cKit+/Lin- cells exhibited extensive self renewal capacity and 
clonogenicity, being able to proliferate for more than 19 months without reaching growth 
arrest or senescence. In addition, when induced to differentiate in vitro, they gave rise to 
CMs, smooth muscle, and ECs, although in vitro differentiated cells were morphologically 
and functionally immature. Furthermore, when injected into an ischemic heart, they 
reconstituted differentiated myocardium with new vessels and myocytes. Since then, 
cKit+/Lin- CSCs have been described in multiple mammalian species, including human 
(Bearzi C et al., 2007; Linke A et al., 2005; Urbanek K et al., 2006). The cKit+/Lin- cardiac 
cell population likely represents a heterogeneous cell population that contains lineage-
committed progenitor cells along with true stem cells. Anversa and colleagues reported 
that cKit+/Lin- cardiac cells included subpopulations that appeared to be more committed 
along the cardiac differentiation (i.e., lineage restricted) based on co-expression of cKit 
and transcription factors of cardiovascular lineages, such as Gata4, Mef2c, Gata-6 , and 
Ets1 (Linke A et al.2005; Urbanek K et al., 2006). Accordingly, a hierarchy among cKit+ 
cardiac cells was proposed, in which cKit+ cardiac cells are further categorized into 
different subpopulations of progenitor cells with variable growth and differentiation 
characteristics (Anversa P et al., (a) 2006). Recently, the same group also identified a 
coronary vascular progenitor cell (VPC) population in the human heart (Bearzi C et al., 
2009). VPCs were found in specialized niches in epicardial coronary arteries, arterioles, 
and capillaries, and characterized by co-expression of cKit and KDR/VEGFR2, an early 
marker of angioblast precursors (Yang L et al., 2008). They also expressed low levels of 
the endothelial cell adhesion molecule CD31 and the smooth muscle cell marker TGF 1 
receptor, while being negative for hematopoietic markers (e.g., CD45 and CD34) and -
sarcomeric actin. Upon differentiation, VPCs preferentially gave rise to the cells of 
vascular lineages (i.e., endothelial and smooth muscle cells) both in vitro and in vivo 
(Bearzi C et al., 2009), indicating that they are more committed to the vascular lineages. 
Collectively, the cKit+/Lin- cardiac cell population may represent several different lineage-
committed progenitor cell populations along with true stem cells. Such finding 
emphasizes the need for more rigorous characterization of the cKit+/Lin- cardiac cell 
population, which is used in both preclinical and clinical settings. It is uncertain if the 
proportions of different progenitors remain relatively constant or vary among individuals, 
especially depending on the disease state or other physiological variables. It will be of 
great interest to study how the changes in cellular composition of the cKit+/Lin- cardiac 
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cell population translate into differences in proliferative and differentiation potentials, and 
ultimately, in the therapeutic efficacy of patient-specific cKit+CSC populations.  
 
Origin of cKit+/Lin- CSCs 
The developmental origin, as well as the origin of adult cKit+/Lin- CSCs have been 
controversial topics. As mentioned above, the initial characterization of adult cKit+/Lin- 
CSCs revealed that they are negative for CD45 and CD34, suggesting that they are not of 
hematopoietic origin (Beltrami AP et al., 2003). Also, the presence of specialized CSC 
niches within the heart argues for their cardiac origin. The CSC niches contain clusters of 
undifferentiated cKit+CSCs and early cardiovascular lineage-committed cells (i.e., cKit and 
Gata4, Mef2c, or Ets1 double-positive cells) (Urbanek K et al., 2006). Moreover, within 
the CSC niche, CSCs and early lineage-committed cells are connected to neighboring 
myocytes and fibroblasts via gap and adherens junctions (Urbanek K et al., 2006). Taken 
together, these observations strongly suggest that CSCs not only reside stably in the 
heart, but are also specifically committed to give rise to multiple cardiac cell types. 
Recently, Ferreira-Martins et al. provided evidence that cKit+CSCs originate from the 
developing heart itself by using transgenic mice that express GFP under the control of the 
cKit promoter (cKit-GFP). The authors utilized two photon microscopy to directly monitor 
in situ the temporal and spatial changes in the GFP+ (i.e., cKit+) putative CSC population 
in the heart of developing cKit-GFP transgenic embryos (Ferreira-Martins J et al., 2012). 
Starting at E6.5, a cluster of cKit+ cells was detected in the cardiogenic mesoderm, and 
by E8.0, cKit+ cells in the heart tube were observed migrating towards the apex. 
Importantly, the authors reported that migration of extra-cardiac GFP+ (i.e., cKit+) into 
the heart was not observed during the window of observation, arguing for the cardiac 
origin of cKit+CSCs. However, it should be noted that rigorous and continuous monitoring 
of GFP+ cells in a developing embryo is technically challenging , and thus the possibility 
that a small number of extra-cardiac (e.g., hematopoietic) stem cells contributing to the 
cardiac cKit+ cell population and to the developing myocardium could not be completely 
ruled out by the study. In contrast, several studies have suggested that cKit+ cardiac cells 
may not represent a stable resident cell population but have an extra-cardiac origin, such 
as bone marrow (BM). This view is, in part, supported by the intriguing observations that 
CMs of non-cardiac origin are detected in patients who have received gender-mismatched 
heart (Quaini F et al., 2002; Muller P et al., 2002), BM (Thiele J et al., 2004; Deb A et al., 
2003), and peripheral blood stem cell (Thiele J et al.,2004) transplants. Fazel and 
colleagues (Fazel S et al., 2006) have shown that cKit+ cells are mobilized from the BM 
and recruited to the heart following MI, and serve cardio-protective functions. 
Interestingly, the majority of them downregulated and no longer expressed CD45. 
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Similarly, others have shown that hematopoietic stem cells are recruited into the 
damaged myocardium and contribute to cardiac repair (Fujita J et al., 2007; Wang Y et 
al., 2006). These studies raised an interesting possibility that the cKit+CSCs may not 
originate from the heart, but from the BM (Segers VF et al., 2008). A recent study tested 
this idea by creating chimeric mice whose BM had been reconstituted, with one 
constitutively expressing GFP (Ellison GM et al., 2013). Using these BM chimeric mice, 
one can easily identify BM-derived cells in different organs based on the GFP expression. 
The chimeric mice were subjected to isoproterenol-induced heart injury, and the 
presence of BM-derived GFP+ cells in the regenerated heart was examined at 28 days of 
recovery. The authors were unable to find any GFP+ cardiomyocytes in the restored 
myocardium, clearly demonstrating that BM-derived cells do not directly contribute to 
myocyte renewal. Interestingly, they also noted that a small fraction of cKit+/CD45- 
cardiac cells was GFP+ (i.e., of BM origin) in both control and isoproterenol-treated hearts 
(Ellison GM et al., 2013). It is not clear, however, if these BM-derived cKit+/CD45- cardiac 
cells eventually acquire the role of resident CSCs and contribute to the maintenance and 
renewal of myocardium. It appears that a genetic fate mapping study is needed to 
resolve the issues surrounding the developmental as well as adult origin(s) of resident 
cKit+ CSCs. Such studies would involve introducing permanent reporter gene expression 
(e.g., LacZ or GFP), specifically in cardiac mesoderm or early cardiac progenitor cells in 
the developing embryo, and tracking the reporter gene expression to the cardiac 
cKit+/CD45- cell population in the adult heart. 
Numerous studies have demonstrated that cKit+/Lin- CSCs isolated and expanded in 
culture exhibit all the properties of bona fide stem cells, and when injected into the 
injured myocardium, they are capable of restoring (to a variable extent) the cardiac 
structure and function in various animal models, as well as in patients suffering from 
ischemic cardiomyopathy (Bolli R et al., 2011; Tang XL et al., 2010). Moreover, CSC 
dysfunction has been implicated in development and progression of cardiac pathologies 
associated with diabetes and anthracycline toxicity (Rota M et al., 2006; De Angelis A et 
al., 2010). However, the precise role of endogenous c-kit+ CSCs in maintenance and 
renewal of the heart has remained poorly understood. 
 
Sca-1+ progenitor cells 
In 2003, Oh et al. (Oh H et al., 2003) reported the isolation of a ‘myocyte depleted’ 
fraction of adult cardiac cells expressing Sca-1 and CD31, but negative for blood cell 
lineage markers (CD34, CD8, B220; Gr-1, Mac-1 and TER119). These cells were also 
positive for cKit, Flt-1, Flk-1, vascular endothelial cadherin, von Willebrand factor and 
hematopoietic stem cell markers CD45. They showed telomerase activity and were able 
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to differentiate into mature CMs when cultured in the presence of 5-azacytidine (Oh H et 
al., 2003). Sca-1 was first reported as a cell surface marker of hematopoietic stem cells 
belonging to the Ly-6 antigen family (van de Rijn M et al., 1989). Recently, many reports 
have demonstrated that multipotent stem cells derived from BM and skeletal muscle also 
express Sca-1. These cells are able to differentiate in vitro into different lineages 
(hepatocytes, CMs, skeletal muscle, neural cells, ECs, adipocytes and myocytes) if they 
are submitted to the appropriate stimuli (Matsuura K et al., 2004). Sca-1 plays a role in 
myoblast differentiation, proliferation, fusion and cell-cycle exit. It appears to 
downregulate muscle cell proliferation, thereby maintaining a pool of functional 
progenitor cells for muscle homeostasis and repair (Holmes C et al., 2007). 
 
Side population cells 
Side population (SP) cells were first described by Goodell et al. as a subpopulation of 
murine bone marrow cells able to block the Hoechst 33342 dye efflux activity (Goodell 
MA et al., 1996). Some years later, the existence of a cardiac SP was reported by Pfister 
et al. (Pfister O et al., 2005). These cells were CD31-/Sca-1+ and they were capable of 
cardiomyogenic differentiation into mature CMs through a process mediated by cellular 
coupling with adult CMs (Pfister O et al., 2005) or in the presence of cardiomyogenic 
agents such as 5-azacytidine (Oh H et al., 2004), oxytocin or trichostatin A (Oyama T et 
al., 2007). This was the first population isolated directly from digested heart tissue. 
Cardiac SP cells are highly enriched for Sca-1, suggesting a possible relationship between 
Sca-1+ cells and SP cells in the heart (Goichberg P et al., 2014). It has also been 
described a Sca+/CD31+ subset in the isolated SP cells that seem to have lower 
cardiogenic potential than Sca+/CD31- cells. In vitro, SP cells can differentiate into CMs, 
SMCs and ECs, and also into glial cells and neurons, suggesting that the origin of these 
cells could be in the neural crest (Tomita Y et al., 2005). More than 93% of adult cardiac 
SP cells are Sca-1+CD45-CD34-, exhibit levels of telomerase expression similar to neonatal 
myocardium and express cardiogenic transcription factors. Moreover, these cells do not 
express cardiac structural genes until stimulated to differentiate in vitro (Holmes C et al., 
2007). However, these cells are relatively rare in the adult tissue, and their ability to 
contribute to the regeneration and functional repair of damaged cardiac muscle remains 
to be determined (Barile L et al., (b) 2007).  
 
Isl1+ progenitor cells 
 Isl1 is a LIM-homeodomain transcription factor that controls cardiomyocyte specification 
and differentiation. Isl1 is a marker of myocardial lineage during mammalian 
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cardiogenesis and identifies a common population of progenitor cells in the heart that can 
differentiate into CMs, SMCs and ECs. Two-thirds of the cells within the entire heart 
originate from Isl1-positive progenitor cells (Fonoudi H et al., 2013). This transcription 
factor promotes postnatal angiogenesis and vasculogenesis by improving the angiogenic 
properties of ECs and MSCs (Barzelay A et al., 2010). Isl1 is a characteristic marker of an 
abundant population in the embryonic heart. Some of these cells remain undifferentiated 
even after the complete heart formation but its number decreases gradually (Leri A, 
2009). In the adult heart, some Isl1+ cardioblasts can be found in atria and ventricles as 
isolated cells. They also express early cardiac differentiation markers such as Nkx2.5 and 
Gata4 but lack mature CMs transcription factors, Sca-1 and cKit (Vanelli A et al., 2011). 
These cells, however, have only been described to date in neonatal specimens, so their 
application for cardiac regeneration may be limited (Barile L et al., (a) 2007). 
 
Cardiospheres and Cardiosphere-derived cells 
In 2004, Messina et al. described a new isolation technique for cardiac resident 
progenitor cells from murine hearts as well as from human atrium and ventricle 
subcultures. After enzymatic digestion of the tissue and seeding in culture flasks, a 
monolayer of adherent cells with fibroblastic morphology grew in the flasks. Some days 
later, some small, round and bright cells started to migrate over this monolayer, being in 
suspension. When these cells were seeded in poly-D-lysine-coated flasks, they gave rise 
to cluster formations that were called cardiospheres  (CS). These cells were clonogenic 
and expressed endothelial progenitors and pluripotency markers, showing the same 
properties of cardiac progenitor cells (CPCs). They were able to self-renew and 
differentiate into cardiac specialized cells as CMs and vascular cells, either in vivo and in 
vitro (Messina E et al., 2004). These CSCs growing as CS represent per se an actual 
cardiac microtissue, where the most differentiated cells are localized in the outer layers, 
while those with a higher differentiation potential and expression of stem cell and 
angiogenesis markers are in the inner core (Gaetani R et al. 2010). Three years after 
their first report, Smith et al. used CS to obtain cardiosphere-derived cells (CDCs) from 
human and porcine tissue. They compared both phenotypes, finding several similarities 
and slight differences (Smith RR et al., 2007). Human CS are cKit+ and CD105+ (one of 
the regulators for the TGF  receptor, important for angiogenesis and hematopoiesis 
processes). CS also show a high expression of connexin 43, a component of the tight 
junctions between cells. CDCs also express connexin 43, which suggests an electric 
coupling potential between these cells as well as between them and cardiac myocytes. 
CDCs are also positive for CD90, CD34 and CD31 and negative for CD133, CD45 and 
blood antigens (Messina E et al., 2004). 
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3. Stem cell therapy 
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Stem cells (SCs) have the potential to restore cellular function in individuals suffering 
from incurable diseases by their capacity to self-renew and to differentiate into one or 
more specialized cell types. Stem cells from various origins have, in addition to their 
regenerative power, the capacity to induce endogenous in situ regeneration/repair. 
Therefore, a paracrine effect is considered as an important therapeutic element in 
addition to the regenerative one. The combined regenerative and paracrine effects are 
therefore two items that should be considered as intrinsic characteristics of any stem cell 
to be translated into valid therapy. 
A majority of the cardiovascular cell therapy clinical trials have used autologous cell 
populations, which obviate immunologic mediated cellular rejection. The mode of delivery 
has been primarily intracoronary, but has also included intramyocardial and endocardial 
routes. Potential side effects associated with cell therapy include arrhythmogenesis, 
tumorigenesis, myocardial injury, infection or immunologic responses.  Nevertheless, 
although these complications are possible, very few side effects have been observed till 
now and cell therapy for cardiovascular disease is relatively safe; it may modulate 
remodeling and may yield a modest improvement in cardiac function. 
 
3.1. Challenges in identifying the best source of stem cells for cardiac 
regeneration 
Before translation of stem cell use from preclinical studies to the clinic, one significant 
challenge is the identification and selection of the best suited stem/progenitor cell types. 
The primary task is to obtain clear evidence on what truly drives the improvement in 
heart function after the administration of stem cells. The mechanism(s) underlying the 
observed functional improvement in the heart remains unclear and is an issue for debate. 
Classically, it is believed that an ideal stem cell should differentiate into CMs that 
integrate both mechanically and electrically with innate myocytes and should be able to 
form blood vessels to boost the blood supply to the scar zone. On the other hand, recent 
studies suggest that paracrine factors secreted by the stem cells may play a more 
important role in the improvement of cardiac function (Chimenti I et al., 2010). This has 
changed the belief that the stem cells must differentiate into cardiac cell types to improve 
cardiac function. Hence, stem cell types which are not multi-potent themselves can still 
improve cardiac function comparable to stem cells committed to cardiac lineages (Urbich 
C et al., 2004). The next step now is to systematically characterise these cells by their 
ability to differentiate into cardiac cell types and their ability to improve cardiac health by 
paracrine mechanisms (Gnecchi M et al., 2008). 
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3.1.1. Practical and technical challenges 
Many of the cell types considered are pluripotent. The stem cells that are committed to 
the myocardial lineage can be selected using different reporter systems linked to the 
endogenous activation and expression of cardiogenic or myogenic genes. For cardiac 
regeneration, it is essential that the selected population of cells shows high cardiogenic 
potential, since the injection of highly proliferative uncommitted pluripotent stem cells 
can lead to carcinogenicity. Due to the large amount of heterogeneity in the number and 
quality of adult stem cells in patient tissue samples, selecting and isolating a pure 
population of cardiac lineage committed stem cells is essential for the safety as well as 
efficacy of stem cell therapy (Kamp TJ, 2011). The number and efficacy of stem cells 
have been shown to change depending on several factors such as age, gender, 
treatments, and pre-existing conditions. Sanada and colleagues (Sanada F et al., 2014). 
reported a marked decline in the cKit+ population with an increase in age. This was 
supported by another study showing a loss of cardio-protective effects in CSCs isolated 
from older patients, which also achieved early senescence during in vitro culture (Avolio E 
et al., 2014). In addition to age, CSCs isolated from patients with pre-existing 
morbidities, such as diabetes and hypertension or end-stage heart disease, also showed 
marked differences in gene expression, cell survival properties, and functional ability 
compared with those isolated from healthy individuals (Itzhaki-Alfia A et al., 2009; 
Seewoodhary J et al., 2013). Similarly, mobilisation of CD34+ cells by granulocyte colony 
stimulating factor (G-CSF) was found to be completely impaired in diabetic patients, 
whereas the levels of CD34+ cells were increased 2.2-fold after mobilisation in non-
diabetics (Fadini GP et al., 2013). However, some important questions remain 
unanswered regarding, for example, the effect of the severity of the disease, the time 
since the acute event, and the duration of pre-existing conditions such as diabetes and 
hypertension on the number and efficacy of stem cells. In addition to these factors, stem 
cells from the same organ source might show functional differences depending on the 
location. For example, CSCs isolated from the atria and the ventricles might have 
differential gene expression and functional efficacies similar to CMs from these two 
regions (Ng SY et al., 2010). Further, gender differences in the aging process of the 
human heart might also occur in terms of differences in CSC quality (Olivetti G et al., 
1995). This evidence suggests the need for more research to develop a personalised 
evaluation protocol in order to identify optimal stem cell sources depending on patient 
need. 
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Challenges in isolation and expansion of stem cells 
The next challenge in translating stem cell therapy from a preclinical to a clinical setting 
is the practicality of its use, such as the ease and efficiency of stem cells isolation and 
expansion. Peripheral blood samples are easy to collect, although the relative expansion 
abilities of the EPCs from the peripheral blood are limited (Itzhaki-Alfia A et al., 2009). In 
contrast, endomyocardial biopsies are difficult to obtain, but CSCs can be isolated and 
expanded from tiny (approximately 5 mg) endomyocardial biopsies (D’Amario D et al., 
2011). Within the heart, CSCs from a particular location may be more effective (CSCs 
from ventricular biopsies) in myocardial regeneration but can be difficult to procure. 
Another tricky task in stem cell therapy is marker-based selection. Selection of the right 
marker for isolation is a critical decision because of the heterogeneity in stem cells such 
as CSCs (Mishra R et al., 2011). In addition, stem cells from the same source can express 
heterogeneous markers. Some stem cell markers represent a ‘moving target’, which 
means that cells retain stem cell-like properties even after losing the expression of these 
markers following subsequent passages in culture. Hence, capturing stem cells based on 
these markers becomes illusive at times (Fadini GP et al., 2008). As above, the severity 
of the disease-associated pre-existing conditions and age also change the expression of 
stem cell surface markers and the overall number of stem cells expressing a particular 
marker. For example, the percentage of cKit+ cells was found to be higher in patients 
with end-stage heart failure compared with patients without end-stage heart failure, 
whereas the number of circulating endothelial progenitor cells was found to decrease 
with age (Scheubel RJ et al., 2003; Ballard VL et al., 2008). The percentage of cKit was 
found to be very low in unfractionated CDCs, while almost 90% of these cells were found 
to be positive for MSC markers (Tateishi K et al., 2007). While the suitability of cKit to 
identify CSCs has been questioned, the above evidence implies that a single marker may 
not be sufficient for identifying an effective cell population (van Berlo JH et al., 2014). 
This is further supported by a study from Li and colleagues (Li TS et al., 2012), who 
demonstrated the superior effect of unsorted CDCs compared with a purified cKit 
subpopulation. Further studies are required to understand the best marker(s). 
In addition to source and marker, isolation technique and culture conditions also offer a 
major challenge in the expansion of stem cells. Studies suggest that differences in the 
intensity of enzymatic digestion may affect the type of cells isolated (Leinonen JV et al., 
2013). Different cell types, growth conditions, passaging methods, and number of cell 
passages also influence the outcomes. Pfister and colleagues attributed the low 
expression of cKit in CDCs to enzymatic cleavage during the digestion process, as 
treatment of cKit+ bone marrow cells with a cardiac digestion regimen resulted in a 
significant reduction in cKit+ cells (Pfister O et al., 2005). One other study showed that 
CD34+ HSCs undergo epigenetic changes involving DNA methylation, which leads to the 
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loss of stemness over subsequent in vitro culture passages (Weidner CI et al., 2013). The 
need for increased numbers of appropriate cells continues to limit the clinical 
development of cell therapy. This has led to a considerable number of studies focussing 
on ex vivo stem cell expansion. Different strategies have been used for the ex vivo 
expansion of stem cells from different sources. A high degree of logistic support may be 
required for the large scale expansion of stem cells. Open system configurations such as 
culture dishes and flasks and closed-systems such as gas-permeable bags, stirred/spinner 
flasks, flatbed perfusion bioreactors, and three dimensional scaffolds have been used for 
culturing and expanding stem cells on a large scale (Madlambayan GJ et al., 2006). 
Amplification of a cell’s proliferation potential is also required. For example, HSCs can be 
expanded ex vivo with the use of specific growth factors and a serum-free media. Some 
of these factors include thrombopoietin, stem cell factor, G-CSF, IL-6, and Fms-related 
tyrosine kinase 3 ligand (Douay L et al., 2001). EPCs are expanded by culturing them on 
fibronectin in the presence of growth factors favouring endothelial cell growth (Peplow PV 
et al., 2014). Fibroblast growth factors have been used for expanding MSCs and CSCs 
(Walenda T et al., 2011). The use of growth factors and favourable culture conditions to 
expand stem cells may also have an effect on their functional properties (Rodrigues M et 
al., 2010). Reports suggest that the use of basic fibroblast growth factor to culture MSCs 
can extend the doublings of these cells up to 80 population doublings (Yanada S et al., 
2006). But as the cells reach senescence, there is a down-regulation of growth factor 
receptors, and hence they may become resistant to the proliferation stimuli (Tran KT et 
al., 2003; Shiraha H et al., 2000). While different combinations of growth factors have 
been used to improve the proliferation and functional efficacy of stem cells, due to the 
effect of cell culture conditions on cell physiology it is difficult to compare and interpret 
the results from these studies (Weidner CI et al., 2013). 
 
Stem cell preconditioning strategies 
“Preconditioning” refers to any pharmacological, environmental or genetic modification of 
the cells for the amplification of their potency. Preconditioning promotes stem cell 
survival and may promote proliferation, differentiation, or its resistance against oxidative 
stress in vitro and in vivo (Mohsin S et al., 2011). While several studies have exclusively 
confirmed the differentiation and proliferative ability of stem cells in in vitro settings, 
these effects are barely seen after transplantation in vivo, with less than 3% of injected 
cells surviving 1 week after transplantation (Malliaras K et al., 2011). To overcome this 
challenge, combinations of molecular approaches, such as chemical and hypoxic 
preconditioning and genetic engineering, have been used in an attempt to boost the 
ability of transplanted cells to withstand the adverse microenvironment, thereby 
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improving their regenerative capacity in vivo (Yu SP et al., 2013). Some of the 
preconditioning techniques include exposing the stem cells to hypoxia, treatment with 
growth factors and anti-aging compounds, irradiation, and modification of the cells using 
microRNAs (Mohsin S et al., 2011). Katare et al. showed that transplanted human 
pericyte progenitor cells repair the infarcted heart through the activation of an angiogenic 
programme involving miR-132 (Katare R et al., 2011). Hence, targeting the expression of 
microRNAs can be a novel possible approach for enhancing the angiogenic potential of 
stem cells. Most of these approaches are aimed at salvaging depleted stem cell function. 
In one of these studies, preconditioning of diabetic MSCs with cardiomyocyte conditioned 
medium markedly improved their efficacy after transplantation into the diabetic heart 
(Khan M et al., 2013). In another study, exposing MSCs to SDF-1 significantly enhanced 
cell survival, proliferation, and engraftment of the transplanted cells into the infarcted 
myocardium via SDF-1/CXCR4 signaling (Pasha Z et al., 2008). Of note, most of the 
autologous transplantations are performed in elderly patients with pre-existing diseases; 
the functional efficacy of stem cells in these cases are often impaired. Hence, a cell 
rejuvenation strategy in the form of preconditioning might be required to salvage the 
therapeutic potential of these cells (Itzhaki-Alfia A et al., 2009). In support of this notion, 
stem cell factor was recently shown to reverse the senescence of cardiac stem cells in the 
aging myocardium (Sanada F et al., 2014). Data from individual studies aimed at 
modulating a single target protein or a set of target proteins within a stem cell are 
inadequate to select the perfect preconditioning strategy. There is thus a need for a high 
throughput screening plan that can be utilised to identify the whole array of pro-survival 
and angiogenic target proteins which can be used as targets for stem cell 
preconditioning. 
Hypoxia and hypoxia adaptation: Hypoxia is a reduction of normal level of tissue oxygen 
tension, occurring for several reasons in some physiological processes such as early 
embryonic growth or stem cell niche maintenance and in a number of pathological 
conditions such as infarction, tumors, diabetes, obesity, pathological hypertrophy, 
neurodegenerative diseases and many others (Eltzschig HK and Carmeliet P, 2011).  
Oxygen tension represents a critical component in the maintenance of the 
stem/progenitor state. In vitro, hypoxic conditions promote proliferation and prevent 
apoptosis of stem/progenitor cells (Studer L et al., 2000) while preserving or enhancing 
their multipotency (Felling RJ et al., 2006; Santilli G et al., 2010).  
Hypoxia has two effects:  
1 -necrosis of cells in the region more distant from tissue vessels. 
2-adaptation of cells in the region along the hypoxic gradient close to the vessels.  
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The O2 shortage causes inhibition of ATP production, rapid fall of the energy charge, and 
loss of ionic gradients with the alteration of cytosolic calcium homeostasis (Schanne FA et 
al., 1979;  Russo MA et al., 1981). The increase of cytosolic Ca++ concentration above  
10-6 M, dramatically activates the peroxidative metabolism (Schanne FA et al., 1979), an 
irreversible contraction and degradation of the cytoskeleton (Russo MA et al., 1981) and 
the activation of Ca++-dependent cytosolic proteases (calpains) and DNA-ases (Smith MA 
and Schnellmann RG, 2012; Nagamalleswari E et al., 2012), all leading to a rapid and 
irreversible cell degradation. Plasmamembrane rupture due to lipoperoxidation is 
responsible for the definitive loss of the ionic gradients and for the release of 
intracellularly segregated molecules, many of which are called alarmins for their ability to 
signal the cell damage to specific receptors on adjacent cells. Adaptation of cells surviving 
to the hypoxia (when they are closer to the vessels) occurs through the activation of HIF-
1 and the expression of a number of genes, such as VEGF, Glut1 and HKII, TERT 
(Semenza GL, 2014), stemness genes and endogenous alarmin receptors, such as RAGE, 
P2X7 (Tafani M et al., (b) 2011), TLRs (Sandholm J et al., 2014), NOD-like receptors 
(Jones HD et al., 2014), etc. . The beneficial effects of these genes can be observed in 
multiple cell or tissue functions and include: vasodilatation and neoangiogenesis to 
increase the local blood supply, metabolic shift from oxidative mitochondrial metabolism 
to anaerobiotic glycolysis, activation of telomerase in stem cells, reprogramming somatic 
cells to stem cells (Tafani M et al., 2014). Importantly, alarmins released by necrotic cells 
(HMGB1, ATP/ADP, membrane debris, nucleic acids, etc.) bind their receptors and 
activate NF-kB with the expression of hundreds of genes of the IRR. Therefore, non 
leukocytic cells in hypoxic tissue microenvironment can present a NF-kB-dependent 
proinflammatory gene response similar to that seen in activated leukocytes. 
Hypoxia increases several secreted factors and their receptors, such as VEGF, C-X-C motif 
chemokine receptor (CXCR) 4, CXCR7, C-X-3C chemokine receptor (CX3CR) 1 and 
hepatocyte growth factor receptor (c-Met), which play a vital role in chemotaxis, viability, 
and homing of  stem cells both in vitro and in vivo (Haque N et al., 2013); 
Stem/progenitor cells cultured in hypoxia might therefore have an increased efficiency for 
migrating to and repairing damaged tissue. 
 
HIF and Oxygen Sensors: Cellular adaptation to hypoxia rely on the transcription factor 
HIF, which is inactive when oxygen is abundant but is activated in hypoxic conditions 
(Semenza GL et al., 2007). Oxygen-dependent hydroxylation of prolyl residues in HIF-1 
or HIF-2 in the HIF heterodimer by prolyl hydroxylaes (PHDs) creates a binding site for 
the von Hippel–Lindau (VHL) gene product, which is a component of the E3 ubiquitin 
ligase complex; the binding of the VHL gene product to HIF-1 (or HIF-2) culminates in 
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the destruction of the  subunit in proteasomes (Kaelin WG, 2007) . In addition, 
hydroxylation of asparagyl residues in HIF-1 (or HIF-2) by factor-inhibiting HIF — an 
oxygen dependent asparagyl hydroxylase — reduces the transcriptional activity of HIF 
(Coleman ML and Ratcliffe PJ, 2009) The functions of both hydroxylases (PHDs and 
factor-inhibiting HIF) depend on oxygen. (Semenza GL et al., 2007; Kaelin WG Jr and 
Ratcliffe PJ, 2008) . Germline mutations in the PHD2 gene have been found in association 
with familial erythrocytosis and with a syndrome of familial erythrocytosis with 
paraganglioma (Ladroue C et al., 2008); inactivating mutations of both copies of the VHL 
gene cause Von Hippel–Lindau disease (which is characterized by hemangioblastomas, 
clear-cell renal carcinomas, and pheochromocytomas) (Kaelin WG, 2007). HIF can be 
activated under normoxic conditions, which allows the initiation of an inflammatory 
response before tissues become hypoxic. Examples of this mechanism are the increase in 
HIF-1 transcription by bacterial lipopolysaccharide (Blouin CC et al., 2004) and the 
stabilization of HIF-1 when ROS and reduced cellular iron inhibit PHD (Cash TP et al., 
2007; Knowles HJ et al., 2006). The phenotype of mice with HIF-1 deficiency differs 
from that one of mice with HIF-2 deficiency, which implies that these components of 
the HIF transcription-factor polypeptides have different target genes (Fraisl P et al., 
2009). The HIF-2 gene in certain forms of familial erythrocytosis has a gain-of-function 
mutation, which probably causes normoxic stabilization of the HIF-2 protein (Percy MJ 
et al., 2008).  
HIF-1 activity is induced by hypoxia through changes in HIF-1 mRNA and protein 
levels in brain, heart, kidney, lung and skeletal muscle. The regulation of HIF-1 mRNA 
levels is not well understood because it is not observed in most cell lines, whereas O2-
dependent prolyl hydroxylation  and asparaginyl hydroxylation of HIF-1 negatively 
regulate its protein stability and transcriptional activity, respectively  (Kaelin WG Jr and 
Ratcliffe PJ, 2008). HIF-1 activates gene transcription by binding to the core DNA 
sequence 5’-RCGTG-3’ (R = A or G), which is embedded within a hypoxia response 
element (HRE) (Semenza GL et al., 1996). HIF-1 directly regulates the expression of 
more than 1.000 human genes. Whereas the expression of a subset  of HIF-1 target 
genes is induced by hypoxia in most or all cell types, the vast majority of these genes are 
induced by hypoxia in a cell type-specific manner. 
Among the HIF-1 target genes are those encoding secreted factors and cell surface 
receptors that control O2 delivery by regulating angiogenesis and vascular remodeling. 
HIF-1 functions as a master regulator in this process because it coordinately regulates 
the expression of a large number of genes whose protein products play critical roles in 
mediating vascular responses to hypoxia and ischemia. In addition to promoting O2 
delivery, HIF-1 also activates the transcription of genes encoding enzymes, 
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transporters, and  mitochondrial proteins that decrease O2 utilization, again functioning 
as a master regulator to switch cells from oxidative metabolism to glycolitic metabolism. 
Ischemia refers to the state in which perfusion in not adequate to supply adequate O2 
and nutrients or to remove toxic metabolites. HIF-1 activity activates transcription of 
genes encoding angiogenic factors. These factors stimulate the remodeling of collateral 
blood vessels, leading to increased blood flow. HIF-1 coordinately activates the 
transcription of genes encoding glucose transporters and  glycolitic enzymes. Increased 
glycolytic flux allows cells to maintain ATP levels under hypoxic conditions. HIF-1 also 
inhibits mitochondrial oxidative metabolism, thereby reducing the generation of ROS 
under conditions of hypoxia or hypoxia-reoxygenations, by multiple strategies. Such 
strategies include: 1) a regulatory subunit switch in cytochrome c oxidase, in which 
COX4-1 is degradated by LON protease and replaced by COX4-2 (Fukuda R et al., 2007); 
2) induction of lactate dehydrogenase A, which converts pyruvate to lactate (Semenza GL 
et al., 1996), 3) induction of pyruvate dehydrogenase kinase 1 (PDK1) or PDK3, which 
inactivates pyruvate dehydrogenase and thereby shunts pyruvate away from the 
mitochondria (Kim JW et al., 2006); 4) induction of miR-210, which inhibits the 
expression of ISCU, an iron-sulfur cluster assembly factor that is required for activity of 
aconitase and electrone transport complex I (Favaro E et al., 2010), 5) induction of 
BNIP3 and BNIP3L, which trigger mitochondria-selective autophagy (Zhang H et al., 
2008). 
Hypoxia Signaling and NF-κB: Members of the nuclear factor κB (NF-κB) family of 
transcription factors regulate inflammation and orchestrate immune responses and tissue 
homeostasis (Naugler WE et al., 2008; Vallabhapurapu S and Karin M, 2009;  Pasparakis 
M, 2008). Members of this family interact with members of the PHD–HIF pathway in 
ways that link inflammation to hypoxia (Taylor CT, 2008). Additional interactions between 
hypoxia and inflammation are seen in the IκB kinase complex, a regulatory component of 
NF-κB (Cummins EP et al., 2006) and in the regulation of HIF-1 transcription by NF-κB 
before and during inflammation (Bonello S et al., 2007; Rius J et al., 2008). Hypoxia 
amplifies the NF-κB pathway by increasing the expression and signaling of TLRs, which 
enhance the production of antimicrobial factors and stimulate phagocytosis, leukocyte 
recruitment, and adaptive immunity (Kuhlicke J et al., 2007). 
 
3.1.2. Stem cell delivery to the patient 
Finally, when it comes to the delivery of stem cells to a patient, three important factors 
need to be considered: first is the type and nature of the injury, second the timing of the 
therapy, and third the ability of the cells to engraft to the host myocardium. The decision 
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to select a particular cell type should be influenced mainly by the nature of the injury. For 
example, in cases of chronic ischaemia with a functional myocardium, the purpose is to 
rescue the non-necrotic ischaemic myocardium and improve the blood supply to it. 
Hence, it is desirable to use a cell type that secretes pro-angiogenic factors, such as 
BMCs, or cells that induce vascular regeneration, such as EPCs. On the other hand, if the 
goal is to regenerate an infarcted myocardium with severe loss of functional myocardial 
tissue, it would be more suitable to use a progenitor cell type, such as CSCs with 
cardiomyogenic and vasculogenic capability, or consider the delivery of functional ESC-
CMs or iPSC-derived cardiomyocytes (Timmers L et al., 2008).  
As in other cases, a huge dilemma still remains regarding the best time for stem cell 
delivery to patients. A comparison of two large clinical trials (LateTIME and Reinfusion of 
Enriched Progenitor Cells and Infarct Remodelling in Acute Myocardial Infarction 
(REPAIR-AMI)) in which patients underwent intracoronary infusion of BMCs either 3 to 5 
days (REPAIR-AMI) or 2 to 3 weeks (LateTIME) after an acute event showed significant 
enhancement of LVEF only in patients who received BMCs within 5 days after the acute 
event (Mills JS and Rao SV, 2007; Traverse JH et al., 2011). This suggests that cell 
therapy may be efficacious only if administered early after acute MI, which is impossible 
in the case of autologous transplantation using CSCs. However, the SCIPIO and 
CADUCEUS trials have demonstrated benefits in patients even when cell therapy was 
initiated 4 months and 2 to 4 weeks, respectively, after an acute event, although it is not 
clear if this benefit overweighs the benefit of the REPAIR-AMI trial (Chugh AR et al., 
2012; Makkar RR et al., 2012). The researchers who designed the SCIPIO trial argue that 
cell therapy was initiated after 4 months to separate the effects of CSCs from those of 
surgical revascularisation immediately after therapy, as in many patients LVEF is known 
to improve spontaneously during the first few months after coronary artery bypass graft 
(CABG) surgery (Shivalkar B et al., 1996). However, due to the lack of immune reactions 
with CSCs, they can be embraced as an off-the shelf product if future studies confirm 
that an early time point could be ideal for stem cell  transplantation (Torella D et al., 
2005). In addition to choosing the best stem cell type and the best timing for the 
treatment, the most important factor after transplantation is the ability of the cells to 
engraft into the host myocardium. Several studies have reported that cellular 
engraftment after transplantation into damaged tissues is inadequate and that 
transplanted cells are susceptible to the hostile ischaemic environment and tend to 
disappear within a few days (Cho HJ et al.,  2012). Several ongoing research studies 
have used different methods to precondition stem cells prior to transplantation in order to 
increase their potential to withstand the adverse microenvironment following 
transplantation, with the aim of improving their engraftment and survival. Direct cell 
delivery into the myocardium has been shown to have disadvantages in terms of meagre 
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cell engraftment and poor mechano-electrical coupling. Cardiac regeneration approaches 
are evolving from cell therapy to advanced tissue engineering. Cardiac tissue engineering 
is an alternative strategy in which cell transplantation is accompanied by the support of 
biomaterials (called scaffolds) and regulatory factors (for example, growth factors) (Le 
Huu A et al., 2013). The in vitro engineering of beating cardiomyocyte containing tissue 
constructs and the engineering of stem cell-containing tissue constructs are the two 
strategies currently used for cell implantation. The cardiac tissue constructs are formed 
by seeding cardiomyocytes in three-dimensional scaffolds and culturing under 
appropriate conditions to develop cell alignment, electrical communication, and 
spontaneous beating in vitro (Zimmermann WH et al., 2002). Apart from using the tissue 
constructs of beating cardiomyocytes, engineered stem cell sheets are also an attractive 
choice for therapeutic delivery, owing to their paracrine effects and plasticity (Narita T et 
al., 2013). In the future, these bio-engineered cardiac patches or cell sheets may become 
the preferred approach for delivering stem cells into the diseased heart (Zhang G et al., 
2008). 
 
3.1.3. Survival and retention of CSCs following transplantation 
A number of studies have reported that stem cells of various sources suffer low viability, 
and only few persist several weeks following transplantation into the injured myocardium 
(Tang YL et al.,2005; Laflamme MA et al., 2005; Reinecke H et al., 1999; Toma C et al., 
2002; Robey TE et al., 2008). Similarly, one of the problems with the current therapy 
with cKit+CSCs is the poor survival and retention of the injected cells in the heart (Li Q et 
al., 2011). It is thought that myocardial ischemia/reperfusion and infarction create a 
hostile environment for stem cells, because of the presence of inflammatory cells and 
cytokines/mediators, lack of ECM and supporting cells, and poor supply of oxygen and 
nutrients, all of which conspire to promote death of the grafted cells (Forrester JS et al., 
2007; Penn MS et al., 2008). For this reason, increasing survival and retention of the 
transplanted CSCs in the heart currently constitutes one of the major challenges in the 
field of CSC therapy. Troubleshooting this issue would require close and accurate 
monitoring of the number, distribution, and fate of the transplanted donor cells, and 
correlation of these variables with changes in functional parameters. 
Several studies have tested different strategies to overcome the problem of poor survival 
or retention of the cells in the hostile environment of the infarcted heart. For example, 
Mohsin and colleagues tested the effect of ex vivo gene delivery of a pro-survival gene, 
Pim-1 kinase on survival/engraftment and reparative potential of human CSCs using a 
mouse model of ischemic cardiomyopathy (Mohsin S et al., 2012). The same group had 
previously identified Pim-1 as a kinase responsible for cardioprotection downstream of 
53 
 
pro-survival Akt signaling (Muraski JA et al., 2007; Wang Z et al., 2001). Human CSCs 
engineered to overexpress Pim-1 were superior over the control cells in terms of cellular 
engraftment and differentiation. Bioluminescence imaging analysis of luciferase-
expressing donor cells (Wu JC et al., 2003) showed that the presence of Pim-1 CSCs 
persisted up to 8 weeks post transplantation, whereas control cells became undetectable 
by 1 week. Moreover, the persistence of cells in the recipient heart was accompanied by 
improvement in vasculature and reduction in infarct size, which were coupled with 
increased hemodynamic performance at 20 weeks post-transplantation (Mohsin S et al., 
2012). Interestingly, a subsequent report by the same group showed that the increases 
in proliferation and telomere lengths observed in Pim-1-expressing CSCs are only 
transient, suggesting that Pim-1 overexpression does not lead to immortalization or 
oncogenic transformation of CSCs (Cottage CT et al., 2012). The results are promising 
and indicate that ex vivo delivery of a pro-survival gene prior to transplantation may 
serve a viable option in overcoming current limitations in the field. Such strategy also has 
proven fruitful in terms of promoting survival and therapeutic efficacy of other stem cell 
sources, including MSCs (Xu M et al., 2012; Huang W et al., 2012). One of the first 
attempts to improve post-transplantation donor MSC survival was reported by Mangi and 
colleagues (Mangi AA et al., 2003). They genetically engineered rat MSCs ex vivo using 
retroviral transduction to overexpress the pro-survival gene Akt1 (Datta SR et al., 1999; 
Fujio Y et al., 2000). At 24h following intramyocardial injection of MSCs into the rat MI 
heart, they observed a greater number of donor cells and a lower rate of apoptosis with 
MSCs overexpressing Akt (Akt-MSC) compared to the control GFP-expressing MSCs 
(Mangi AA et al., 2003). Subsequently, transplantation of MSCs into the ischemic heart 
significantly reduced intramyocardial inflammation, fibrosis and myocyte hypertrophy, 
and normalized cardiac function. The study reported that Akt-MSCs restored fourfold 
greater myocardial volume compared to the control MSCs. Another study tested the utility 
of stably introducing heme oxygenase-1 (HO-1) expression in MSCs (Laflamme MA et al., 
2005). HO-1 is known to exert a potent anti-apoptotic, anti-oxidant and cytoprotective 
activity in an ischemic environment (Melo LG et al., 2002; Vulapalli SR et al., 2002). 
When they injected HO-1-MSCs into acute MI heart, their survival was fivefold greater 
than that of the control MSC group (expressing lacZ) at 7 days of implantation, and this 
was consistent with a significantly reduced rate of apoptosis among HO-1-MSCs. 
Importantly, HO-1 MSCs were also superior over the control cells in attenuating left 
ventricular remodeling and enhancing the functional recovery of injured hearts. Similarly, 
the pro-survival or cardio-protective effects of various candidate genes, including GATA4 
(Xu M et al., 2012), heat shock protein 27 (McGinley LM et al., 2013), miRNA-1, and 
protein kinase G1 (Wang L et al., 2013), have been recently exploited to promote 
survival and efficacy of MSCs in the context of hypoxia-reoxygenation injury.  
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Pharmacologic activation of innate cytoprotective mechanisms seems to be another 
attractive option to enhance the survival and engraftment of CSCs. In a recent study, Cai 
et al. showed that treatment of human cKit+CSCs with cobalt protoporphyrin (CoPP), a 
well known HO-1 inducer (Shan Y et al., 2000), promoted cell survival after increased 
oxidative stress in vitro (Cai C et al., 2012). The cytoprotective effects of CoPP were 
dependent on the upregulation of HO-1, cyclooxygenase-2 (COX-2), and nuclear factor-
like 2 (NRF2). Interestingly, preconditioning CSCs with CoPP also led to a global increase 
in release of a variety of cytokines, and the conditioned medium from cells pretreated 
with CoPP conferred naive CSCs remarkable resistance to apoptosis, demonstrating that 
cytokines released by preconditioned cells also play a major role in the pro-survival 
effects of CoPP (Cai C et al., 2012). Another study by Zafir and colleagues examined the 
role of protein O-GlcNAcylation (-O-linkage of N-acetylglucosamine, O-GlcNAc), a 
universal cytoprotective pathway (Ngoh GA et al., 2010) in the protection of mouse CSCs 
against hypoxia-reoxygenation injury (Zafir A et al., 2013). Protein O-GlcNAcylation was 
significantly elevated in post-hypoxic CSCs upon reoxygenation. Reduction in the O-
GlcNAc signal via pharmacological inhibition sensitized CSCs to post-hypoxic injury, 
whereas increasing O-GlcNAc levels enhanced cell survival. The study has an important 
implication because pharmacologic augmentation of protein O-GlcNAc levels can be 
effective in priming CSCs for survival within the unfavorable environment of the infarcted 
myocardium. 
Likewise, preconditioning of cells prior to transplantation or co-treatment with different 
agents has been shown to be a successful strategy for reinforcing viability and 
therapeutic efficacy of the donor MSCs (Ye L et al., 2013; Iso Y et al., 2013; Herrmann JL 
et al., 2010; Penna C et al., 2013; Pendergrass KD et al., 2013). Preconditioning or 
priming the stem cells with pharmacological agents prior to autologous transfer is likely 
to be clinically viable, because it is relatively easy to implement and does not involve 
direct genetic manipulation of the cells. Undoubtedly, identification of important 
cytoprotective mechanisms within CSCs and potential pro-survival candidate genes will be 
critical in developing novel strategies for augmenting post-transplantation survival and 
engraftment of donor CSCs. 
 
Lack of robust, direct differentiation of transplanted CSCs 
Although a variety of stem cell populations, including cKit+CSCs, have been shown to play 
regenerative and/or protective functions following transplantation in animal models of 
acute and chronic MI, it has been widely accepted that therapeutic benefits of stem cell 
therapy are mainly contributed by paracrine factors secreted by the donor cells, rather 
than by direct differentiation of transplanted stem cells into cardiac cell types (Gnecchi M 
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et al., 2011; Mirotsou M et al., 2011). Regardless of the cause, there is a disconnection 
between functional benefits of CSC therapy and the lack of robust differentiation of 
transplanted cells. Based on this, one can argue that the contribution of direct 
cardiovascular differentiation of the donor stem cells to the salutary effects is negligible. 
However, previous studies on transplantation of non-cardiac stem cells suggests that 
direct cardiac differentiation of the donor stem cells is essential for the functional benefits 
they provide. Yoon and colleagues investigated the contribution of cardiovascular 
differentiation of BM-derived mononuclear cells (BMMNCs) to the renewal of myocardium 
following acute MI by using a system in which the differentiated progenies of the donor 
cells can be selectively ablated in a temporally controlled manner (Yoon CH et al., 2010). 
They engineered the donor cells to express a vector that encoded a prodrug-activated 
suicide gene (herpes simplex virus thymidine kinase; HSV tk) under the control of 
endothelium (eNOS)-, smooth muscle (SM22)-, or cardiomyocyte (-MHC)-specific 
promoters, which permitted selective depletion of the individual cardiac lineage acquired 
by the donor cells via administration of a prodrug, ganciclovir. When each donor cell-
derived lineage was ablated two weeks after transplantation of the engineered BMMNCs, 
they found that depletion of endothelium-committed or smooth-muscle–committed cells, 
but not cardiomyocyte-committed cells, induced a significant decline in ejection fraction 
(EF) (Yoon CH et al., 2010). This demonstrated that vascular differentiation is one of the 
essential mechanisms by which BMMNCs contribute to the functional recovery of the 
injured heart. Another study by Behfar et al. also suggested that cardiogenic potential of 
the donor BM-derived MSC population dictates the functional outcome of stem cell 
therapy (Behfar A et al., 2010). While the majority of patient-derived MSC failed to elicit 
significant improvements in EF (ejection fraction), stem cells from few individuals 
harbored a spontaneous capacity to improve cardiac performance in an animal model of 
chronic ischemic cardiomyopathy. Interestingly, the stem cells exhibiting the reparative 
activity expressed relatively high basal levels of early (e.g., NKX-2.5, TBX5, and MESP1) 
and late (e.g., MEF2C) cardiac transcription factors, compared to the non-effective MSC 
counterparts. Based on this observation, the authors formulated a “cardiogenic cocktail” 
(containing TGF 1, BMP-4, activin A, retinoic acid, IGF-1, FGF-2, -thrombin, and IL-6) 
to stimulate cardiogenic potential/differentiation of naïve MSCs prior to transplantation. 
This strategy not only potentiated expression of cardiac transcription factors across 
different patient MSC populations, but also enhanced therapeutic efficacy of MSCs against 
chronic ischemic cardiomyopathy in mice (Behfar A et al., 2010). The study provides an 
interesting implication that enhancing differentiation potential or properties of donor stem 
cells is feasible, and is an effective strategy to further improve the efficacy of stem cell 
therapy. 
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The paracrine hypothesis 
Stem cell therapy for tissue repair and regeneration holds great therapeutic potential 
(Hodgkinson  CP et al., 2010). It has been shown that injection of adult stem cells into 
the injured heart has beneficial effects. Originally it was thought that these stem cells 
engrafted into the damaged tissue and differentiated into cardiomyocytes, vascular or 
other cells (Asahara T et al., 1997; Orlic D et al., 2001). However, it has been shown that 
after injection, adult stem cells had poor survivability (Gnecchi M et al., 2008). Moreover, 
it has not been possible to reproduce the earlier studies which showed that bone 
marrow-derived stem cells differentiate into cardiac cells. Using a GFP mouse, Balsam et 
al. (Balsam LB et al., 2004) could not find any evidence that bone marrow-derived 
hematopoietic lineage negative/cKit positive cells differentiated into CMs when injected 
into infarcted myocardium. Instead, these cells adopted a typical hematopoietic fate. 
These findings, and others, have called into question the plasticity of bone marrow-
derived stem cells and their direct role in tissue regeneration. On the basis of above 
studies, it is now clear that although engraftment can result in improved cardiac function 
(Hatzistergos KE et al.,2010), the small number of adult stem cells engrafted cannot 
directly generate sufficient cardiomyocytes to account for the therapeutic benefits 
observed. Recent evidence suggests the importance of the paracrine mechanism of stem 
cell action. These observations have led to the proposal that adult stem cells exert their 
therapeutic benefits via the release of biologically active proteins, or paracrine factors, 
acting on resident cells. Indeed, there is now a large body of evidence supporting the 
hypothesis that paracrine factors are essential for the reparative effects of adult stem 
cells after delivery into the injured heart. Adult stem cells secrete a wide variety of 
growth factors and chemokines that can promote cardiac repair. Elevated levels of 
proteins such as vascular endothelial growth factor (VEGF), basic fibroblast factor (FGF), 
hepatocyte growth factor (HGF), and insulin-like growth factor-1 (IGF-1) are found in the 
heart after injection of adult stem cells (Yoon YS et al., 2005). 
It has been demonstrated that paracrine factors promote cardiac regeneration through 
several mechanisms, including cardiomyocyte proliferation, cytoprotection, differentiation 
of resident stem cells, neovascularisation, and by limiting inflammatory and profibrotic 
processes. 
It has been shown that cell culture medium conditioned by hypoxic MSCs reduces rat 
cardiomyocyte apoptosis and necrosis when exposed to conditions that promote cell 
death (Gnecchi M et al., 2005). These studies validate that MSCs promote cardiomyocyte 
survival via paracrine factors and that Akt is crucial for this process (Gnecchi M et al., 
2006). Takahashi et al. (Takahashi M et al., 2006) showed that rat BMMNCs release 
proteins such as VEGF, platelet-derived growth factor, IGF-1, and IL-1, some of which 
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were significantly enhanced by hypoxia. The conditioned media of bone marrow 
mononuclear cells strongly inhibited cardiomyocytes apoptosis and preserved their 
contractile capacity. Moreover, Uemura et al. (Uemura et al., 2006) demonstrated that 
bone marrow stromal cells, which showed upregulation of Akt after brief anoxia, 
prevented cardiomyocytes apoptosis in a cocultured model. This study went on to show 
that bone marrow stromal cells markedly inhibited LV remodeling after MI. 
Adult stem cells when injected into myocardium dampen the inflammatory state 
associated with injury by downregulating expression of proinflammatory cytokines such 
as TNF, IL-1, IL-6, and monocyte chemoattractant protein-1 (Ohnishi S et al., (a) 
2007). These effects have a paracrine component; conditioned media prepared from 
cultured MSCs was found to inhibit damage to isolated adult CMs in response to 
monocyte chemoattractant protein-1 (Ohnishi S et al., (b) 2007). MSCs posses 
immunomodulatory properties that affect a broad range of cells involved in the immune 
response. MSCs inhibit T-cell proliferation and cytoxicity, rendering the T cells 
unresponsive (Glennie S et al.,2005). Paracrine factors released by MSCs, such TGF , 
HGF, nitric oxide, indoleamine 2,3-dioxygenase and prostaglandin-E2 inhibit T-cell 
function (Baraniak PR et al., 2010). Under certain conditions, MSCs release T-cells 
activators such as IL-6, IL-1 and RANTES (Baraniak PR et al., 2010). Depending on the 
strength of the stimulus, MSCs either promote or inhibit IgG production by B cells 
(Rasmusson I et al., 2007). MSCs also prevent dendritic cell maturation and function via 
the release of IL-6 and prostaglandin-E2 (Spaggiari GM et al., 2009). MScs also secrete 
interleukin 1 receptor antagonist, which inhibits the release of the proinflammatory 
cytokine TNF from activated macrophages (Ortiz LA et al., 2007). 
Macrophages can promote angiogenesis and tissue healing through many secreted 
molecules (Yano T et al., 2006). After transplantation of MSCs into infarcted tissue, large 
numbers of macrophages collect at the sites of injection despite an overall reduction in 
the population of these cells in the heart (Amsalem Y et al., 2007). Various reports have 
indicated that MSCs switch macrophages from the proinflammatory M1 phenotype to the 
anti-inflammatory M2 phenotype both in vitro and in vivo (Zhang QZ et al., 2010), 
potentially through secreted factors such IGF-1 (Santini MP et al., 2008) and IL-10 
(Burchfield JS et al., 2008). These studies suggest that MSCs contribute to the overall 
recovery of cardiac function after MI, in part, via their effects on macrophages. 
Cardiac injury with significant loss and functional impairing leads to cardiac remodeling, 
which is mediated by a significant change in the ECM including fibrosis, CM hypertrophy, 
and changes in ventricular dimension and function. Paracrine factors released by adult 
stem cells can alter the ECM and prevent post-infarction remodeling. Stem cells, such as 
MSCs, express many proteins that regulate the ECM such as MMPs, serine proteases and 
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serine protease inhibitors, suggesting that transplanted MSCs can inhibit fibrosis through 
a paracrine action (Ohnishi S et al., (a) 2007). MSCs transplantation has been shown to 
inhibit post-MI increases in the expression of collagen-I and collagen-III as well as the 
tissue inhibitor of MMP1 (Xu X et al.,2005). There is also evidence that the administration 
of adult stem cells promotes cardiac contractility. Takahashi et al. (Takahashi M et al., 
2006) found that conditioned media from BMMNCs maintained fractional shortening and 
maximal rate of re-lengthening of adult rat ventricular CMs in culture. Conditioned media 
was more effective in preserving contractility if the BMMNCs were exposed to hypoxia. 
This suggests that the release of inotropic paracrine factors is increased by hypoxia. The 
identity of these inotropic paracrine factors is currently unknown, however it is well 
known that IGF-1, a growth factor released by MSCs, can promote cardiomyocyte 
contractility in vitro (Freestone NS et al., 1996). 
Another important effect of adult stem cells in the ischemic myocardium is 
neovascularisation. The molecular pathways that control angiogenesis are well 
characterized and involve proteins such as VEGF, basic FGF, HGF, and angiopoietin, 
among others. VEGF is an important proangiogenic paracrine factor as ablation of this 
gene significantly inhibits the ability of MSCs to promote functional recovery in the 
injured heart (Hodgkinson CP et al., 2013). However, antibody targeting VEGF and FGF 
only partially attenuated the effect of conditioned media (Kinnaird T et al., 2004), 
indicating that MSCs release other proangiogenic proteins besides these two growth 
factors. EPCs also promote angiogenesis via paracrine mechanism. VEGF and stromal-
derived factor-1 are among the responsible bioactive molecules. Both proteins are 
secreted by EPCs and promote EC migration and capillary formation via differentiation 
independent mechanisms (Urbich C et al.,2005). 
The heart contains many resident stem cells, which are defined by several markers 
including cKit and Sca-1. The cKit cardiac progenitor cell (CPCs) are thought to be 
capable of promoting regeneration via mobilization into injured tissue and differentiation 
into mature cardiac cells (Bolli R et al., 2011). However, in all studies, it was apparent 
that donor cKit+ cell differentiation into mature cardiac cells, such as CMs, was too low to 
account for the functional benefits. The authors concluded that paracrine effect must be 
responsible for the regenerative effects of the injected cKit+CSCs (Tang XL et al., 2010). 
The nature of these paracrine factors remains to be identified. 
What has become apparent is that paracrine factors released by stem cells are 
pleiotropic. This pleiotropic ability of stem cell-derived paracrine factors allows them to 
influence cardiac repair at multiple points after myocardial injury. Many paracrine factors, 
as IGF-1, FGF, platelet-derived growth factor and VEGF, posseses pleiotropic properties. 
Given the fact that response to cardiac injury involves complex, dynamic, and time-
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dependent events, paracrine factors can influence myocardial patho-biology, a 
multifaceted temporal manner on different cell types and via different mechanisms. 
 
3.2. Immunological barriers of stem cell-based therapies 
The concept that stem cells may have an immune privilege status explains the initial lack 
of concern for the potential immunologic conflict between transplanted cells and a host. 
An exogenous cell delivered to a host is expected to encounter some form of host 
resistance. Recognition of foreign antigen initiates an immune response that involves the 
activation and proliferation of specific immune cells. 
Immunogenicity is the recent concern of stem cell therapies whether using embryonic or 
adult, or autologous or allogeneic stem cells (Zhao T et al., 2011; Charron D et al., 2009; 
Dhodapkar KM et al., 2010; Charron D et al., 2012). The idea of acquired immunogenicity 
of autologous stem cells is disclosed as: too long-term culture periods, genomic 
instability, combination with matrix structures, genetic manipulation, epigenetic 
reprogramming, and impair stem cell immune privilege status. In the allogeneic scenario, 
the expression of immune relevant molecules, notably the polymorphic major 
histocompatibility complex (MHC) classes I and II antigens [human leukocyte antigen 
(HLA) class I and II in humans] is the backbone of rejection problems. The MHC antigens 
were originally recognized for their role in initiating T-cell responses that lead to the 
rejection of transplanted tissue. By binding to foreign antigens, MHC molecules form 
complexes that are recognized by specific T cells, thus initiating a cascade of events to 
identify and eliminate foreign invaders. The MHC class I antigens are traditionally 
associated with the activation of CD8 cytotoxic T lymphocytes, whereas MHC class II 
antigens are recognized by CD4 T lymphocytes. However, many stem cells express no or 
only low levels of MHC antigens and have been considered to be immunoprivileged, or 
lacking in the ability to induce an immune response. In fact, ESCs and MSCs have been 
presented as the prototype of the immunoprivileged cell for cell transplantation studies 
(Menendez P et al., 2005; Yang XF et al., 2007). Human ESCs express low level of HLA 
class I that significantly increases after differentiation (Drukker M et al., 2006) and 
expanding MSC in vitro remarkably increases their MHC II. The MHC disparities are by far 
the most formidable immunological barrier to transplantation (Erlich HA et al., 2001). 
Rejection occurs because of allelic differences between grafts and hosts mainly at 
polymorphic class I and class II MHC loci. Models of ESC transplantation using murine 
ESCs showing that the administration of these cells into the injured myocardium of 
allogeneic animals resulted in robust inflammatory responses and cellular infiltration by 
both the innate and adaptive composites of the immune system questioned their immune 
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privilege status (Kofiis T et al., 2005). The cellular-based immune responses by innate 
natural killer (NK) and adaptive T cells upon recognition of allogeneic MHC are major 
mechanism of immune rejection (Clarkson MR et al., 2005; Crespo M et al., 2015; 
Moreau A et al., 2013). Another mechanism widely recognized as an important 
component of allograft failure in organ transplantation is the antibody-mediated rejection 
(AMR) (Terasaki PI et al., 2005; Lefaucheur C et al., 2013). 
MI leads to an intense inflammatory cell influx within the myocardium and the activation 
of local and systemic immune signaling pathways. Thus, stem cells are delivered into an 
immunologically activated milieu when applied after MI, which some investigators 
consider as a trigger for the up-regulation of stem cell MHC expression. Moreover, stem 
cells themselves can produce various immunomodulatory signaling factors, including both 
proinflammatory and anti-inflammatory molecules (Patel SA et al., 2008; Rameshwar P et 
al., 2010). 
 
 
Limitations of autologous cell therapy 
Most clinical trials of cell therapy have been conducted using autologous cells. While 
autologous cell therapy carries no risk of immune rejection, it requires patient-specific 
tissue harvesting, cell manufacturing and quality control and is, therefore, associated 
with important limitations. First, autologous tissue harvesting is invasive and not risk-
free. Second, culture of autologous cells may be complicated by technical manufacturing 
failures; third, expansion of autologous heart-derived cells to clinically relevant numbers 
poses significant timing constraints which prohibit administration of autologous heart-
derived cellular products in acute MI or early post-MI. Fourth, donor age and 
comorbidities may (or may not) negatively impact upon cell quality, resulting in 
decreased cell potency. Finally, the technical, economic and logistic constraints 
associated with autologous cell therapy preclude broad adoption of cell therapy and limit 
its clinical  application to few specialized centers. 
The aforementioned limitations of autologous therapy could be overcome by the use of 
allogeneic cells. The obvious disadvantage of allogeneic therapy is the risk of immune 
rejection of transplanted cells, which could limit effectiveness of cell therapy (due to rapid 
rejection of transplanted cells), raise safety concerns (as it could theoretically result in 
immune related myocardial injury), and induce allosensitization of the recipient, which (if 
robust and persistent) could complicate future organ transplant. However, if allogeneic 
cell therapy were proven to be safe and effective, it would open up a new paradigm in 
cellular therapeutics. Large scale expansion of cells derived from allogeneic tissues could 
be performed in specialized manufacturing labs under strict quality control. In the case of 
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heart-derived cells, attractive sources of allogeneic tissue include hearts explanted from 
organ donors but not used for transplantation and surgical myocardial discards. Highly 
standardized, ‘off-the-shelf’ allogeneic cellular products would subsequently be shipped to 
hospitals throughout the world and banked for future use, thus enabling broad adoption 
and timely application of cell therapy in a cost-efficient manner. This attractive novel 
paradigm has motivated researchers to investigate the safety and efficacy of allogeneic 
therapy for myocardial repair. A critical step in the clinical translation of cell therapy, as 
mandated by regulatory authorities, is development of relevant potency assays (i.e., tests 
to measure potency of manufactured cellular products). This is particularly important for 
allogeneic cell therapy, as development of appropriate potency assays would enable 
prospective identification of donor cells with greater potential for clinical efficacy. 
However, the fact that cell therapy products appear to have complex, multifactorial and 
not fully characterized mechanisms of action presents difficulties in establishing which 
cellular attributes are most relevant to measuring potency. Given that, potency assays 
should ideally represent the cellular product’s mechanism of action and multiple lines of 
evidence suggest that the mechanism of action of adult cells is indirect (i.e., is mediated 
by paracrine mechanisms), it appears logical that in vitro biological assays measuring 
paracrine factor secretion may serve as appropriate potency assays for cellular products. 
Allogeneic MSCs are considered the prototypical ‘universal donor’ cells for cardiac 
applications. MSCs exhibit an immunologic profie that renders them attractive for 
allogeneic transplantation without concurrent immunosuppression: they express MHC 
class I, but lack expression of MHC class II surface antigens or costimulatory molecules. 
In addition, MSCs exert multiple immunosuppressive and immunomodulatory effects in 
vitro, as they have been shown to interact with virtually all immune cells involved in 
adaptive and innate immunity. More specifically, MSCs (through both paracrine and 
contact-dependent mechanisms) inhibit T-cell and B-cell proliferation, inhibit the 
maturation and cytotoxicity of NK cells, dampen the respiratory burst of neutrophils, 
inhibit the maturation of monocytes into dendritic cells and impair the antigen-presenting 
function of dendritic cells (Uccelli A et al., 2008).  Preclinical studies in large animal 
models of ischemic cardiomyopathy have demonstrated that allogeneic MSC 
transplantation without immunosuppression is safe and produces benefits that appear 
equivalent to those produced by autologous cells (Jansen Of Lorkeers SJ  et al., 2015). 
With regard to clinical translation, early-phase clinical testing of allogeneic MSCs in 
patients with heart disease has yielded promising results; allogeneic human MSCs have 
demonstrated a favourable safety profile (without eliciting a significant immune memory 
response in transplanted recipients) and have produced encouraging hints of efficacy 
(Hare JM et al., 2009; Hare JM et al., 2012; Ascheim DD et al., 2014). It should be noted 
that even immunoprivileged cells like MSCs are eventually rejected after in vivo 
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transplantation without concurrent immunosuppression (Eliopoulos N et al., 2005; Badillo 
AT et al., 2007; Poncelet AJ et al., 2007; Zangi L et al., 2009); however, since their 
mechanism of action is indirect (Weil BR et al., 2015), rejection of MSCs may not be of 
therapeutic signifiance if it is delayed long enough to allow them to exert their reparative 
paracrine effects. 
Undifferentiated ESCs are characterized by the basic traits of self-renewal, clonogenicity, 
and pluripotency (for differentiation into multiple cell types). Our current understanding 
of the immunoprivileged status of human ESCs is based on in vitro and in vivo 
xenogeneic transplantation studies (Menendez P et al., 2005). These studies have 
collectively shown that human ESCs express low levels of MHC class I antigens but do not 
express MHC class II antigens or costimulatory molecules (Drukker M et al., 2002;  
Fandrich F et al., 2002;  Li L et al., 2004). Furthermore, human ESCs have been found to 
evade recognition by NK cells and inhibit T-cell–induced stimulation by antigen-
presenting cells. These studies have also shown that human ESCs do not induce an 
inflammatory response, or presumably, an immune response upon injection into 
immunocompetent mice and are, thus, candidates for immunomodulation and tolerance 
induction (Menendez P et al., 2005). In regenerative studies, ESCs have been reported to 
have salutary effects on organ repair, including the heart (Caspi O et al., 2007; Kupatt C 
et al., 2005;  Hodgson DM et al., 2004; Min JY et al., 2002). However, some studies 
contradict the idea of ESC immunoprivilege and suggest that ESCs are associated with 
immune rejection and teratogenicity (van der Bogt KE et al., 2006; Lee AS et al., 2009; 
Nussbaum J et al., 2007; Dai W et al., 2007). Transplantation of undifferentiated 
allogeneic murine and human ESCs into mouse hearts has led to the formation of cardiac 
teratomas in immunodeficient animals (Lee AS et al., 2008; Nussbaum J et al., 2007). 
Furthermore, treatment of immunocompetent animals with undifferentiated murine and 
human ESCs has resulted in immunologic rejection and intense inflammation after several 
weeks and the up-regulation of class I and class II MHC molecules (Swijnenburg RJ et 
al., 2008). In a comparative experiment, mouse ESCs were injected into the injured 
myocardium of syngeneic, allogeneic, and severe combined immunodeficient (SCID) 
mouse recipients (Kofidis T et al., 2005). In allogeneic mice, ESCs triggered an intense 
cellular inflammatory response consisting of T lymphocytes (CD3) and dendritic cells 
(CD11c), as well as a humoral response. However, fewer CD3+ T cells were elicited in the 
syngeneic group, and no CD3+ T cells were elicited in the SCID mice. Immunologic 
reactions and lymphocytic infiltration have also been observed after the transplantation of 
neural stem cells derived from ESCs (Preynat-Seauve O et al., 2009). These observations 
indicate that up-regulation of MHC expression occurs when ESCs are used to treat 
conditions associated with ongoing inflammation (Yang XF, 2007). This becomes of 
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particular consideration in the cardiac field as inflammation and immune cells play a 
prominent role in the early phases of MI. 
Although the use of autologous stem cells is widely accepted from an immunological 
point of view, for a clinical use and to extend the therapeutic use of CSCs to a wide range 
of patients, the autologous administration of CSCs becomes very difficult (Sanganalmath 
SK et al., 2013). Although new automated and high-throughput cell culture systems are 
being developed (Kami D et al., 2013), for autologous therapies, growing the patient’s 
own CSCs is likely to be time consuming, expensive and require sophisticated 
instrumentation, and therefore it would be available to a very limited number of patients. 
The immunogenicity and immunomodulatory properties of MSCs have been extensively 
described in the past (Le Blanc K et al., 2008; Garcia-Castro J et al., 2008) but less 
information is available regarding CSCs. Since the mechanism of action of these cells is 
still not fully understood, it would be difficult to fully elucidate the immunogenicity of 
CSCs in an allogeneic setting. Nowadays, there are different hypotheses concerning the 
mechanisms through which CSCs could provide a clinical benefit. In the past years, the 
transdifferentiation hypothesis attempted to explain the beneficial effect of CSC 
transplantation (Anversa P et al., (b) 2006). However, the in vivo differentiation of adult 
stem cells into cardiac myocytes has not been demonstrated conclusively and, if it occurs, 
its frequency would be very low (Gersh BJ et al., 2009). From an immunological 
perspective, the transdifferentiation of stem cells into cardiac or vascular cells does have 
an import on the immunogenicity of the implanted cells. In vitro experiments using MSCs 
have demonstrated that undifferentiated cells expressed very low levels of MHC class I 
and class II molecules. After differentiation toward myocytes, SMCs or ECs, these cells 
acquire an increased expression of MHC class Ia and II together with an increased 
susceptibility to allogeneic cytotoxic T cells (Huang XP et al., 2010). The in vivo 
experiments using allogeneic MSCs in a rat model have clearly demonstrated that 
differentiated allogeneic cells are eliminated from the host tissue more rapidly than 
undifferentiated cells. Finally, it is important to note that very similar results have been 
found in allogeneic and xenogeneic settings where the transplanted cells were lost from 
the infarcted rat heart within 5 weeks (Huang XP et al., 2010) and 6 weeks (Grinnemo 
KH et al., 2004), respectively. For these reasons, it is now accepted that 
transdifferentiation cannot be the main mechanism to explain improvements in cardiac 
function after stem cell therapy. The paracrine hypothesis is gaining adepts. Published 
evidence demonstrates that stem cells release soluble factors and extracellular vesicles 
with analogous effects in MSCs (Timmers L et al., 2011) and CSCs (Ibrahim AG et al., 
2014). The transplanted allogeneic CSCs have been proved to release paracrine factors 
that stimulate endogenous repair mechanisms, and experimental evidences in the 
infarcted rat model have shown that allogeneic cells survive in the myocardium only for a 
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short period (Caspi O et al., 2007). According to the paper published by Marban’s 
laboratory in 2012 using mismatched CDCs, this short period is long enough to stimulate 
regenerative pathways (Caspi O et al., 2007). The administration of rat-derived CDCs in 
allogeneic recipients has demonstrated that these cells are hypoimmunogenic and did not 
induce a humoral response. However, it is important to note that, in these in vivo 
experiments, a cellular immune response was reported and alloreactive lymphocytes 
exhibited an enhanced proliferation against CSCs. If CSCs truly induce memory T cells for 
clinical trials, the fact that repeated administrations of these cells may induce a robust 
secondary immune response should be taken into account, since this will result in a rapid 
clearance of administered cells. Looking toward clinical translation, the allogeneic 
rejection risk of CSCs has been described in a recent paper from Al-Daccak et al. In this 
paper, the authors demonstrated that human CPCs shift their signaling capacities within 
the allogeneic setting toward signals that promote the development, maintenance and 
functioning of anti-inflammatory response (Lauden L et al., 2013). Moreover, the authors 
demonstrated that  programmed death-ligand 1 (PD-L1) plays a key role to identify low-
risk allogeneic cardiac cells. Further studies are still needed to assure that allogeneic 
CSCs are safe and to explore the host response to this allogeneic therapy, but the 
evidence available so far is encouraging, and considering the enormous potential of 
cardiac-derived cellular products, Phase I clinical trials have been started using CDCs 
(ALLSTAR) and hCPCs (CAREMI). The ALLSTAR study is the first randomized, double-
blind, placebo-controlled trial to determine the safety and efficacy of intramyocardial 
delivery of allogeneic CDCs in patients with ischemic left ventricular dysfunction following 
MI. The CADUCEUS study provided the foundation for the ALLSTAR trial with major 
difference between CADUCEUS and ALLSTAR being the source of the CDCs (autologous 
vs. allogeneic CAP-1002) (Makkar RR et al., 2012; Malliaras K et al., 2014) . The principal 
goal of ALLSTAR is to establish the safety of intramyocardial delivery of allogeneic CDCs. 
In parallel, signals of potential efficacy will be evaluated by a primary efficacy endpoint 
(infarct size by MI, similar to the CADUCEUS study) and other structural and functional 
measures. 
 
Rodent studies with allogeneic cardiac-derived products 
The work performed so far with truly allogeneic cells is strictly limited since most studies 
in small rodents use either SCID mice and human cells (Chimenti I et al., 2010; Messina 
E et al., 2004) or syngeneic cells (Monnet E et al., 2005). Most works describing a cellular 
type for the first time have also provided some rodent data to support their regenerative 
capabilities. Thus, the pioneering work performed by Beltrami et al. (Beltrami AP et al., 
2003) describing cKit+/Lin- cells demonstrated their capability to improve cardiac function 
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in rats, as later corroborated by other works (Bearzi C et al., 2007). Similarly, the first 
study published using CS (Messina E et al., 2004) injects human CS in the peri-infarct 
area in SCID mice, using echocardiography to assess functional progress and reporting a 
preserved infarct wall thickness and percent fractional shortening, in the absence of 
changes to infarct size between treated and control animals. They describe the existence 
of bands of regenerating myocytes and neovascularization. Further down the road, works 
from the same laboratory (Smith RR et al., 2007) describe the first preclinical use of 
CDCs in a similar study, also using human cells in SCID mice. In this case, 
echocardiographic follow-up showed an improvement in global LVEF in CDC-treated 
animals versus controls, and while no differences in infarct size between groups were 
seen either, there were regions of viable myocardiocytes (stained red with Masson’s 
Trichrome) within the infarct area in the treated hearts but not in the control animals. In 
an attempt to decrease the time needed for cell culture, cells directly grown from cardiac 
explants (outgrowth cells), that represents an intermediate step in the generation of CS, 
were compared to CDCs (Davis DR et al., 2010). After a thorough characterization 
including in vitro differentiation, secretome and phenotyping, infarcted rats were injected 
with CDCs, outgrowth cells, fibroblasts or phosphate-buffered saline, and followed up 
using MRI, which is the gold standard for functional cardiac evaluation. These cells 
possessed genetic and surface markers of CPCs, were able to differentiate into a cardiac 
phenotype, secreted cardioprotective and angiogenic cytokines (including VEGF and IGF-
1, but not HGF or PDGF) and could influence cardiac function, with LVEF 3 weeks after 
infarction being significantly higher in CDC- or outgrowth cells-injected animals compared 
to the phosphate buffered saline- or fibroblast-injected groups. Moreover, a trend toward 
decreased infarct size compared to controls was also evidenced in treated rats. Since no 
clear difference was seen between the two treatment groups, outgrowth cells may 
represent an alternative requiring less time-consuming processing prior to administration. 
Studies performed in small animals have also been used to determine the capabilities of 
cardiac-derived cellular products prior to advancing to more clinically relevant species. 
For example, the ability of CSCs to cross the vessel wall and reconstitute all cardiac 
tissues when delivered in a clinically relevant manner was demonstrated by Dawn et al. 
(Dawn B et al., 2005). In this work, cKit+/Lin- CSCs expressing enhanced green 
fluorescent protein (EGFP) were administered in infarcted rats via the coronary tree, and 
echocardiographic follow-up revealed a preservation of cardiac anatomy and function in 
CSC-treated animals compared to controls, where a clear deterioration of functional 
parameters was seen. EGFP+ cells were found in clusters of small cells of an immature, 
neonatal appearance within the infarcted myocardium, whereas in non infarcted areas 
they were dispersed and of a much greater size (and mature phenotype). Independently 
of the different degree of maturation, which is a concern that still needs to be addressed 
in the field, this work proved that CSCs administered into the coronary tree could home 
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to the myocardium. Another interesting study performed with the same type of cells 
(Rota M et al., 2008) looked into the differential effect of the activation of endogenous 
CPCs with growth factors (GFs) or the direct implantation of CPCs, finding that both 
therapies had a salubrious effect on the scar, with the infarcted wall being significantly (p 
> 0.001) thicker and showing more viable myocytes in the treated groups compared to 
controls. They conclude that both treatments are able to salvage up to 45% of the 
infarcted tissue and replace it with functional myocardium. An interesting part of this 
study is that they also evaluated the ability of the injected or activated CPCs to migrate 
to the scar, demonstrating that the cells migrate via the expression of different MMPs, 
that have a marked catalytic effect easing the migration of CPCs from the border toward 
the center of the scar. Moreover, rodent studies are pivotal in discriminating the relative 
roles of different strategies or mechanisms of action, as proven by Chimenti et al. 
(Chimenti I et al., 2010). This group injected human CDCs in the peri-infarct area of SCID 
mice after permanent coronary ligation to assess the direct and paracrine contributions of 
cardiac-derived cell therapy to the regeneration obtained after administration in an 
infarcted heart and quantify the relative contributions of each mechanism to the 
beneficial effects observed after therapy. They demonstrated that human CS and CDCs 
have the ability to secrete growth factors such as IGF-1, HGF and VEGF in vitro and in 
vivo. Since the cells are implanted in a mice model, and the secreted GFs come from 
human cells, they were able to prove the existence of in vivo secretion by finding the 
factors secreted by human cells at 1 and 3 weeks after administration. In terms of 
engraftment, they showed that at 1 week only about 30% of the signal intensity from 
luciferase-labeled CDCs remained and no cells could be detected by this nonquantitative 
method at 3 weeks. To calculate the relative contribution of paracrine and direct action of 
CDCs, they identified the new cells at both vascular structures and the myocardium, 
reporting that only about 20% of the new capillaries were human in origin. Since the 
paracrine effects can be exerted both on the myocardium and on endogenous stem cells, 
they studied the possible activation of endogenous CSCs by the injected hCDCs, finding 
an increase in endogenous c-kit positive cells around the human CDCs. This thorough 
study concludes that the mechanism of regeneration is threefold (direct differentiation, 
indirect paracrine effect on the myocardium and indirect paracrine effects on the 
endogenous CSCs), but the major contributors are represented by paracrine effects, in 
their two dimensions. A recent study aimed to explore repeated administration of CDCs. 
Considering that the inflammatory milieu of the heart immediately after reperfusion could 
be detrimental for cell engraftment, Carr et al. (Carr CA et al., 2011) administered CDCs 
labeled with GFP and micron-sized particles of iron oxide intramyocardially immediately 
after reperfusion and systemically via the tail vein at 2 days after the infarction, and the 
evolution of cardiac function demonstrated improved functionality in CDC-treated 
animals. An interesting finding is that cells positive for GFP and micron-sized particles of 
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iron oxide were found in these animals at 16 weeks after injection, thus pointing to 
greatly improved cell retention and survival with this administration regimen. To assess 
the feasibility and safety of an allogeneic therapy, Malliaras et al. (Malliaras K et al., 
2012) aimed to establish the safety of allogeneic CDC administration in the absence of 
immunosuppression. Considering the evidence pointing toward a mainly paracrine effect, 
these authors consider that rejection may not be an issue for this therapy, since if the 
cells are cleared after exerting their beneficial paracrine effects their disappearance 
would not present a problem. However, the potential limitations of allogeneic therapy are 
not only related to their effectiveness but also to safety concerns. Therefore, they 
characterized the in vitro immunological properties of CDCs, monitoring the signs of 
immunorejection (such as inflammatory cytokine secretion, leukocyte infiltration and 
development of cellular or humoral memory response) and the survival of the cells as 
well as their functional effect. They injected CDCs of syngeneic, allogeneic and 
xenogeneic origin, as well as a control group, in the peri-infarct area in rats, quantifying 
the levels of circulating inflammatory cytokines to assess immunogenicity of the cells as 
well as performing a post-mortem pathological evaluation of the immune response. The 
baseline immunophenotype of the studied cells suggests that they may be useful as an 
allogeneic product: expression of MHC class I antigens confers the cells with protection 
against NK cell-mediated deletion, while the absence of MHC class II antigens allows 
CDCs to escape direct recognition from CD4+ T helper cells. They found that during the 
first 3 weeks after injection, the clearance of syngeneic cells was slower than allogeneic 
cells, while cells of xenogeneic origin were rejected within 1 week. However, allogeneic 
and syngeneic transplantations exerted comparable and sustained beneficial effects on 
infarcted heart structure and function as evidenced by decreased infarct size, increased 
infarcted wall thickness and limited remodeling when compared to xenogeneic and 
control animals. These benefits persisted over time, up to 6 months post treatment, 
which supports the paracrine activation of endogenous cells as the mechanism of action. 
In terms of immunogenicity, there was a slight transient lymphohistiocytic infiltration at 3 
weeks in the allogeneic group that was much lower than the one observed with 
xenotransplantation and that had completely subsided at 6 months. To further explore 
the effect of allotransplantation, researchers from the same laboratory (Tseliou E et al., 
2013) performed intramyocardial injection of CS (not CDCs) in infarcted rats. First, they 
completed a characterization of the immunological profile of the CS, and, as happened 
with CDCs, showed that the outer cell layers expressed intermediate levels of MHC I in 
their surface, but no detectable MHC II. Interestingly, effects were very similar between 
allogeneic and syngeneic transplantation, with improvements in LVEF and ventricular 
volumes present as soon as 1 week and sustained for up to 6 months. Cell engraftment 
was low, as expected, with no cells being detected in the allogeneic transplantation group 
after 1 week. Despite this low engraftment, benefits were sustained over time. Pathology 
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showed no immune rejection signs in syngeneic or allogeneic groups, but a robust cell-
mediated response was seen in the xenogeneic group. Curiously, inflammatory cytokines 
at day 7 were lower in the syngeneic and allogeneic groups (when compared with the 
control group), which points to an immunomodulatory action, consistent with reports 
from other groups (Lauden L et al., 2013) that could be responsible, at least in part, for 
the sustained effect seen over time. Considering the multitude of cell types currently 
underevaluation for cardiac therapy, Li et al. (Li TS et al., 2012) performed a direct head-
to-head comparison of various stem cell types of human origin, namely, CDCs, bone 
marrow-derived MSCs, adipose tissue-derived MSCs and BMMNCs. These authors showed 
that cardiac-derived cells showed the greatest in vitro potential for myogenic 
differentiation and angiogenesis induction, along with a balanced and relatively high 
production of angiogenic and antiapoptotic factors. Similarly, cardiac-derived cells 
provided the greatest functional benefit in an SCID mice model of experimental 
infarction, enhancing cell engraftment and myogenic differentiation rates with the lowest 
number of apoptotic cells and the best preserved/repaired heart architecture. In a further 
study, they compared the effects of CDCs with that of a subpopulation of cKit+ cells 
purified from CDCs and reported that CDCs performed better than c-kit+ in terms of 
functional benefit, which could be attributed to the fact that CDCs secreted higher 
amounts of paracrine factors than cKit+ cells, which could account for the better results 
with these cells. In other direct comparison, Oskouei et al. (Oskouei BN et al., 2012) 
studied the relative therapeutic and biological efficacy of human cKit+ CSCs of fetal and 
adult origin (36,000 CSCs of each kind per animal, respectively) versus two doses of bone 
marrow-derived MSCs (36,000 and 1,106 cells) in infarcted SCID mice. Eight weeks after 
administration, they reported a greater effect of fetal CSCs on preserving ventricular 
volumes and LVEF and decreasing infarct size. While adults CSCs performed on a level 
with the high-dose MSCs administered, the amount of cells needed for a similar effect 
was 30-times greater, which points to a greater potency of these cells. In terms of 
engraftment, as identified using human-specific DNA probes, CSC-treated hearts showed 
significantly higher incorporation of human stem cells, which was much lower in the high-
dose MSC group and almost negligible in the low-dose MSCs (they report the appearance 
of only a few stained cells). Moreover, evidence of myocyte differentiation was seen in 
CSC-treated animals but not in MSC-treated animals with either dose. Their results 
indicate a greater potential of human CSCs compared to MSCs. However, not all rodent 
studies have reported good results. In an independent study, Li et al. (Li Z et al., 2009) 
used a transgenic mouse strain expressing firefly luciferase and EGFP as CSCs donor and 
followed up the fate of the cells after intramyocardial administration in an infarction 
model using bioluminescence imaging. Two days after injection, a robust signal was 
detected. However, this signal decreased dramatically over time, to 6.7% of baseline at 
day 7, and to just 0.4% after 8 weeks, indicating poor cell retention. Along these lines, 
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cardiac function, as monitored by multiple techniques (they used echocardiography, MRI, 
pressure–volume loops analysis, PET scan and pathological determination of the infarct 
size) deteriorated similarly in treated and control animals, while it remained stable in 
sham mice. These results, strikingly different from those reported by other groups with 
cardiac- derived cell products, could be attributed to differences in isolation techniques, 
donor cell sources, animal model (reperfused vs nonreperfused), etc. Similarly, van Berlo 
et al. (van Berlo JH et al., 2014) have recently reported that the contribution of cKit+ cells 
to the heart’s CMs is minimal, on the order of 0.03% or less, while they mostly gave raise 
to cardiac endothelial cells. For this study, they used a mouse model in which they used 
the Kit locus for tracing the cells and assess the frequency with which c-kit+ cells 
generate CMs in vivo. This work, however, refers to the in situ cKit+ cell performance, 
which may not reflect the regenerative potency of ex vivo proliferated cells. Along these 
lines, another group (Ellison GM et al., 203) has reported that these cells are necessary 
and sufficient for cardiac regeneration. After ablating the proliferating endogenous CSCs 
and their progeny with 5-fluorouracil, no regeneration or functional recovery was 
forthcoming in an isoproterenol induced damage in the murine model, while those 
animals that had only received isoproterenol, but not the 5-fluorouracil, slowly recovered 
cardiac function over 28 days, as expected from this model. Taken together, these 
conflicting results advise caution with the use of exogenous cardiac-derived cells in 
clinical trials. The amount of mechanistic studies available to elucidate the mechanisms 
by which this therapeutics could improve cardiac function is still scarce. 
 
 
3.3. Clinical trials 
 
Different studies have proven that CSCs are present in the heart of mammal species, 
including man, and can be used to help regenerate the infarcted myocardium in different 
ways. Human studies have been performed and even completed in some cases, with 
CSCs from autologous origin, with extremely good results.  
SCIPIO (cardiac Stem Cell Infusion in Patients with Ischemic Cardiomyopathy) is a first-
in-human, phase 1, randomized, open-label clinical trial designed to explore the effects of 
autologous c-kit-positive CSCs in patients with ischemic cardiomyopathy. The trial is still 
ongoing. C-kit-positive cells were isolated and grown from the right atrial appendage. 
Consequently, only patients undergoing ”on-pump” CABG (coronary artery bypass 
grafting) surgery were enrolled in the trial, as the appendage is routinely removed in 
these cases to allow access for right atrial cannulation. 
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Interim results indicates that intracoronary infusion of autologous CSCs results in 
improved LVEF (assessed by 3D echocardiography), functional capacity (assessed by the 
NYHA class), and quality of life (assessed by the Minnesota Living With Heart Failure 
Questionnaire) (Bolli R et al., 2011). The salient findings of the study can be summarized 
as follows: 1) harvesting and processing the right atrial appendage in the operating room 
for subsequent isolation and expansion of CSCs was eminently feasible in all 33 patients 
enrolled in the study, yielding successful CSC cultures in each case despite the fact that 
these patients have severe coronary artery disease, severe heart failure, and multiple 
comorbidities; 2) this new method for obtaining autologous stem cells did not interfere 
with standard surgical procedures or with surgical outcomes, and thus appears to be 
feasible in most patients undergoing CABG; 3) CMR (cardiac magnetic resonance) 
(generally considered the most accurate technique for these analyses (Soliman OI et al., 
2008; Grothues F et al., 2002; Wu E et al., 2001; Kim RJ et al., 2000; Hendel RC et al., 
2006) demonstrated that intracoronary infusion of autologous CSCs ~4 months after 
CABG surgery resulted in a striking increase in LVEF (+ 7.7 EF units) 4 months later and 
an even greater increase (+13.6 EF units) 12 months later, accompanied by a parallel 
increase in regional contractile function in the infarcted regions that were infused with 
CSCs; 4) this improvement in LV function was coupled with a concomitant decrease in 
infarct size, which was consistently observed with three different CMR methods 
(reductions at 4 and 12 months after CSC infusion, respectively: -22.7 % and -30.2 % by 
manual delineation, -38.1% and -44.8% by a semi-automated method [FWHM], and -
49.7% and -58.6% using non-viable mass), and was accompanied by an increase in LV 
viable mass (+11.6 g at 4 months and +31.5 g at 12 months after CSC infusion), 
implying robust regeneration of myocardial tissue. Taken together, these results, 
obtained with the best methodology currently available (CMR), indicate that 
administration of autologous CSCs obtained from a surgical specimen is effective in 
improving LV function and promoting cardiac regeneration in patients with chronic 
ischemic cardiomyopathy. 
CADUCEUS (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar 
dySfunction) trial is based on previous preclinical studies that found that Cardiosphere-
derived cells (CDCs) reduce scarring after MI, increase viable myocardium, and boost 
cardiac function. This study aimed to assess safety of such an approach in patients with 
left ventricular dysfunction after MI. 
Percutaneous endomyocardial biopsies are used to obtain source tissue and the 
cardiosphere culture method  (Messina E et al., 2004) to yield tens of millions of CDCs in 
a timely manner  (Smith RR et al., 2007). 
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Six-month primary endpoint analysis of the trial demonstrated the feasibility of 
harvesting, expanding, and delivering autologous (Smith RR et al., 2007) by 
intracoronary infusion in post-MI patients. 
CADUCEUS study showed an increase in viable myocardial tissue as a result of cell 
therapy. Although two clinical studies of BMMNCs have reported reductions in scar size 
with cell therapy, the effect was attributable only to reduced scar mass. Even when the 
discussion is restricted to scar reduction, CDC therapy is about 3–5 times more effective 
than BMMNCs. This study showed that CDCs have an unprecedented ability to reduce 
scar and simultaneously stimulate the regrowth of healthy myocardial tissue. The basis 
for the apparently improved efficacy of CDCs remains to be fully elucidated, but they 
have noted that CDCs outperform BMMNCs, MSCs, and cKit+ cells in terms of paracrine 
potency, anti-apoptotic properties, tissue engraftment, and regenerative efficacy when 
the various cell types are compared directly in mice after MI (Li TS et al.,2012) . 
However, the CADUCEUS trial did not show any changes in this parameter compared to 
the control group after 1 year, despite demonstrating a 11.1% reduction in scar size 
(compared to unchanged scar size in control patients) and an increase in viable 
myocardium by 22.6 g in patients treated with CDCs versus 1.8 g in controls (Malliaras K 
et al., 2014).  
Building on the preclinical experience discussed above, and considering the highly 
encouraging results of the autologous therapy trials, two clinical trials are underway with 
allogeneic heart-derived cellular products (ALLSTAR, CAREMI) for AMI. The first results 
from an allogeneic cardiac-derived stem cell product trial were advanced in the 63rd 
American College of Cardiology Meeting held in March 2014. In this meeting, the 
preliminary results (with a follow-up of at least 3 months after injection) from the Phase I 
ALLSTAR trial were reported. This trial aims to determine the safety profile of allogeneic 
CDCs administered via the infarct related coronary artery between 4 weeks and 12 
months after infarction. Phase I was an open-label, dose-escalating study, and its results 
are being highly encouraging, meeting the first safety endpoint at 1 month after infusion: 
there were no acute myocarditis attributable to the infusion, no deaths due to ventricular 
tachycardia or fibrillation, no sudden deaths and no major adverse cardiac events. Phase 
II has been approved by the data safety monitoring board and enrollment is reported to 
be ongoing for the double-blind, randomized, placebo controlled Phase II 
(Schwarzenberger P et al., 2000). On the other hand, the CAREMI trial has recently 
started its dose-escalating phase. Considering the preclinical and in vitro results reported 
by this Consortium (Baez-Diaz C et al., 2014;  Crisostomo V et al., 2014; Lauden L et al., 
2013), the results from this trial will be awaited eagerly. 
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4. Aim of the study 
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The first aim of this study is to verify the response of cKit+CSCs under hypoxic conditions 
focusing on the activation of specific pathways leading to an inflammatory and reparative 
response (IRR). 
Then, the second aim of the present study is to verify if the hypoxia adaptation of 
cKit+CSCs with activation of an IRR leads to a cardioprotective effect after transplantation 
in a mouse model of MI. 
Third, this study wants to evaluate the immune response differences between an 
allogeneic and a syngeneic cKit+CSC  transplantation in a mouse model of myocardial 
infarction, to verify the safety and feasibility of  allogeneic treatment with cKit+CSCs. 
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5. Materials and Methods 
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5.1. Animal model and in vivo study 
Myocardial infarction (MI) was induced by coronary artery ligation in 8 weeks old BalbC 
and C57BL6 female mice (20 gr body weight), as previously described (Limana F et al., 
2005). Briefly, in mice under anesthesia (100 mg/kg ketamine and 1mg/kg 
acepromazine) and mechanically ventilated, thoracotomy via the third left intercostal 
space was performed. Then the left coronary artery was ligated and 5X104 cKit+CSCs 
cells in 10 μL phosphate buffer saline (PBS) solution were injected through a 32-gauge 
needle. Four injections (2.5 μL per injection) were performed in the ventricular wall 
bordering the viable myocardium. Control infarcted mice were injected with 200 ng of 
phosphate buffer saline (PBS). Sham operated mice were treated similarly, except that 
the ligature around the coronary artery was not tied. Animals were sacrified three and 
twenty one days after surgery. Hearts were excised and the border and infarcted regions 
of infarcted mice hearts were collected and stored at –80°C to be processed for protein 
extraction; specifically, the infarcted area was recognized as a pale zone caused by gross 
necrosis of the myocardium, due to interruption of the blood supply to the area while the 
border zone was identified as the area between the end of necrosis and the septum. The 
hearts of mice that did not undergo any surgery were used to isolate cardiomyocytes by 
collagenase digestion of the left ventricle (LV). 
All experimental procedures complied with the Guidelines of the Italian National Institutes 
of Health, with the Guide for the Care and Use of Laboratory Animals (Institute of 
Laboratory Animal Resources, National Academy of Sciences, Bethesda, MD) and were 
approved by the Institutional Animal Care and Use Committee.  
 
5.2. Cell isolation and in vitro culture 
Cardiac-derived cells were isolated from BalbC female mice at 2–3 months of age by 
collagen digestion (280 U/mL; Worthington, Lakewood, N.J., USA) through the coronary 
arteries and myocyte were removed by centrifugation. Mononuclear cells were cultured in 
F12:DMEM 1:1 supplemented with 10% fetal bovine serum and expanded. cKit+ cells 
were selected with immunomagnetic CD117 microbeads, mouse (Miltenyi Biotec) and 
were expanded in Ham’s F12 medium supplemented with 10% fetal bovine serum (FBS), 
penicillin-streptomycin 1X and Erythropoietin (Sigma-Aldrich) 2,5 mg in 500 ml (Bearzi et 
al., 2007)  
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5.3. Hypoxia 
Hypoxic conditions were achieved by incubating cKit+CSCs in a humidified incubator 
Galaxy 14S (Eppendorf) at 37°C with 5% CO2 and 1% O2 for 6, 24, 48 hours. 
 
5.4. FACS analysis 
For FACS analysis, cKit+CSCs were fixed in 4% paraformaldehyde for 15 minutes at room 
temperature and incubated with anti-CD45 antibody (BD Pharmingen). Isotype control 
was performed (mouse polyclonal IgG; Santa Cruz Biotechnology). Specifically, cells were 
incubated with the primary antibody for 45 minutes at 37°C. Flow cytometry was 
performed with FACSAria instrument (Becton Dickinson, San Jose, CA). Cellular debris 
and aggregates were gated out based on forward and side scatter. Gating on the signal 
of the nuclear stain DAPI was employed to exclude additional artifacts. Isotype-matched 
negative controls were utilized to define the threshold for each specific signal and 
establish the appropriate gate for positive cells. Data were analyzed with Kaluza Flow 
Cytometry Analysis software (D’Amario et al., 2011). 
 
5.5. mRNA isolation and quantification 
Total RNA was extracted from cKit+CSCs following 6, 24 and 48h of normoxia and 
hypoxia (n=3/group). Quality of RNA was checked using the Agilent 2100 Bioanalyzer 
and Nanodrop 1000. mRNAs levels were analyzed using the SYBR-GREEN qPCR method 
(5 ng/assay, Applied Biosystems). Then mRNA was quantified with ABI Prism 7000 SDS 
(Applied Biosystems). Relative expression was calculated using the comparative Ct 
method (2–[delta][delta]Ct) (Livak et al., 2001). 
 
5.6. Real time RT-PCR 
Real-time RT-PCR amplification was carried out in the 7900 Real-time PCR system 
(Applied Biosystems, CA, USA) using Real Time SyBr Green qPCR Superscript (Invitrogen, 
Milan, Italy).  
All reactions were carried out in triplicate. The threshold cycle (CT), which correlates 
inversely with the levels of target mRNA, was measured as the number of cycles at which 
the reporter fluorescence emission exceeds the preset threshold level. The amplified 
77 
 
transcripts were quantified using the comparative CT method with the formula for 
relative fold change = 2–ΔΔCT. The mean was calculated, and possible significant 
differences were analyzed using Student’s t test. P < 0.05 was considered significant. 
The primers used are reported in Table 1. 
 
HIF1A_mm_fw gcactagacaaagttcacctgaga 
HIF1A_mm_rev cgctatccacatcaaagcaa 
VEGFa_mm_fw caggctgctgtaacgatgaa 
VEGFa_mm_rev gctttggtgaggtttgatcc 
EPO_mm_fw tctgcgacagtcgagttctg 
EPO_mm_rev cttctgcacaacccatcgt 
Glut1_mm_fw gaccctgcacctcattgg 
Glut1_mm_rev gatgctcagataggacatccaag 
NFkB_mm_fw ctggcagtccttctcaaagc 
NFkB_mm_rev tccaggtcatagagaggctca 
Rage_mm_fw agtcagaggaagcggagatg 
Rage_mm_rev aaggaggaattgggatggaatg 
Cox2_mm_fw caagcagtggcaaggcctcca 
Cox2_mm_rev ggcacttgcattgatggtggct 
Nos2_mm_fw ctttgccacggacgagac 
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Nos2_mm_rev cattgtactctgagggctgac 
Tlr2_mm_fw accgaaacctcagacaaagc 
Tlr2_mm_rev agcgtttgctgaagaggact 
Tlr4_mm_fw ggactctgatcatggcactg 
Tlr4_mm_rev ctgatccatgcattggtaggt 
P2rx7_mm_fw aagtgcagacgctgtgtcc 
P2rx7_mm_rev gcagaactttaggccagctc 
Ptx3_mm_fw cgctgtgctggaggaact 
Ptx3_mm_rev gggaagaaaattgctgtttcac 
Cxcr4_mm_fw tggaaccgatcagtgtgagt 
Cxcr4_mm_rev gggcaggaagatcctattga 
MMP2_mm_fw taacctggatgccgtcgt 
MMP2_mm_rev ttcaggtaataagcacccttgaa 
MMP9_mm_fw acgacatagacggcatcca 
MMP9_mm_rev gctgtggttcagttgtggtg 
Timp3_mm_fw cacggaagcctctgaaagtc 
Timp3_mm_rev tcccacctctccacaaagtt 
Timp4_mm_fw agggagagcctgaatcatca 
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Table  1 :  mRNA primers list. 
 
5.7. Western blot analysis 
Proteins from cardiac tissue or cKit+CSCs were homogenized and extracted with RIPA 
buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP40, 1% Deoxycolic acid, 0.1% SDS 
and 10% Glycerol) containing protease and phosphatase inhibitors (2 mM 
phenylmethylsulfonyl fluoride, 100 U/ml of aprotinin, 10 g/ml of leupeptin and 
pepstatin, 10 mM sodium fluoride, 20 mM sodium vanadate). Equal amounts of total 
cellular proteins (100 g/lane) were resolved by SDS-polyacrylamide gel electrophoresis 
and transferred to nitrocellulose membrane (Amersham Pharmacia Biotech, Little 
Chalfont, UK). Membranes were probed with rabbit monoclonal  anti HIF-1 (Cell 
Signaling Technology, Danvers, MA), goat polyclonal anti HXK2 (Santa Cruz 
Biotechnology, Dallas, TX) rabbit polyclonal anti CAIX (Thermo Fisher Scientific, Whaltam, 
MA), rabbit polyclonal anti NF-kB (Santa Cruz Biotechnology), rabbit monoclonal anti 
COX2 (Cell Signaling Technology), goat polyclonal anti RAGE (Santa Cruz Biotechnology), 
goat polyclonal anti CXCR4 (Santa Cruz Biotechnology), goat polyclonal anti alfa-MHC and 
mouse monoclonal anti beta-MHC (Santa Cruz Biotechnology), mouse monoclonal anti 
CSRP3 (Santa Cruz Biotechnology), rabbit polyclonal anti collagen I (Abcam, Cambridge, 
UK), rabbit polyclonal anti LC3B (Novus Biologicals, Littleton, CO), rabbit polyclonal anti 
Cdk4 (Santa Cruz Biotechnology), rabbit monoclonal anti Atg7 (Cell Signaling 
Technology), rabbit polyclonal anti Bax (Santa Cruz Biotechnology), rabbit polyclonal anti 
Cleaved Caspase-3 (Cell Signaling Technology),  mouse monoclonal anti Bcl-2 (BD 
Biosciences Pharmingen, Sparks, MD), mouse monoclonal anti CD45RA (Millipore, 
Darmstadt, Germany), rabbit monoclonal anti CD3 (Abcam, Cambridge, UK) and rabbit 
polyclonal anti CD68 (Abcam) followed by horseradish peroxidase-coupled secondary 
antibodies and developed by a chemiluminescence-based detection system (ECL, 
Amersham Pharmacia Biotech.). 
 
 
Timp4_mm_rev gcactgcatagcaagtggtg 
GUSB_mm_fw ctctggtggccttacctgat 
GUSB_mm_rev cagttgttgtcaccttcacctc 
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5.8. Luminex Assay 
Blood was collected in all animals just before sacrifice; the levels of circulating cytokines 
have been determined using: Bio-Plex Pro™ Mouse Cytokine Th1/Th2 Assay reagent kit 
(Bio-Rad, Hercules, CA)  for pro-inflammatory cytokines (GMCSF, INF, IL-2, IL-12), anti-
inflammatory cytokines (IL-4, IL-5, IL-10), TNF  and IL-17a and a Bio-Plex Pro™ TGF  
Assay reagent kit (Bio-Rad)  for TGF , TGF 2 and TGF 3. Data were acquired on the 
Bio-Rad Bio-Plex 200 reader equipped with a magnetic workstation and analyzed using 
Bio-Plex software version 6.0 (Bio-Rad). 
 
 
5.9. ImmunoSorbent Assay-ELISA 
ELISA analysis for mouse IGF-1 and HGF (R&D Systems, Minneapolis, USA) was 
performed following the manufacturer's instructions. Briefly, this assay employed the 
quantitative sandwich enzyme immunoassay technique. A monoclonal antibodies specific 
for IGF-1 or HGF has been pre-coated onto a microplate. Standards and samples 
(conditioned media) were pipetted into the wells and any IGF-1 or HGF present was 
bound by the immobilized antibody. After washing away any unbound substances, an 
enzyme-linked monoclonal antibody specific for IGF-1 and HGF was added to the wells. 
Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution 
was added to the wells and color developed in proportion to the amount of IGF-1 and 
HGF bound in the initial step. The color development was stopped and the intensity of 
the color was measured. Optical density of each well was determined within 30 minutes, 
using a microplate reader set to 450 nm, with wavelength correction set to 540 nm or 
570 nm. 
 
 
5.10. Immunofluorescence analysis 
Organs used in cryostat section were snap frozen in OCT-filled molds (Bio-Optica, Milan, 
Italy). The frozen organs were cut into sections with a thickness of 4 m in a cryostat at  -
20°C, mounted on glass slides and postfixed in ice cold acetone (1:1). 
For immunofluorescence on tissue sections, tissue slides were stained with mouse 
monoclonal anti CD45RA (Millipore, Darmstadt, Germany), rabbit monoclonal anti CD3 
(Abcam, Cambridge, UK) and rabbit polyclonal anti CD68 (Abcam). Nuclei were identified 
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using Hoechst staining or SYTO 82 orange fluorescent nucleic acid staining (Molecular 
Probes, USA). Coverslips were mounted on antifade mountant (ProLong Diamond 
Antifade Mountant, Life Technologies). Fluorescence intensity was visualized with an LSM 
510 confocal microscope (Zeiss, Milan, Italy). Results were obtained by quantification of 
the number of positive cells/mm2 for each marker. 
 
 
5.11. Data collections and Statistics  
Data shown as bar graphs are means ± error standard. Statistical significance between 
two measurements was evaluated by unpaired Student's t test. A probability value of 
p<0.05 was considered significant. Data were analyzed using Prism software (version 7, 
Graph Pad, San Diego, California). 
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6. Results 
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6.1. Hypoxia regulates expression of pro-inflammatory genes and 
proteins in cKit+ CSCs 
 
Several evidences suggest that in a hypoxic tissue, inflammation can be activated 
causing damage as well as repair. This response, named inflammatory and reparative 
response (IRR), can occur in many important human pathologies and involve chiefly 
distant and resident leukocytes. Nevertheless, HIF-dependent adaptation and 
expression of proinflammatory genes has been also observed in hypoxic stem cells and 
progenitors (De Girolamo et al, 2013). 
To verify whether cKit+CSCs are able to adapt to an hypoxic environment by the IRR, 
these cells were cultured and incubated either in normoxia and hypoxia for 6, 24, and 
48 hours (h).  
Importantly, in normoxic condition, cKit+CSCs examined in our study did not show any 
significant presence of leukocytes as shown by CD45 FACS analysis (Fig. 1). Hypoxia 
clearly influenced the expression of pro-inflammatory genes and proteins. Specifically, 
mRNA expression for HIF-1 was significantly increased following 24h of hypoxia (Fig. 
2A) while its target gene VEGF increased at all three time points (Fig. 2B). Among the 
other HIF-1 target genes, as showed by RT_PCR, the expression level of the glucose 
transporter GLUT1 gradually increased from 6 to 48h (Fig. 2C) while EPO expression 
strongly increased at all three time points showing a peak after 24h of hypoxia (Fig. 
2D). 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 : Bivariate distribution of CSCs in forward and side light scatter. Expression of surface 
marker in Negative control (upper panel) is indicated. Distribution of CD45 (lower panel) in 
CSCs. CD45 expression is shown as percentage of positive cells.  
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Fig.2 : Hypoxia enhances  mRNA expression of HIF-1 and its target genes  in cKit+CSCs. 
cKit+CSCs were incubated under normoxic and hypoxic conditions for 6, 24 and 48h. mRNA 
expression levels for (A) HIF-1, (B) VEGF, (C) GLUT1 and (D) EPO were determined by real time 
PCR. The bar graphs show fold increases in expression of the studied genes in cKit+CSCs with 
respect to control normoxic cells, set at 1. Data were normalized to GUSB, a housekeeping gene, 
and represent means ± SEM for three separate experiments, each repeated in triplicate. *, P < 
0.05. 
 
Importantly, alarmin receptors such as the Receptor for Advanced Glycation End 
products (RAGE), the purinergic receptor P2X ligand-gated ion channel 7 (P2X7R), the 
Toll-like receptors 2 and 4 (TLR2 and TLR4) were activated by hypoxia. The membrane 
receptor RAGE showed a transient induction by hypoxia at 6h and a low induction at 24 
and 48h (Fig. 3A). The expression of the other membrane receptor P2X7R was 
increased only following 48h of hypoxia (Fig.3B). TLR2 and TLR4 showed a similar 
expression pattern: a decrease at 6h and a significant increase both at 24 and 48h 
(Figs. 3C-D). 
The activation of these receptors resulted in the activation of NF-kB (Fig.3E) that led to 
the expression of genes belonging to the family of the IRR (all involved in defence, 
protection and repair of cells and tissues of the IRR as well) as the pro-inflammatory 
proteins cyclooxygenase-2 (COX2), pentraxin-3 (PTX3), chemokine (C-X-C motif) 
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receptor 4 (CXCR4) and nitric oxide synthase-2 (NOS2). In particular, hypoxia increased 
the expression of the inducible enzymes COX2 (Fig.3F) and NOS2 (Fig.3G) mainly at 
48h but significantly at all three time points. Conversely, the expression of PTX3 was 
induced by hypoxic condition only at 6h (Fig.3I). Finally CXCR4 was induced by hypoxia 
at 48h (Fig.3H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3 : Hypoxia enhances  mRNA expression of NF-kB and its target genes  in cKit+CSCs. 
cKit+CSCs were incubated under normoxic and hypoxic conditions for 6, 24 and 48h. mRNA 
expression levels for (A) RAGE, (B) P2X7R, (C) TLR2, (D) TLR4, (E) NF-kB, (F) COX-2, (G) NOS2, 
(I) PTX3 and (H) CXCR4 were determined by real time PCR. The bar graphs show fold increases 
in expression of the studied genes in cKit+CSCs with respect to control normoxic cells, set at 1. 
Data were normalized to GUSB, a housekeeping gene, and represent means ± SEM for three 
separate experiments, each repeated in triplicate. *, P < 0.05. 
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However, in all experimental conditions, we always observed an increased expression of 
the genes related to HIF-1 and NF-kB in CSCs under hypoxia compared to normoxia. 
For several markers, increased protein expression levels were obtained by WB analysis 
under normoxic and hypoxic conditions mainly at 24h (Figs. 4-5). Noteworthy, the 
protein expression of metabolic enzyme hexokinase 2 (HK2), regulated by HIF-1, was 
increased both following 24h and 48h of hypoxia (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4 : Hypoxia enhances  protein expression levels of HIF-1 and its target genes  in cKit+CSCs. 
Western blot analysis showing the expression of (A) HIF-1, HK2 and CAR9 in cKit+CSCs under 
hypoxic conditions (H) at 6, 24 and 48h compared to normoxic conditions (N). The same filter 
was probed with anti-CDK4 pAb to show the equal loading. Left panel: A representative Western 
blotting of three independent experiments is shown. Right panel: Densitometric analysis of 
Western blot. Data are shown as means ± SEM. *P < 0.05 vs normoxic conditions (N). 
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Fig.5: Hypoxia enhances  protein expression levels of NF-kB, alarmin receptors and markers of 
the  NF-kB-dependent inflammatory and reparative response in cKit+CSCs. Western blot analysis 
showing the expression of RAGE, NF-kB, COX2 and CXCR4 in cKit+CSCs under hypoxic conditions 
(H) at 6, 24 and 48h compared to normoxic conditions (N). The same filter was probed with anti-
CDK4 pAb to show the equal loading. Left panel: A representative Western blotting of three 
independent experiments is shown. Right panel: Densitometric analysis of Western blot. Data 
are shown as means ± SEM. *P < 0.05 vs normoxic conditions (N). 
88 
 
6.2. cKit+CSCs reduce apoptosis and  induce autophagy following 
acute MI 
 
Since activation of the IRR leads to protection and repair of damaged cells, we 
hypothesized that following transplantation in a infarcted myocardium, cKit+CSCs would 
exert a cardioprotective effect. To test this hypothesis, cKit+CSCs were transplanted into 
the damaged heart of an ischemic mouse. Firstly, by Luminex assay, we detected 
circulating levels of different pro- and anti-inflammatory cytokines three days following 
surgery: we did not find differences among infarcted injected hearts and controls 
except for IL-10, a potent anti-inflammatory cytokine, that resulted significantly up 
regulated (Fig.6).  
 
 
 
 
 
 
 
Fig. 6 : Circulating levels of pro- and anti-inflammatory cytokines  detected by Luminex assay 
three days following surgery in the plasma of PBS treated infarcted mice used as controls (MI, 
n=4) and cKit+CSC transplanted infarcted mice (MI+cKit+CSCs, n=4), all normalized for their 
controls. Data were obtained using samples from 4 mice/each group. Data are shown as means 
± SEM. *P<0.05 vs MI. 
 
At the same time point, we verified the antiapoptotic effect of these cells. Specifically, 
we evaluated caspase-3 cleavage by WB analysis in the border zone of infarcted hearts 
(Fig. 7A). Treated hearts showed lower expression levels of cleaved caspase-3 
compared to controls. Further, we also measured the expression levels of apoptotic 
downstream targets, including the anti-apoptotic protein Bcl-2 as well as the pro-
apoptotic protein Bax (Figs 7B-C). Results showed that the protein expression of Bcl-2 
was significantly increased in the border zone of three-day infarcted hearts by cKit+CSC 
transplantation (Fig.7B). Conversely, cell treatment significantly inhibited Bax 
expression compared to the control group (Fig.7C).  
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Since recent studies have indicated a protective role of the autophagic process in 
ischemic heart disease (Schiattarella and Hill, 2015; Nishida and Otsu, 2015), we tested 
whether reduced apoptotic rate in the peri-infarct region of transplanted hearts was 
associated to increased autophagy. Firstly, we analyzed the expression of the ubiquitin-
like modifier LC3 by WB analysis (Fig.7D). Results showed that, three days following MI, 
there was a significant increase in LC3II formation in the border zone of cKit+CSC 
transplanted hearts compared to controls indicative of autophagosome formation. 
Further, the infarcted hearts were also characterized, following cell transplantation, by 
upregulation of the protein levels of the autophagy-related gene 7 (Atg7), another 
important protein for autophagosome formation (Fig.7E). 
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Fig. 7 : Western blot analysis showing the expression of (A) cleaved-caspase 3, (B) Bcl-2, (C) 
Bax, (D) LC3 and (E) Atg7, in the border zone of  three days infarcted hearts following cKit+CSC 
transplantation (MI+cKit+CSCs, n=3). Infarcted hearts treated with PBS were used as control 
(MI, n=3). Left panel: A representative Western blotting of three independent experiments is 
shown. Right panel: Densitometric analysis of Western blot. Data are shown as means ± SEM. 
*P < 0.05 vs MI. 
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6.3. cKit+CSCs attenuate cardiac remodeling (hypertrophy) in the 
infarcted murine heart 
 
Muscle LIM Protein (MLP), also known as cysteine rich protein 3 (CSRP3, CRP3), has a 
significant impact on cardiac muscle physiology and pathology. Specifically, in mice, 
reduced expression of CSRP3 leads to myocardial hypertrophy followed by dilated 
cardiomyopathy and heart failure (Buyandelger B et al., 2011). In our experimental 
model, we detected, by WB analysis, a higher  expression level of CSRP3 in the border 
zone of 21 day-infarcted hearts following cKit+CSC transplantation compared to controls 
(Fig. 8A). 
Cardiac hypertrophy is characterized by a switch of expression from -myosin heavy 
chain (-MHC), the mature isoform, to -MHC, the embryonal isoform (Izumo et al., 
1987, Frustaci et al., 2006). 21 days after cell therapy, we observed, in the border zone 
of infarcted hearts, the presence of lower levels of -MHC and of higher levels of  -
MHC, as showed by WB leading to a marked decrease in MHC - ratio (Fig.8B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8 : The relative levels of (A) CSRP3 and (B) -MHC/-MHC were investigated in the border 
zone of twenty one days infarcted control hearts (MI, n=3) or cKit+CSC transplanted hearts 
(MI+cKit+CSCs, n=3) by Western blot (left panel) and relative densitometry of three 
independent experiments (right panel). Data are shown as means ± SEM. *P < 0.05 vs MI. 
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6.4. cKit+CSCs reduce cardiac fibrosis  following acute MI 
TGF  is an indicator of cardiac fibrosis that plays an important role in the pathogenesis 
of cardiac remodeling. In our experimental model, 3, 7 and 21 days following cKit+CSC 
treatment, infarcted mice were characterized by circulating levels of TGF 1, detected 
by LUMINEX assay, significantly lower than in controls suggesting an attenuation in 
adverse remodeling (Fig.9A). 
In the infarcted murine heart, TGF  promotes myofibroblast transdifferentiation and 
matrix synthesis. Accordingly to our results on circulating TGF 1, we detected lower 
expression of collagen I protein in the infarcted hearts 21 days following stem cell 
transplantation compared to control hearts (Fig.9B). Further, in order to account for 
these results, we evaluated whether hypoxic cKit+CSCs had an effect on the expression 
of matrix matalloproteinases (MMPs) and their inhibitors (TIMPs). 24 h of hypoxia had 
no significant effect on MMP2 mRNA while it markedly enhanced MMP9 mRNA in 
cKit+CSCs (Fig.9C). Further, when we examined the mRNA expression of the MMP 
inhibitors, we found that TIMP4 was significantly lower in hypoxic cKit+CSCs than in 
normoxic cells (Fig.9D). In contrast, there was no effect on TIMP3 expression (Fig.9D). 
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Fig. 9 : cKit+CSCs reduces the expression of fibrotic markers. (A) Circulating levels of TGF 1 
detected by Luminex assay 3,7 and 21 days following surgery in the plasma of PBS treated 
infarcted mice used as controls (MI, n=4) and cKit+CSC transplanted infarcted mice 
(MI+cKit+CSCs, n=4), all normalized for their controls. Data were obtained using samples from 
4 mice/each group. Data are shown as means ± SEM. *P<0.05 vs MI. (B) Collagen I expression 
in twenty one day infarcted control hearts (MI, n=3) or cKit+CSC transplanted hearts 
(MI+cKit+CSCs, n=3) by Western blot (left panel) and relative densitometry of three 
independent experiments (right panel). Data are shown as means ± SEM. *P < 0.05 vs MI. (C) 
MMP2 and MMP9, (D) TIMP3 and TIMP4 mRNA expression by real time PCR in  normoxic and 
hypoxic cKit+CSCs at 24h. Data were normalized to GUSB, a housekeeping gene and represent 
means ±SEM; Data were obtained from three independent experiments. *p< 0.02 vs normoxic 
cKit+CSCs. 
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6.5. cKit+CSCs enhances the production of IGF-1 and HGF under 
hypoxia conditions 
ELISA assays were performed to measure the levels of two growth factors, both 
involved in cardioprotection, in the conditioned medium of normoxic and hypoxic 
cKit+CSCs. After 48h of hypoxia, we detected a significant increase in IGF-1 (Fig.10A) 
and HGF levels (Fig.10B) in conditioned media of cKit+CSCs compared to normoxia. 
 
 
 
 
 
 
 
Fig. 10 : IGF-1 and HGF levels increase in the conditioned medium of hypoxic  cKit+CSCs. ELISA 
detection of (A) IGF-1, (B) HGF in in the conditioned medium of normoxic and hypoxic cKit+CSCs 
(n= 3 independent experiments). Results are presented as means ± SD. *P < 0.001 vs normoxic 
conditions. 
 
6.6. Allogeneic cKit+CSC transplantation doesn’t increase immune 
response in mouse after MI 
Most clinical trials of cell therapy to-date have been conducted using autologous cells. 
While autologous cell therapy carries no risk of immune rejection, it requires patient-
specific tissue harvesting, cell manufacturing and quality control and is, therefore, 
associated with important limitations, that could be overcome by the use of allogeneic 
cells. The obvious disadvantage of allogeneic therapy is the risk of immune response, 
which could limit effectiveness of cell therapy, raise safety concerns and induce 
allosensitization of the recipient, which could complicate future organ transplant. If 
allogeneic cell therapy were proven to be safe and effective, the possibility to use 
allogeneic CSCs to repair infarcted hearts would be an alternative of paramount 
importance to autologous procedures. This possibility has been already demonstrated 
for cardiospheres, another source of CSCs, but not for cKit+CSCs (Baez-Diaz C et al., 
2014;  Crisostomo V et al., 2014; Lauden L et al., 2013).  
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Then, to verify whether allogeneic cKit+CSC transplantation could exert an increase in 
the immune response,  we decided to isolate and expand cKit+CSCs from Balb C murine 
hearts and then to transplant them into the hearts of Balb C mice (to have a syngeneic 
transplant) or in the hearts of C57 BL6 mice (to have an allogeneic transplant). At three 
different time points (3,7 and 21 days) hearts were collected from mice and used for 
immunohistochemistry and WB analyses.  Specifically, using these techniques, we 
detected and quantified different markers of primary and secondary inflammation 
among the different groups of mice to verify the presence of an immune response: 
CD45RA to identify B monocytes, CD3 for lymphocytes and CD68 for macrophages. 
For western blot analysis, we collected the entire left ventricle (LV) of sham mice while 
we separated the infarcted zone from the survived zone of the border zone of infarcted 
mice. 
First, we did not detect significative differences in the expression levels of the three 
inflammatory markers between sham BalbC and C57 BL6 mice (Fig.11 and Fig.12). 
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Fig. 11 : Western blot analysis showing the expression of CD45RA, CD3 and CD68 in the heart of 
Sham BalbC and C57 mice 3 days following operation (SO, n=3). Left panel: A representative 
Western blotting of three independent experiments is shown. Right panel: Densitometric 
analysis of Western blot. Data are shown as means ± SEM. *P < 0.05 vs SO BalbC. 
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Fig. 12: Western blot analysis showing the expression of CD45RA, CD3 and CD68 in the heart of 
Sham BalbC and C57 mice 21 days following operation (SO, n=3). Left panel: A representative 
Western blotting of three independent experiments is shown. Right panel: Densitometric 
analysis of Western blot. Data are shown as means ± SEM. *P < 0.05 vs SO BalbC. 
 
By western blot, the same results were obtained comparing sham BalbC and C57 BL6 
mice both transplantated with cKit+CSCs at all three time points (Fig.13, Fig.14, Fig.15) 
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Fig. 13: Western blot analysis showing the expression of CD45RA, CD3 and CD68 in the heart of 
transplanted Sham BalbC (syngenic) and C57 (allogeneic) mice 3 days following operation (SO+ 
cKit+CSCs, n=3). Left panel: A representative Western blotting of three independent 
experiments is shown. Right panel: Densitometric analysis of Western blot. Data are shown as 
means ± SEM. *P < 0.05 vs SO BalbC+cKit+CSCs. 
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Fig. 14: Western blot analysis showing the expression of CD45RA, CD3 and CD68 in the heart of 
transplanted Sham BalbC (syngenic) and C57 (allogeneic) mice 7 days following operation (SO+ 
cKit+CSCs, n=3). Left panel: A representative Western blotting of three independent 
experiments is shown. Right panel: Densitometric analysis of Western blot. Data are shown as 
means ± SEM. *P < 0.05 vs SO BalbC+ cKit+CSCs. 
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Fig. 15: Western blot analysis showing the expression of CD45RA, CD3 and CD68 in the heart of 
transplanted Sham BalbC (syngeneic) and C57 (allogeneic) mice 21 days following operation 
(SO+ cKit+CSCs, n=3). Left panel: A representative Western blotting of three independent 
experiments is shown. Right panel: Densitometric analysis of Western blot. Data are shown as 
means ± SEM. *P < 0.05 vs SO BalbC+ cKit+CSCs. 
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A similar situation was detected in infarcted hearts from the two strains of mice both in 
the absence and in the presence of transplanted cKit+CSCs (syngeneic transplant versus 
allogeneic transplant) at all three time points: We did not detect significative differences 
in the expression levels of the three inflammatory markers between MI BalbC and C57 
BL6 mice and between syngeneic and allogeneic transplant (Fig.16, Fig.17, Fig.18, 
Fig.19, Fig.20, Fig.21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16: Western blot analysis showing the expression of CD45RA in the border zone and in the 
infarcted region of three days infarcted hearts following syngeneic (MI BalbC+cKit+CSCs) and 
allogeneic (C57+cKit+CSCs) transplantation (MI+cKit+CSCs, n=3). Infarcted hearts treated with 
PBS were used as control (MI+PBS, n=3). Left panel: A representative Western blotting of two 
independent experiments is shown. Right panel: Densitometric analysis of Western blot. Data 
are shown as means ± SEM. *P < 0.05. 
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Fig. 17: Western blot analysis showing the expression of CD3 and CD68 in the border zone and 
in the infarcted region of three days infarcted hearts following syngeneic (MI BalbC+cKit+CSCs) 
and allogeneic (C57+cKit+CSCs) transplantation (MI+cKit+CSCs, n=3). Infarcted hearts treated 
with PBS were used as control (MI+PBS, n=3). Left panel: A representative Western blotting of 
four independent experiments is shown. Right panel: Densitometric analysis of Western blot. 
Data are shown as means ± SEM. *P < 0.05. 
103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18: Western blot analysis showing the expression of CD45RA and CD3 in the border zone 
and in the infarcted region of seven days infarcted hearts following syngeneic (MI 
BalbC+cKit+CSCs) and allogeneic (C57+cKit+CSCs) transplantation (MI+cKit+CSCs, n=3). 
Infarcted hearts treated with PBS were used as control (MI+PBS, n=3). Left panel: A 
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representative Western blotting of four independent experiments is shown. Right panel: 
Densitometric analysis of Western blot. Data are shown as means ± SEM. *P < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19: Western blot analysis showing the expression of CD68 in the border zone and in the 
infarcted region of seven days infarcted hearts following syngeneic (MI BalbC+cKit+CSCs) and 
allogeneic (C57+cKit+CSCs) transplantation (MI+cKit+CSCs, n=3). Infarcted hearts treated with 
PBS were used as control (MI+PBS, n=3). Left panel: A representative Western blotting of two 
independent experiments is shown. Right panel: Densitometric analysis of Western blot. Data 
are shown as means ± SEM. *P < 0.05. 
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Fig. 20: Western blot analysis showing the expression of CD45RA and CD3 in the border zone 
and in the infarcted region of twenty one days infarcted hearts following syngeneic (MI 
BalbC+cKit+CSCs) and allogeneic (C57+cKit+CSCs) transplantation (MI+cKit+CSCs, n=3). 
Infarcted hearts treated with PBS were used as control (MI+PBS, n=3). Left panel: A 
representative Western blotting of four independent experiments is shown. Right panel: 
Densitometric analysis of Western blot. Data are shown as means ± SEM. *P < 0.05. 
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Fig. 21: Western blot analysis showing the expression of CD68 in the border zone and in the 
infarcted region of twenty one days infarcted hearts following syngeneic (MI BalbC+cKit+CSCs) 
and allogeneic (C57+cKit+CSCs) transplantation (MI+cKit+CSCs, n=3). Infarcted hearts treated 
with PBS were used as control (MI+PBS, n=3). Left panel: A representative Western blotting of 
four independent experiments is shown. Right panel: Densitometric analysis of Western blot. 
Data are shown as means ± SEM. *P < 0.05. 
 
Immunoflorescence was performed to evaluate the presence of the same three markers 
on myocardial frozen sections. The number of positive cells/mm2 for each marker has 
been considered. Results showed that, in each mouse strain, comparing the number of 
labeled cells in infarcted and transplanted hearts with the number of labeled cells in 
infarcted and PBS-treated hearts, we obtained similar increments in syngeneic and 
allogeneic groups. This lack of difference between the two groups was detected for all 
the three markers of inflammation at 3 and 21 days following MI and transplantation 
(Fig.22). 
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Fig. 22: Immunofluorescence analysis and CD45RA+, CD3+ and CD68+cell counts in mice 
infarcted hearts three and twenty one days following syngeneic (MI BalbC+cKit+CSCs) and 
allogeneic (C57+cKit+CSCs) transplantation (MI+cKit+CSCs, n=3). Values are expressed as fold 
change compared to the relative control (MI+PBS, n=3). Data are shown as means ± SEM. *P < 
0.05. 
 
 
 
 
Therefore, we did not find a different immune response comparing the syngeneic group 
to the allogeneic group both by WB analysis and by immunofluorescence. Specifically, 
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the presence of monocytes, lymphocytes and macrophages was similar in the two 
groups at 3, 7 and 21 days following infarction and transplantation. 
 
 
6.7. Allogeneic and syngeneic transplantations show comparable 
levels of pro-inflammatory and anti-inflammatory cytokines in mouse 
after MI 
 
In our experimental model, 3,7 and 21 days following cKit+CSC treatment, blood was 
collected in all animals just before sacrifice to determine the levels of circulating 
cytokines using the LUMINEX Assay. We used a panel (Th1_Th2 panel) for pro-
inflammatory cytokines (IFN, TNF, IL-2, IL-12, GMCSF) and anti-inflammatory 
cytokines (IL-4, IL-5, IL-10) to identify and quantify the immune response mediated by 
T helper lymphocytes (Th). Furthemore, we also quantified the expression level of the 
cytokine IL-17A, involved in inflammation and defense mechanisms. 
Plasma quantification of these pro- and anti-inflammatory cytokines at 3,7 and 21 days 
following MI and transplantation, showed that the differences between the syngeneic 
and allogeneic groups are not statistically significant, thus confirming the data obtained 
by WB analysis and immunofluorescence (Fig.23 and Fig.24). 
 
 
 
 
 
 
 
 
 
Fig. 23: Circulating levels of pro- and anti-inflammatory cytokines detected by Luminex assay in 
the plasma of treated mice three days following treatment (n=4/ each  group). Data are shown 
as means ± SEM. *P < 0.05. 
 
1: SO BalbC+cKit+CSCs/SO Balbc 
2: SO C57+cKit+CSCs/SO C57 
3: MI BalbC+cKit+CSCs/MI BalbC+PBS 
4:MI C57+cKit+CSCs/MI C57+PBS 
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Fig. 24: Circulating levels of pro- and anti-inflammatory cytokines detected by Luminex assay in 
the plasma of treated mice seven and twenty one days following treatment (n=4/ each  group). 
Data are shown as means ± SEM. *P < 0.05. 
 
1: SO BalbC+cKit+CSCs/SO Balbc 
2: SO C57+cKit+CSCs/SO C57 
3: MI BalbC+cKit+CSCs/MI BalbC+PBS 
4:MI C57+cKit+CSCs/MI C57+PBS 
 
In conclusion, we demonstrated the feasibility of an allogeneic transplantation using 
CSCs as demonstrated by comparable expression levels of inflammatory cytokines 
between the syngeneic and allogeneic groups both in the cardiac tissue, following MI 
and transplantation, and in the bloodstream. 
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7. Discussion 
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In the present study, we have demonstrated that cardiac cKit+CSCs adapt to hypoxia 
and acquire an inflammatory and reparative phenotype through the expression of HIF-
1 and NF-kB target genes. In vivo, following intramyocardial injection of these cells, 
hypoxia adaptation led to cardioprotection of the infarcted myocardium. Specifically, 
cKit+CSC transplantation after acute MI lowered apoptosis, induced autophagy and 
attenuated adverse remodeling by reducing hyperthophy and fibrosis. 
Following myocardial injury, necrotic cardiomyocytes release DAMPs that activate innate 
immune signaling pathways in leukocytes (Frangogiannis NG et al., 2015). In particular, 
DAMPs bind their receptors, i.e. RAGE, P2X7R (Tafani M et al., 2011), Toll-like receptors 
(Sandholm J et al., 2014), NOD-like receptors (Jones HD e al., 2014), and activate NF-
kB that leads to the expression of genes that are involved in the protection and repair 
of the injured tissue, known as IRR. Therefore, leukocytes play a critical role in 
regulating the inflammatory and reparative response that follows MI. In our in vitro 
model, we found that cardiac cKit+CSCs can activate a gene response similar to that 
present in activated leukocytes. Accordingly, hypoxic conditions induced in our cells the 
activation of HIF-1 allowing them to adapt to the reduced oxygen level. Hypoxia-
mediated activation of HIF-1 determined the transcription of genes encoding 
angiogenic factors (Semenza GL, 2014). Indeed, we detected an increased mRNA 
expression of VEGF and EPO in cardiac cKit+CSCs following 6, 24 and 48 hours of 
hypoxia. Another important target gene of HIF-1 is represented by the glucose 
transporter GLUT1. The switch from oxidative to glycolytic metabolism represents one 
of the most important intracellular adaptation to hypoxia mediated by HIF-1 (Iyer NV 
et al., 1998). In a recent study, it has been demonstrated that in vitro treatment of 
bone marrow-derived angiogenic cells (BMDACs) with an inducer of HIF resulted in a 
metabolic reprogramming of these cells as reflected by the increased expression levels 
of glucose transporters, metabolic enzymes and pH regulators (Rey S et al., 2011). 
These alterations in metabolism allowed the survival of pretreated  BMDACs in the 
ischemic hindlimb. In our in vitro experiments, we found that HIF-1 induction in 
hypoxic cardiac cKit+CSCs determined higher expression of the glucose transporter 
GLUT1 indicative of a potential switch from oxidative to glycolytic metabolism that may 
promote their survival in the infarcted heart. Several recent reports suggest that 
metabolic and cell survival pathways are closely related (Roberts DJ et al., 2014). HK2 
regulates glucose metabolism by glucose phosphorylation. Nevertheless, it is 
increasingly recognized that it functions also as a protective signaling molecule. 
Specifically, in the heart, cardiac-specific HK2 overexpression prevents maladaptive 
hypertrophy by decreasing ROS accumulation (McCommis KS et al., 2013). 
Interestingly, hypoxia enhanced protein expression levels of HK2 in our cells. 
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The receptors for DAMPs were firstly localized in tissue resident leukocytes (Iwasaki A 
and Medzhitov R, 2004; Bianchi ME, 2007), but have been also described in many other 
cells and tissues. In particular, under stress conditions, these receptors can be induced 
and expressed de novo in resident or recruited stem cells and pluripotent 
undifferentiated progenitors from many tissues (Tafani M et al., 2011; Ryan BJ et al., 
2014; Reuter S et al., 2010). For instance, mesenchymal stem cells (MSCs) express TLR 
(DelaRosa O et l., 2010; Feng Y et al., 2011; Faure E et al., 2000) and upon their 
stimulation, paracrine factors are released and may boost or reduce their 
immunosuppressive capacities (van den Akker F et al., 2013). In the setting of I/R 
injury, two different studies suggested that TLR2 presence and activation on injected 
MSCs could be essential for myocardial recovery (Abarbanell AM et al., 2010) while 
TLR4 activation would have deleterious effects (Wang Y et al., 2010). Nevertheless, it 
should be noted that since both studies used a I/R injury in an isolated rat heart model, 
no immune system was present and therefore the effect of TLR2 and TLR4 activation 
on immunomodulation by MSC remains unclear. In our experimental setting, we found 
that TLR2 and TLR4 were both activated by hypoxia in cKit+CSCs at 24 and 48h. On the 
other end, RAGE, another important DAMPs receptor, showed a significant mRNA up-
regulation mainly after 6h of hypoxia and increased expression of protein levels at 24 
and 48h. Interestingly, in a prior study, we have already demonstrated that cardiac 
cKit+ cells express RAGE and their regenerative responses, elicited by intramyocardial 
injection of HMGB1 following acute MI, are mediated, at least in part, by the interaction 
HMGB1-RAGE (Limana et al., 2013). Adipose-derived stem cells, bone 
marrow stromal cells (Forostyak O et al., 2016; Li W et al., 2015) and MSCs (Peng H et 
al., 2016) express the purinergic P2X7R and its activation is involved in their migration 
and differentiation. Additionally, it has been also demonstrated a key role for P2X7R as 
an essential pro-survival signal in embryonic stem cells (Thompson BA et al., 2012). In 
a model ex vivo of rat heart, agonists of this receptor  are responsible for the release of 
cardioprotectants induced by ischemic pre- and post-conditioning (Vessey DA et al., 
2011). Our findings have shown a significant up-regulation of P2X7R mRNA  in 
cKit+CSCs 48h following hypoxia. The precise role of the up-regulation of all these 
receptors in our hypoxic cells is not clear but, as already mentioned at the beginning if 
this section, it should be noted that following MI, necrotic cardiomyocytes release 
DAMPs that, through the activation of these receptors in leukocytes, trigger a specific 
gene expression NF-kB-dependent, responsible for the IRR (Tafani M et al., 2011). 
 
The mRNA expression levels of the inducible enzymes COX2 and NOS2 were up-
regulated by hypoxia at all three time points and the increased COX2 mRNA was 
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associated with an increase in COX2 protein expression following 24h of hypoxia. 
Interestingly, Dr. Bolli’s group, using a molecular genetic approach and a model of MI, 
has demonstrated that the cardioprotection afforded by NOS2 gene therapy is mediated 
by COX2 upregulation via NF-kB activation (Li Q et al., 2007). In particular, 
upregulation of COX2 determines an increase in myocardial production of two 
cytoprotective prostanoids (Bolli R et al., 2002). 
 
The long pentraxin PTX3 is expressed in the heart under inflammatory conditions and 
has a cardioprotective role in acute myocardial infarction in mice (Salio M et al., 2008). 
Specifically, PTX3-deficient mice showed larger infarcts compared to wild type mice and 
the use of recombinant PTX3 reduced heart damage and inflammation. More recently, it 
has been demonstrated that PTX3 deficiency is associated with increased 
atherosclerosis, macrophage accumulation and inflammation in the atherosclerotic 
lesions suggesting a modulation by PTX3 of the vascular associated inflammatory 
response (Norata GD et al., 2009). Together these observations support the possibility 
that PTX3 may exert a cardiovascular protective effect through the modulation of the 
immunoinflammatory balance. Our results showed that PTX3 expression is influenced 
by hypoxia only at the earliest time point following hypoxia. 
Finally, we detected a significant up-regulation of the receptor for CXC chemokines 
CXCR4 in hypoxic cKit+CSCs after 48h of hypoxia. Hypoxic preconditioning of cKit+ 
cardiac progenitor cells improves their survival following MI (Yan F et al., 2012) by 
inducing CXCR4 expression. Further, CXCR4 overexpression in MSCs attenuates cardiac 
remodeling after MI and this cardioprotective effect is mediated by the release of the 
antifibrotic enzyme MMP9 (Huang W et al., 2012). It is noteworthy that in our in vitro 
experiments, we detected a significant increase in the mRNA expression of MMP9 and  
a significant decrease in the mRNA expression of the MMP inhibitor TIMP4 in hypoxic 
cKit+CSCs compared to normoxic cells. 
 
The activation of NF-kB mounts a regenerative response by inducing genes that encode 
growth factors with the potential to mediate different cardioprotective effects. Our cells 
secreted high levels of IGF-1 and HGF under hypoxia conditions. These secreted 
paracrine factors have been demonstrated to exert beneficial effects on cell survival and 
cardiac remodeling. For instance, myocardial injury induced by cardiotoxin injection in 
transgenic mice with cardiac-restricted mIGF-1 expression determined restoration of 
cardiac function. This effect was in part mediated by modulation of the inflammatory 
response. Specifically, mRNA IL-10, a potent anti-inflammatory cytokine, was found to 
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rapidly increase in transgenic hearts 24 hours after cardiac injury and this increase was 
even higher at 1 week (Santini MP et al., 2008). It should be noted that IL-10 has been 
showed to attenuate left ventricular remodelling after MI by reducing inflammation-
mediated fibrosis (Krishnamurthy P et al., 2009). Most importantly, transplantation of 
bone marrow mononuclear cells in infarcted mouse hearts led to the secretion of 
significant amounts of IL-10 that were associated to decreased reactive hypertrophy 
and myocardial collagen deposition. These effects resulted in a significant improvement 
in cardiac function (Burchfield JS et al., 2008). Interestingly, in our in vivo model, we 
detected higher levels of circulating IL-10 in mice at 3 days following cKit+CSC 
transplantation compared to controls. In the same mice, at 3 days but also at later time 
points, we also found decreased levels of circulating TGF 1 and, at 3 weeks, a reduced 
expression of collagen I in the border zone of treated infarcted hearts. Reduction in LV 
remodeling was also supported by a decrease in hypertrophy in transplanted infarcted 
hearts compared to controls as evidenced by down modulation of the -MHC/-MHC 
ratio and up-regulation of CSRP3. Expression of - and -myosin heavy chain (MHC), 
the two functionally distinct cardiac MHC isoforms is species-dependent and tightly 
controlled by developmental and hormonal factors (Everett AW et al., 1984; Allen DL et 
al., 2001). Relative expression levels of these isoforms can be altered in disease states 
such as cardiac failure or hypertrophy (Nadal-Ginard B et al., 1989). -MHC is 
characterized by lower adenosine triphosphatase activity and lower filament sliding 
velocity, but can generate cross-bridge force with a higher economy of energy 
consumption than -MHC (Holubarsch C et al., 1985; Sugiura S et al., 1998). This 
suggest that a shift from - to -MHC might be an adaptive response in order to 
preserve energy. On the other hand, depressed contractile function can promote 
disease progression (Kiriazis H et al., 2000; Fatkin D et al., 2000). Therefore, it is 
conceivable that the decrease in contractile function due to increased -MHC might 
outweigh the benefits of improved economy and ultimately dictate clinical outcome. 
MLP, the protein encoded by CSRP3, belongs to the LIM-only domain family, a large 
protein family with diverse functional roles, including transcriptional regulation, cell fate 
determination, cell adhesion and motility, cytoskeleton organization and signal 
transduction (Schmeichel KL and Beckerle MC, 1997; Kadrmas JL and Beckerle MC, 
2004; Zheng Q and Zhao Y, 2007). Its diverse functional roles have significant impact 
on cardiac and skeletal muscle physiology and pathology. At the nucleus level, CSRP3 
serves as a positive regulator of myogenesis, promoting myogenic differentiation (Arber 
S et al., 1994). Accordingly, various studies have demonstrated that CSRP3 
overexpression results in enhanced myotube differentiation (Arber S et al., 1994; Kong 
Y et al., 1997; Vafiadaki E et al., 2014). 
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IL-10 negatively affects cardiac remodelling also by attenuating apoptosis 
(Krishnamurthy P et al., 2010). These data are in accordance with our results that 
showed the induction of autophagy and the attenuation of apoptosis in infarcted hearts 
three days after cKit+CSC transplantation. Importantly, an antiapoptotic effect on 
cardiomyocytes is also exerted by HGF (Deuse T et al., 2009) and transplantation of 
MSCs overexpressing HGF in a mouse model of MI was associated with less 
cardiomyocyte apoptosis (Zhao L et al., 2016). 
Growing evidences suggest that stem cell therapy following MI could improve cardiac 
function not by differentiation into cardiomyocytes and vascular cells but most likely by 
the production of paracrine factors which have beneficial effects (Hodgkinson CP et al., 
2016). In recent years, the immune system represents one of the most studied system 
that could be influenced by these paracrine factors. In particular, it has been 
demonstrated by several reports that stem cell therapy could activate a subset of 
reparative macrophages (Weirather J et al., 2014). For instance, transplantation of 
MSCs into the infarcted heart contribute to the recovery of cardiac function, in part, by 
switching macrophages from a pro-inflammatory to an anti-inflammatory and reparative 
phenotype through secreted factors such as IGF-1 and IL-10 (Dayan V et al., 2011; van 
den Akker F et al., 2013; Ben-Mordechai T et al., 2013; de Couto G et al., 2015) Thus, 
a possible scenario is that cKit+CSCs, following transplantation in a hypoxic environment 
as the infarcted heart, exert cardioprotective effects by modulating the activation of 
macrophages via a paracrine mechanism. Indeed, in a very recent paper, it has been 
postulated that cardiac cKit+ progenitors originate from a cardiac myeloid lineage, i.e. 
macrophage progenitor cells (Leinonen JV et al., 2016) suggesting the potential of cKit+ 
progenitors to display functional characteristics of macrophages. 
Immunogenicity is the recent concern of stem cell therapies whether using embryonic 
or adult, or autologous or allogeneic stem cells (Charron D et al., 2009; Dhodapkar KM 
et al., 2010; Zhao T et al., 2011; Charron D et al., 2012). An exogenous cell delivered 
to a host is expected to encounter some form of host resistance. Recognition of foreign 
antigen initiates an immune response that involves the activation and proliferation of 
specific immune cells. The MHC disparities are by far the most formidable 
immunological barrier to transplantation (Erlich HA et al., 2001). Cardiosphere-derived 
cells (CDCs) were the first therapeutic modality to demonstrate a reduction in scar 
tissue associated with an increase in the presence of viable, functional tissue in the 
randomized, placebo controlled CADUCEUS trial (Makkar RR et al., 2012; Malliaras K et 
al., 2014). The intracoronary (IC) administration of autologous CDCs also improved 
regional function of infarcted myocardium with an excellent safety profile (Makkar RR et 
al., 2012; Malliaras K et al., 2014). However, widespread applicability of autologous 
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CDC therapy, as for others cardiac-derived stem cells, is challenged by the need for 
patient-specific tissue harvesting with myocardial biopsy, cell processing and quality 
control resulting in delays to therapy and imposing significant logistic and economic 
constraints (Malliaras K et al., 2014). In addition, cell potency has also been reported to 
be affected by age and presence of comorbidities (Zhuo Y et al., 2010). Autologous 
CSCs can be induced to proliferate and differentiate ex vivo before transplanting them 
into the  damaged  heart. However, several limitations exist in the isolation and 
expansion of this pool of cells in short periods and in quantities that can be employed 
therapeutically.  Thus,  the  use  of  an  allogeneic  CSC  approach  would be of primary 
clinical relevance. The use of allogeneic stem cells, if proven safe and effective, has the 
potential to overcome the limitations of autologous cardiac stem cell therapy with the 
ability to provide a ready to use, “off-the-shelf” product for widespread clinical usage. 
The safety and feasibility has been already demonstrated for CDCs in rat (Malliaras K et 
al., 2012; Makkar RR et al., 2012; Malliaras K et al., 2014). In a “proof-of-concept” 
study of allogeneic CDCs in a rat MI model, allogeneic CDC transplantation without 
immunosuppression was noted to be safe and resulted in cardiac regeneration and 
improvement in cardiac function (Malliaras K et al., 2012). Similarly, administration of 
allogeneic cardiospheres in a rat model resulted in increased viable myocardium, 
decreased scar, and improved cardiac function with attenuation of adverse remodeling 
(Tseliou E et al., 2013). The cardioprotective effects of allogeneic CDCs and 
cardiospheres were durable for at least 6 months, although allogeneic cells disappeared 
within 4 weeks (Malliaras K et al., 2012; Tseliou E et al., 2013). Allogeneic MSCs 
delivered IM during left ventricular assist device implantation in patients with severe 
heart failure were well-tolerated with a trend towards improvement in wearing 
parameters (Ascheim DD et al., 2014). The ALLSTAR study is the first randomized, 
double-blind, placebo-controlled trial to determine the safety and efficacy of 
intramyocardial delivery of allogeneic CDCs in patients with ischemic left ventricular 
dysfunction following MI. The results from the ALLSTAR Phase 1 trial demonstrated that 
IC infusion of allogeneic cardiosphere-derived cells was safe and feasible (Chakravarty 
T et al., 2016). We performed allogeneic cKit+CSC transplantation in our mouse MI 
model to evaluate immune response to transplant. We analysed, by WB and 
immunofluorescence, the expression of three markers of primary and secondary 
inflammation, respectively CD45RA to identify B monocytes, CD3 for lymphocytes and 
CD68 for macrophages. After 3, 7 and 21 days, we detected comparable levels of 
immune cells infiltration between allogeneic and syngeneic transplantation. Moreover, 
we detected comparable circulating levels of pro- and anti-inflammatory cytokines. Our 
results showed safety and feasibility of an allogeneic transplantation using cKit+CSCs for 
MI treatment in a MI mouse pre-clinical model. Moreover, our results agree with others 
clinical studies, which have used different stem cells as MSCs, for cardiac repair (Hare 
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JM et al., 2009; Hare JM et al., 2012; Ascheim DD et al., 2014; Perin EC et al., 2015). 
However, if allogeneic cell therapy were proven to be safe and effective, it would open 
up a new paradigm in cellular therapeutics. Large scale expansion of cells derived from 
allogeneic tissues could be performed in specialized manufacturing labs under strict 
quality control. In the case of heart-derived cells, attractive sources of allogeneic tissue 
include hearts explanted from organ donors but not used for transplantation and 
surgical myocardial discards. Highly standardized, ‘off-the-shelf’ allogeneic cellular 
products would subsequently be shipped to hospitals throughout the world and banked 
for future use, thus enabling broad adoption and timely application of cell therapy in a 
cost-efficient manner. 
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